Modified Cells and Methods

Multispecific binding agents with chimeric antigen ligands (CALs) address the challenges of CAR T cell therapies by providing precise control over immune cell activity, enhancing cancer treatment efficacy and safety through shorter half-life and reduced toxicity.

JP7577430B2Active Publication Date: 2024-11-05NOVOSCOPE IP LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2018544203
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-02-19
Filing Date
2017-02-13
Publication Date
2024-11-05
Estimated Expiration
2037-02-13

AI Technical Summary

Technical Problem

Existing CAR T cell therapies face challenges such as unpredictable activity, long half-life of IgG, and potential toxicity due to cytokine release syndrome, limiting their controlled application in cancer treatment.

Method used

Development of multispecific binding agents, specifically chimeric antigen ligands (CALs), which are engineered immune cells with shorter serum half-lives and flexible tuning, allowing precise control over immune cell activity through cross-linking agents that are smaller than IgG, reducing dependence on Fc interactions and enabling finer control of immune cell activity.

Benefits of technology

The approach provides precise and controlled modulation of immune cell activity, reducing off-target effects and toxicity, enhancing the efficacy of cancer treatments by allowing for tailored and safer administration of engineered immune cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577430000001
    Figure 0007577430000001
  • Figure 0007577430000002
    Figure 0007577430000002
  • Figure 0007577430000003
    Figure 0007577430000003
Patent Text Reader

Abstract

The present invention relates to modified cells, modified chimeric antigen ligands (CALs), novel uses of multispecific binding agents to crosslink cells, and therapeutic methods. The present invention also provides modified cells with adapted mutations. [Selection diagram] None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to novel uses of multispecific binding agents for crosslinking engineered immune cells (e.g., CAR T cells or CAL T cells) to target cells, engineered immune cells, engineered chimeric antigen ligands (CALs), and methods of immunotherapy, e.g., human adoptive CAR T cell or CAL T cell therapy. The present invention also provides CAR and CAL cells with adapted human mutations for performing precision immunotherapy. [Background technology]

[0002] background One approach to immunotherapy involves modifying a patient's own (or a donor's) immune cells to express cell surface antigen receptors (CARs) that recognize and attack tumors. This approach, called adoptive cell transfer (ACT), has so far been limited to small clinical trials, but treatment with these modified immune cells has produced some remarkable responses in patients with advanced cancer.

[0003] Chimeric antigen receptors (CARs) consist of an antibody-derived targeting domain fused to a T cell signaling domain that, when expressed by a T cell, confers on the T cell an antigen specificity determined by the targeting domain of the CAR. CARs can potentially redirect the effector function of T cells towards any protein and non-protein target expressed on the cell surface, so long as an antibody-based targeting domain is available. This strategy thereby circumvents the need for antigen processing and presentation by the target cell and is applicable to non-classical T cell targets such as sugars. This circumvention of HLA restriction means that the CAR T cell approach can be used as a general tool to broaden the possible applications of adoptive T cell therapy. See, for example, Methods Mol Biol. 2012;907:645-66. doi:10.1007 / 978-1-61779-974-7_36, "Chimeric antigen receptors for T-cell based therapy," Cheadle EJ et al.

[0004] The first CAR T construct was described in a 1989 paper by immunotherapy pioneer Zelig Eshhar in PNAS. The structure of CARs now includes a transmembrane polypeptide chain that is a chimera of different domains from different cellular proteins. For example, CARs have an extracellular portion connected (often by a linker and / or hinge region) to an intracellular portion, and the transmembrane portion of the CAR embeds a receptor in the membrane of an immune cell, usually a T cell. The extracellular portion includes an antibody binding site (usually in the form of an scFv, such as those derived from mouse mAbs) that recognizes a target antigen, typically a tumor-associated antigen (TAA) on the surface of a cancer cell. Such antigen recognition obviates the need to rely on a TCR, which requires MHC-restricted antigen presentation, in which case the binding affinity may be relatively low. The intracellular portion of the CAR typically includes a CD3 zeta (CD3ζ) domain for intracellular signaling when an antigen is bound to the extracellular binding site. Later generation CARs also include additional domains that enhance T cell-mediated responses, often the 4-1BB (CD137) or CD28 intracellular domains. Upon encountering a cognate antigen ligand for the CAR binding site, the CAR can activate intracellular signaling, thus activating the CAR T cell and enhancing tumor cell killing.

[0005] Most CAR Ts are expanded in vivo and therefore difficult to titrate in the traditional sense, and in many cases the modified T cells seem to be active "forever." That is, evidence of ongoing B cell aplasia has been seen in most CD19 CAR T clinical studies to date. This poses serious problems for the CAR T cell approach. Some observed risks are discussed in Discov Med. 2014 Nov;18(100):265-71, "Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer," Magee MS & Snook AE, which describes how the first serious adverse event after CAR-T cell therapy occurred in a patient with colorectal cancer metastasizing to the lung and liver (Morgan et al., 2010). The patient was treated with T cells expressing a third generation CAR targeting epidermal growth factor receptor 2 (ERBB2, HER2). This CAR contained scFv derived from the 4D5 antibody (trastuzumab), which is FDA approved for the treatment of HER2-positive breast cancer (Zhao et al., 2009). 10 After receiving a single dose of CAR-T cells, the patient developed respiratory distress within 15 minutes, followed by multiple cardiac arrests over a period of 5 days, ultimately resulting in death. Serum analysis at 4 hours after treatment revealed a significant increase in the cytokines IFNγ, GM-CSF, TNFα, IL-6, and IL-10. CAR-T cells were found in the lungs, abdominal, and mediastinal lymph nodes, but not in tumor metastases. The researchers concluded that the cause of toxicity was recognition of HER2 in the lung epithelium resulting in the release of inflammatory cytokines, leading to pulmonary toxicity, and cytokine release syndrome (CRS) causing multiple organ failure (Morgan et al., 2010). Trials utilizing a second-generation HER2-targeted CAR derived from a different antibody (FRP5) following a conservative dose-escalation strategy are currently being conducted by others in a variety of HER2+ malignancies (clinicaltrials.gov identifiers NCT01109095, NCT00889954, and NCT00902044). Summary of the Invention [Problem to be solved by the invention]

[0006] Another CAR T cell subject is an antibody-binding T cell receptor (ACTR) therapeutic that uses CD16A (FCγRIIIA) to bind to the Fc region of tumor-specific IgG (see, for example, WO2015 / 058018). The aim is to allow further control of CAR T cell activity in vivo by titrating the IgG administered to the patient. The CD16 binding site of the CAR T cell is free but can also bind to the patient's endogenous IgG, which reduces the attractiveness of this approach. This approach also has to take into account the inherently long half-life of IgG in the body (approximately 20 days for IgG in humans), which may limit the control of CAR cell activity. Ongoing studies will evaluate this risk. To avoid potential complications in using IgG to control activity, it is desirable to provide another way to control immune cell-based therapy, such as the CAR-T cell approach. [Means for solving the problem]

[0007] Description of the invention The present invention provides a solution by using novel engineered immune cells with a multispecific small fragment-based approach as a switch that is independent of Fc binding and provides flexible tuning by easily tailoring the switch half-life. One type of this new approach uses constructs that the inventors call "chimeric antigen ligands" (CALs), which are carried by CAL T cells and other immune cells.

[0008] The present invention also provides embodiments that differ from the prior art and take advantage of the relatively short serum half-life of the binding fragment approach. As such, the present invention improves upon existing T cell engager antibody approaches in the art (such as Amgen's BiTE™) and improves the use of Ig for CAR cell regulation. Several other advantages are provided by the approach of the present invention, as described below.

[0009] The present invention also provides methods of precision immunotherapy that are tailored to humans and human cells by matching immune cells, CARs, CALs, grafts, and natural human genotypic and phenotypic variations.

[0010] To this end, the present invention provides the following configuration.

[0011] In the first configuration: 1. A method of targeting an immune cell to a target cell, comprising: A. providing a cross-linking agent, the agent being i. a first antigen-binding site that specifically binds a first target antigen; and ii. a second antigen-binding site that specifically binds a second target antigen. providing a cross-linking agent which is a multispecific antigen-binding fragment comprising: B. Providing a chimeric antigen ligand (CAL)-immune cell, the immune cell comprising a transmembrane ligand, the ligand comprising: iii. an extracellular portion comprising a second antigen linked to the transmembrane domain; iv. an intracellular portion comprising a first signaling domain for intracellular signaling upon binding of the agent to a second antigen; providing a chimeric antigen ligand (CAL)-immune cell comprising an altered combination of: C. Combining the CAL-immune cells and the cross-linking agent with a target cell, the target cell comprising said first target antigen, the first target antigen being an extracellular antigen; v. The cross-linking agent thereby binds the first and second antigens to target immune cells to the target cells; vi. Thereby inducing intracellular signaling in immune cells to regulate immune cell activity Combining The method includes:

[0012] This allows for embodiments in which the crosslinker has a human serum half-life shorter than that of IgG, thereby allowing for finer control than has previously been possible with traditional CAR-T approaches and potentially avoiding reliance on Fc interactions (which may not be easily distinguishable from the patient's own antibody Fc region).

[0013] In the second configuration: 1. A chimeric antigen ligand (CAL)-immune cell for targeted binding to an antigen-specific agent, comprising: A. The drug is i. a first antigen-binding site that specifically binds a first target antigen; and ii. a second antigen-binding site that specifically binds a second target antigen. a multispecific antigen-binding fragment comprising: B. The CAL-immune cell contains a transmembrane ligand, the ligand being iii. an extracellular portion comprising a second antigen linked to the transmembrane domain; iv. an intracellular portion comprising a first signaling domain for intracellular signaling upon binding of the agent to a second antigen; including modified combinations of; C. When the CAL-immune cells and the crosslinking agent are combined with a target cell, the target cell comprises said first target antigen, and the first target antigen is an extracellular antigen; v. A cross-linking agent binds the first and second antigens to target immune cells to the target cells; vi. Thereby inducing intracellular signaling in immune cells to regulate immune cell activity; Chimeric antigen ligand (CAL)-immune cells.

[0014] In the third configuration: A graft comprising CAL immune cells or a plurality of such cells for use in a method for treating or reducing the risk of a disease or condition (e.g., cancer) in a human, the method comprising administering to the human CAL cells and the above-mentioned crosslinking agent, wherein the CAL cells and human target cells are combined and crosslinked by the crosslinking agent, thereby upregulating signaling in the CAL cells to increase the cytotoxicity (e.g., ADCC-mediated killing activity) of the CAL cells' target cells, thereby treating or reducing the risk of the disease or condition in the human.

[0015] In the fourth configuration: A graft comprising CAL immune cells or a plurality of such cells for use in a method for treating or reducing the risk of a disease or condition in a human (e.g., an autoimmune disease, GvHD, or allograft rejection), the method comprising administering to a human CAL cells and the above-mentioned crosslinking agent, wherein the CAL cells and human target cells are combined and crosslinked by the crosslinking agent, thereby upregulating signaling in the CAL cells to reduce the cytotoxicity (e.g., ADCC-mediated killing activity) of the CAL cells, thereby treating or reducing the risk of the disease or condition in the human.

[0016] In the fifth configuration: 1. A method of targeting an immune cell to a target cell, comprising: A. providing a cross-linking agent, the agent being i. a first binding moiety; and ii. A second binding moiety providing a cross-linking agent which is a multispecific binding fragment comprising: B. Providing immune cells, the immune cells iii. an extracellular portion comprising a third binding moiety linked to the transmembrane domain, wherein the second and third moieties form a specific binding pair (SBP1), such that one moiety specifically binds to the other moiety; iv. an intracellular portion comprising a first signaling domain for intracellular signaling when the second and third portions bind together. providing an immune cell expressing a transmembrane protein comprising an altered combination of: C. combining the immune cells and the cross-linking agent with a target cell, the target cell comprising a fourth binding moiety, the fourth binding moiety being extracellular; v. whereby the first and fourth moieties form a specific binding pair (SBP2), whereby one moiety specifically binds to the other moiety to target the immune cell to the target cell; vi. The second and third portions bind together, thereby inducing intracellular signaling in the immune cell to modulate immune cell activity. Combining and D. The molecular weight of the crosslinker is 125 kDa or less; method.

[0017] This is beneficial in order to take advantage of the serum half-life of the cross-linker, which has a size of 150 kDa, which is shorter than the half-life of Ig.

[0018] In the sixth configuration: 1. An immune cell for targeting binding to an antigen-specific agent, comprising: A. The drug is i. a first binding moiety; and ii. A second binding moiety a multispecific binding fragment comprising: B. Immune cells iii. an extracellular portion comprising a third binding moiety linked to the transmembrane domain, the second and third moieties forming a specific binding pair (SBP1), one moiety specifically binding to the other moiety; iv. an intracellular portion comprising a first signaling domain for intracellular signaling when the second and third portions bind together. expressing a transmembrane protein comprising an altered combination of C. When the immune cells and crosslinking agent are combined with a target cell (the target cell includes a fourth binding moiety, where the fourth moiety is extracellular), v. the first and fourth moieties form a specific binding pair (SBP2), where one moiety specifically binds to the other moiety to target the immune cell to the target cell; vi. the second and third portions bind together, thereby inducing intracellular signaling in the immune cell to modulate immune cell activity; and D. The molecular weight of the crosslinker is 125 kDa or less; immune cells.

[0019] In the seventh configuration: 1. A human immune cell comprising a modified transmembrane protein, Protein, A. an extracellular portion comprising one or more ligand binding domains or one or more ligand domains; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain (SD1); Includes; D. the variant protein SD1 is encoded in the cell by a first nucleotide sequence (S1) that includes a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of SD1; E. the genome of the cell comprises a second nucleotide sequence (S2) that comprises SNP1 and encodes a second signaling domain (SD2), the second signaling domain being (i) identical to SD1 and comprising R1 or (ii) a variant of a naturally occurring SD1 and comprising R1; and F. S2 is an endogenous genomic sequence of the cell, and SNP1 is a non-synonymous SNP; Human immune cells.

[0020] 1. A human immune cell comprising a modified transmembrane protein, Protein, A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain Includes; D. a first antigen or ligand domain of the variant protein is encoded in the cell by a first nucleotide sequence (S1) that includes a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of the antigen or ligand domain; E. the genome of the cell comprises a second nucleotide sequence (S2) that comprises SNP1 and encodes a second antigen or ligand domain, the second antigen or ligand domain being (i) identical to the first antigen or ligand domain, respectively, and comprising R1, or (ii) a variant of a naturally occurring first antigen or ligand domain, respectively, and comprising R1; and F. S2 is an endogenous genomic sequence of the cell, and SNP1 is a non-synonymous SNP; Human immune cells.

[0021] 1. A human immune cell for use in a method for treating or reducing the risk of a disease or condition (e.g., cancer or an autoimmune disease, e.g., as disclosed herein), the method comprising administering to a human patient an immune cell, the immune cell comprising a modified transmembrane protein, the protein comprising: A. an extracellular portion comprising one or more ligand binding domains or one or more ligand domains; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain (SD1); Includes; D. the variant protein SD1 is encoded in the cell by a first nucleotide sequence (S1) that includes a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of SD1; E. the human genome comprises a second nucleotide sequence (S2) that comprises SNP1 and encodes a second signaling domain (SD2), where SD2 is (i) identical to SD1 and comprises R1 or (ii) a naturally occurring variant of SD1 and comprises R1; F. S2 is a human endogenous genomic sequence and SNP1 is a non-synonymous SNP; and G. the human genome comprises S2 prior to said administration of immune cells; and H. A human immune cell, wherein the method treats or reduces the risk of a disease or condition in a human.

[0022] 1. A human immune cell for use in a method for treating or reducing the risk of a disease or condition (e.g., cancer or an autoimmune disease, e.g., as disclosed herein), the method comprising administering to a human patient an immune cell, the immune cell comprising a modified transmembrane protein, the protein comprising: A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. an intracellular portion comprising the first signaling domain; Includes; D. a first antigen or ligand domain of the variant protein is encoded in the cell by a first nucleotide sequence (S1) that includes a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of the antigen or ligand domain; E. the human genome comprises a second nucleotide sequence (S2) that comprises SNP1 and encodes a second antigen or ligand domain, the second antigen or ligand domain being (i) identical to the first antigen or ligand domain, respectively, and comprising R1, or (ii) a variant of a naturally occurring first antigen or ligand domain, respectively, and comprising R1; F. S2 is a human endogenous genomic sequence and SNP1 is a non-synonymous SNP; and G. the human genome comprises S2 prior to said administration of immune cells; and H. A human immune cell, wherein the method treats or reduces the risk of a disease or condition in a human.

[0023] In the eighth configuration: 1. A human immune cell comprising a modified transmembrane protein, Protein, A. an extracellular portion comprising one or more ligand binding domains or one or more ligand domains; B. A transmembrane portion; and C. an intracellular portion comprising the first signaling domain; Includes; D. The first signaling domain is a CD3 intracellular domain selected from the CD3 ζ (CD3 zeta) domain and the CD3 η (CD3 eta) domain, and is selected from V53, K54, F55, R57, S58, D60, Y64, Q65, Q68, L71, E74, L75, N76, L77, G78, R80, E81, Y83, L86, R89, G91, P94, E95, G98, K99, R102, Q107, G109, Y111, N112, E113, L114, Q11 5, K116, D117, K118, M119, E121, A122, Y123, S124, E125, I126, G127, G130, R134, G135, H138, D139, L141, Y142, Q143, G144, S146, T147, T149, K150, D151, D154, H157, M158, Q159, L161 and P162 (position numbers correspond to positions in SEQ ID NO:1); and E. the genome of the cell comprises an endogenous nucleotide sequence encoding a second signaling domain, the second domain being a CD3 ζ (CD3 zeta) domain or a CD3 η (CD3 eta) domain that comprises at least 40 (e.g., 45 or all) of the selected residues; Human immune cells.

[0024] 1. A human immune cell for use in a method for treating or reducing the risk of a disease or condition (e.g., cancer or an autoimmune disease, e.g., as disclosed herein), the method comprising administering to a human patient an immune cell, the immune cell comprising a modified transmembrane protein, the protein comprising: A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. an intracellular portion comprising the first signaling domain; Includes; D. The first signaling domain is a CD3 intracellular domain selected from the CD3 ζ (CD3 zeta) domain and the CD3 η (CD3 eta) domain, and is selected from V53, K54, F55, R57, S58, D60, Y64, Q65, Q68, L71, E74, L75, N76, L77, G78, R80, E81, Y83, L86, R89, G91, P94, E95, G98, K99, R102, Q107, G109, Y111, N112, E113, L114, Q11 5, K116, D117, K118, M119, E121, A122, Y123, S124, E125, I126, G127, G130, R134, G135, H138, D139, L141, Y142, Q143, G144, S146, T147, T149, K150, D151, D154, H157, M158, Q159, L161 and P162 (position numbers correspond to positions in SEQ ID NO:1); and E. the human genome comprises an endogenous nucleotide sequence encoding a second signaling domain, the second domain being a CD3 ζ (CD3 zeta) domain or a CD3 η (CD3 eta) domain that comprises at least 40 (e.g., 45 or all) of the selected residues; F. The method treats or reduces the risk of a disease or condition in a human; Human immune cells.

[0025] In the ninth configuration: 1. A human immune cell comprising a modified transmembrane protein, Protein, A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain (SD1); Includes; D. SD1 is a CD28 intracellular domain comprising at least 13, 14, 15, 16, 17 or 18 amino acid residues selected from the group consisting of R180, S181, K182, R183, S184, R185, L186, D190, Y191, N193, P196, P199, T202, K204, Q207, F215, A217 and Y218 (position numbers correspond to positions in SEQ ID NO: 13); and E. The genome of the cell comprises an endogenous nucleotide sequence encoding a second signaling domain (SD2), wherein SD2 is a CD28 intracellular domain that comprises at least 10 (or 11, 12, or 13) of the selected residues. Human immune cells.

[0026] 1. A human immune cell for use in a method for treating or reducing the risk of a disease or condition (e.g., cancer or an autoimmune disease, e.g., as disclosed herein), the method comprising administering to a human patient an immune cell, the immune cell comprising a modified transmembrane protein, the protein comprising: A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain (SD1); Includes; D. SD1 is a CD28 intracellular domain comprising at least 13, 14, 15, 16, 17 or 18 amino acid residues selected from the group consisting of R180, S181, K182, R183, S184, R185, L186, D190, Y191, N193, P196, P199, T202, K204, Q207, F215, A217 and Y218 (position numbers correspond to positions in SEQ ID NO: 13); E. the human genome comprises an endogenous nucleotide sequence encoding a second signaling domain (SD2), where SD2 is a CD28 intracellular domain that comprises at least 10 (or 11, 12, or 13) of the selected residues; and F. The method treats or reduces the risk of a disease or condition in a human; Human immune cells.

[0027] In the tenth configuration: 1. A human immune cell comprising a modified transmembrane protein, Protein, A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain (SD1); Includes; D. SD1 is a 4-1BB intracellular domain that includes at least 10, 11, 12, 13, 14 or all of the amino acid residues selected from the group consisting of R215, R217, K218, Y222, P227, M229, V232, Q236, D239, C241, R244, E247, E250, G252 and C253 (position numbers correspond to positions in SEQ ID NO: 16); and E. The genome of the cell comprises an endogenous nucleotide sequence encoding a second signaling domain (SD2), wherein SD2 is a 4-1BB intracellular domain that comprises at least 8 (or 9 or 10) of the selected residues. Human immune cells.

[0028] 1. A human immune cell for use in a method for treating or reducing the risk of a disease or condition (e.g., cancer or an autoimmune disease, e.g., as disclosed herein), the method comprising administering to a human patient an immune cell, the immune cell comprising a modified transmembrane protein, the protein comprising: A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain (SD1); Includes; D. SD1 is a 4-1BB intracellular domain that includes at least 10, 11, 12, 13, 14 or all of the residues selected from the group consisting of R215, R217, K218, Y222, P227, M229, V232, Q236, D239, C241, R244, E247, E250, G252 and C253 (position numbers correspond to positions in SEQ ID NO: 16); and E. the human genome comprises an endogenous nucleotide sequence encoding a second signaling domain (SD2), wherein SD2 is a 4-1BB intracellular domain that comprises at least 8 (or 9 or 10) of the selected residues; F. The method treats or reduces the risk of a disease or condition in a human; Human immune cells.

[0029] The invention also provides grafts, cell populations, kits and devices comprising the CAL immune cells and / or crosslinking agents of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] Detailed Description In its various aspects, the invention is based on the following considerations: · The use of relatively small, multispecific ligand-binding fragments to switch and control immunotherapy (in CAL cell immunity and CAR immune cell applications); The possibility to repurpose existing mAbs and Ig or non-Ig antigen-binding fragments in combination with immune cell-mediated activities, enabling new modalities based on, for example, FDA or EMA approved mAbs; · Provision of CAL cells as a new type of immune effector cell in vivo and ex vivo; The utility of in vivo CAR and CAL cell expansion to reduce the reliance on administration of polyspecific fragments with high toxicity levels as seen in the art; The utility of in vivo CAR and CAL cell expansion to reduce the reliance on long-term (e.g., continuous pump infusion) administration of polyspecific fragments as seen in the art; · Better tumor penetration potential of fragments as opposed to mAbs to address solid tumors; The possibility of utilizing tumor infiltrating lymphocytes (TILs) in combination with a fragment approach to address solid tumors, including the possibility of using low dose co-administration of immune upregulators such as IL-2; and Observing natural human polymorphic variation in the CAR and CAL binding domains, and adapting to genotypic and phenotypic variations in humans and human cells, to provide what the inventors call "precision immunotherapy".

[0031] The utility of polyspecific fragments The use of crosslinkers with multiple ligand binding sites according to the present invention allows the use of relatively small sized bispecific, trispecific and multispecific fragments (e.g., antibody-based fragments known in the art) with relatively short half-lives (much shorter than IgG, which has an average half-life of about 20 days in human serum). Thus, the present invention allows for rapid titration of the crosslinker that acts as a switch to induce signaling changes in the immune cells of the present invention. This provides a titratable method that allows for a convenient way to easily alter the activity of immune cells in immunotherapy, such as CAR cells (e.g., CAR T cells, CAR NK cells and CAR TIL cells) or CAL cells (e.g., CAL T cells, CAL NK cells and CAL TIL cells) administered to patients, thereby controlling potent therapy. This helps address concerns in the art of how to avoid unwanted overactivity of CAR cell therapy in patients. It may also be advantageous to use relatively small fragments as crosslinkers to allow for closer access between the target cells crosslinked according to the present invention and the immune cells.

[0032] Existing bispecific fragment technologies such as BiTE™ (Amgen) or other bispecific T cell binders can be readily used as cross-linking agents according to the present invention, thereby making the present invention convenient (especially where the agent is already FDA or EMA approved). One example is Blinatumomab (Amgen's Blincyto™), which has an scFv binding site for human CD3 delta linked to an scFv binding site for human CD19 (tumor associated antigen, TAA). Blinatumomab has been approved for certain cancer treatments where CD3 binding activates T cell killing of tumor cells.

[0033] Front Oncol. 2014;4:63; Published online 2014 Mar 31; doi:10.3389 / fonc.2014.00063; PMCID:PMC3978294; "Blinatumomab, a Bi-Specific Anti-CD19 / CD3 BiTER Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications"; Lindsey M. Hoffman and Lia Gore are referenced, which describes the relatively short half-life of this BiTE™ (approximately 2 hours) and the drug administration by continuous infusion via pump, which requires hospitalization. As exemplified by blinatumomab, it is recognized that therapy using such small fragments is hindered by the relatively short half-life of the drug, and in the case of linatumomab, to address this, large doses are administered to patients by implanted pumps that continuously pump the drug for 4 weeks.This is inconvenient because it requires the placement of the pump by medical staff and the patient is inconveniently connected to the pump for up to 24 hours a day during the treatment period.Furthermore, side effects of administering relatively large doses of multispecific fragments in general may occur.

[0034] Contrary to long-standing attitudes in the art, the present invention is instead actually useful in the approach of bispecific, trispecific and multispecific fragments with relatively short half-life. The inventors have realized that such agents can be used as easily controllable switches for finer control of activated T cells, NK cells, TILs, etc., to kill target cells. In particular, in one example, this allows for finer tuning of modified immune cell activity, such as ADCC-like activity, in patients, which was not previously possible with earlier CAR-T approaches. In doing so, the benefits of CAR cell-mediated and bispecific T cell engager (e.g., BiTE™)-mediated treatment of disease (e.g., cancer) can be realized in a more controlled manner than was previously possible. The advantage is therefore that immune cell-based therapy can be more easily tuned, opening up even greater possibilities for such breakthrough strategies. Also, the perceived undesirable consequences of small multispecific fragment therapy would be reduced, thereby allowing for the possibility of lower dosages of engager drugs and reduced reliance on continuous drug pumps over long periods of time, as currently seen with, for example, blinatumomab and other small multispecific fragment approaches.

[0035] Furthermore, rather than relying on sufficiently large amounts of the multispecific fragment in the patient to promote target cell killing, as in blinatumomab, the present invention can instead exploit the proliferation capacity of modified immune cells to provide enhanced killing or regulation of target cells. For this reason, the amount of crosslinker can be reduced in certain settings, thereby reducing the risk of side effects and off-target killing or undesired regulation of normal cells. The ability to use reduced amounts of crosslinker in the present invention can be advantageous in reducing undesired targeting of normal cells that also express low levels of the first target antigen. Therefore, the present invention can be particularly useful when the first antigen is present at higher levels on target (e.g., tumor) cells than on normal cells, since the stringency of targeting can be controlled to some extent by less titration of the crosslinker. As the invention is based on the possibility of cell-mediated cytotoxicity (e.g. ADCC-like activity) by the immune cells of the invention, with fragments such as blinatumomab, whose activity has been suggested to be dependent on continuous lysis (requiring continuous drug administration), it may be possible using the invention to instead break the dependency on such mechanisms, the effect of which could benefit from the ability of immune cell expansion in the patient.

[0036] Chimeric antigen ligand receptor (CAL) and CAL-immune cells It is recognized that the present invention not only finds utility in the approach of short half-life fragments to provide CAL-immune cells and their uses, but also departs from conventional approaches in certain configurations by swapping antigen ligand / binding site pairs. Prior art CAR-T and CAR-NK approaches rely on providing an antigen binding site as an extracellular feature of the immune cell's "chimeric antigen receptor" (CAR). In contrast, the present invention relies on providing the antigen ligand itself as a cell surface feature of the immune cell, with the binding site instead being placed on a crosslinker. This not only conveniently offers the advantage of using pre-made multispecific fragments (as described above), but also advantageously allows the use of self-antigens as the extracellular antigens of the immune cell's signaling complex (e.g., self-versions of the CD3 extracellular domain or other domains normally found on T cells, NK cells or other relevant immune cells in humans). The inventors refer to these as "chimeric antigen ligands" (CALs) to distinguish them from CARs. Exemplary immune cells of the present invention are CAL T cells, CAL NK cells and CAL TIL cells. The ability to use self-antigens reduces the risk that CAL cells will be targeted and eliminated by the patient's immune system, which has utility for autologous or allogeneic cell transplants. In CAR cells, the antigen-binding site of the receptor contains immunogenic epitopes, so there is a risk that it may be a target of the patient's own immune system, thereby reducing efficiency. The use of CALs allows extracellular antigens to be provided by a type of protein (e.g., CD3 gamma, delta, or epsilon) that is naturally present on the surface of the patient's immune cells (e.g., T cells), which may be useful for compatibility with the patient. Knockout of nucleotide sequences in CAL cells can be used to prevent expression of one or more endogenous domains or proteins of the TCR-CD3 signaling complex, thereby directing signaling instead to the CALs of the invention (or the CAR cells for other configurations of the invention that use CAR cells with crosslinking agents).

[0037] Crosslinking Agent The present invention has a further advantage: the binding affinity of the crosslinker to the CAL can be adjusted to modulate the cytotoxicity or other control caused by the modified immune cells. In conventional CAR-T approaches, the binding interaction is determined by the need to generate a relatively high binding affinity of the extracellular binding site of the CAR to its target antigen on the tumor cell. However, in the approach of the present invention, this consideration is transferred to the first binding site of the crosslinker (the first binding moiety in the fifth and sixth configurations of the present invention), and thus, for example, one is free to select an appropriate affinity that binds strongly to the tumor cell. This allows flexibility in the binding interaction between the second binding site of the crosslinker (the second binding moiety in the fifth and sixth configurations of the present invention) and the second target antigen contained in the CAL (the third binding moiety in the fifth and sixth configurations of the present invention, contained in a transmembrane protein). Therefore, since the modified immune cells proliferate and are activated when crosslinked to the target cell, one can select, for example, a binding strength (e.g., a moderate KD and / or a moderate Koff) to lower or increase the activity of the modified immune cells. Thus, the present invention allows the skilled artisan to purposefully balance half-life and binding affinity for the situation at hand, allowing finer adjustment than was possible with conventional CAR-T approaches. The binding affinity at the two binding sites of the drug is balanced, which allows finer adjustment than selecting the affinity of only one binding site (as with CARs). The use of fragments according to the present invention (such as those containing antibody or non-Ig scaffold domains, which are advantageously modular and easily and cheaply produced by E. coli and other systems) provides a straightforward method for tuning binding affinity, since it allows the use of repertoire selection techniques such as phage or yeast display of binding members, which are convenient and well developed in the art. The present invention is also suitable for using the binding sites of existing well-established monoclonal antibody therapeutics that have been approved and shown to be tolerated by patients.By combining one or more of such binding sites (e.g., binding sites from a first and second, different antibodies) with a CAL binding site (or with a ligand to which a CAR specifically binds), suitable bispecific or trispecific crosslinkers can be generated whose specific affinities are purposely designed for the therapeutic setting at hand. Trispecifics (or higher order multispecifics) are useful, for example, for targeting at least two different cell surface targets on a target cell (e.g., a tumor cell) that are not included on normal cells or are present together at lower levels than on tumor cells. The invention thus provides such crosslinkers in combination with engineered immune cells and uses for treating or reducing the risk of a disease or condition described herein.

[0038] Furthermore, unlike the ACTR approach, which relies on the co-administration of bulky IgG, the present invention allows the use of much smaller binding fragments, so that the molecular weight of the cross-linker can be selected to be much smaller than that of IgG (which is 150 kDa). This also offers the possibility of smaller quantities for patient dosing and potentially lower commodity prices for producing the cross-linker. The closer proximity of the cross-linking cells mentioned above and the ease of production by bacteria (e.g., E. coli) or yeast (e.g., Pichia) are further advantages over the ACTR approach using IgG.

[0039] Exemplary binding fragment sizes are shown in the table below. A binding agent of the invention can be any multispecific binding fragment shown in the table or including any such fragment, where the agent has a size less than an Ig. For example, the molecular weight of the agent is less than 125, 120, 115, 110, 100, 90, 80, 70, 60, 50, or 40 kDa.

[0040] [Table 1] * Indicates the size range in which the fragments were found

[0041] See the figures in "Multivalent antibodies: when design surpasses evolution," Angel M. Cuesta et al., Cell, Vol. 28, No. 7, p. 355-362, July 2010, which is incorporated herein by reference.

[0042] Treatment of solid tumors and tumor infiltrating lymphocytes (TIL) In one embodiment, an advantage of the present invention exploits the tumor-penetrating capabilities of small multispecific binding fragments, which are useful, for example, for treating solid tumors. Such fragments, such as scFv-based fragments, retain the binding specificity of the parent antibody and offer several advantages over full-length mAbs. For example, these fragments can penetrate tumors more rapidly compared to intact antibodies (see, e.g., Chowdhury, P.S.; Viner, J.L.; Beers, R.; Pastan, I. "Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumour activity", Proc. National. Acad. Sci. USA 1998, 95, 669-674; and Deckert, P.M. "Current constructs and targets in clinical development for antibody-based cancer therapy", Curr. Drug Targets 2009, 10, 158-175).It has been argued that the optimal tumor-targeting fragment is a diabody (55-60 kDa) that combines high tissue penetration, target retention and rapid blood clearance (Robinson, MK et al., "Quantitative immuno-positron emission tomography imaging of HER2-positive tumour xenografts with an iodine-124 labeled anti-HER2 diabody," Cancer Res. 2005, 65, 1471-1478; and Sundaresan, G et al., "124I-labeled engineered anti-CEAcea minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice." "The small size of the fragments is a desirable property for tissue penetration, such as in cancer therapy, but also results in a short in vivo half-life, limiting the exposure of the target molecule to the fragments. In the present invention, the relatively short half-life is advantageously used to allow for finer switching of immunotherapy. Without being bound to any particular theory, in vivo capture of the crosslinker by the immune cells of the present invention at the site of the cancer cells can extend the persistence of the drug in the cancer microenvironment, thus compensating for the generally low systemic half-life. For similar reasons, it is useful in some embodiments to use TILs as the basis for the immune cells of the present invention, since these types of cells have been shown to infiltrate solid tumors, which, together with the captured crosslinker, can be beneficial for treating solid tumors using the present invention. Thus, in one embodiment, the immune cells of the present invention are TILs for treating or preventing solid tumors in patients (e.g., humans).Exemplary agents for use with such TILs (or grafts containing a plurality of such TILs) are bi- and trispecific antigen-binding fragments comprising two or three scFv binding sites. As further described below, the advantages of existing mAb solid tumor therapies can be recapitulated in the present invention by using the antibody VH / VL binding sites of such mAbs as the first binding site (or first binding moiety) of the crosslinker of the invention (e.g., provided as an scFv). Thus, the present invention provides immune cells of the invention (e.g., CAL-TILs or CAR-TILs) in combination with the crosslinker of the invention (either mixed together or separately contained in a kit) for treating or preventing solid tumors in patients (e.g., humans), where the binding sites of the agent are scFv binding sites, optionally linked by a linker.

[0043] In examples of these aspects of the invention (or any other aspect herein), the agent is a diabody (e.g., size=55-65 kDa), a triabody (e.g., size=85-95 kDa), or a tetrabody (e.g., size=115-125 kDa). Diabodies have better tumor-blood ratios and outperform monomeric scFvs (Appl Microbiol Biotechnol 2013 May;97(9):3855-63.doi:10.1007 / s00253-012-4632-9 Epub 2012 Dec 19, "Production and characterization of a CD25-specific scFv-Fc antibody secreted from Pichia pastoris", Wan L et al.). Therefore, recombinant antibodies of 60-100 kDa have been found to exhibit efficient tumor penetration and fast circulatory clearance compared to intact antibodies, and are therefore well suited for in vivo tumor targeting. Therefore, in the examples of any embodiment herein, the size of the agent is 60-100 kDa.

[0044] In alternative examples, the CAL cell(s) are CAL T cells or CAL NK cells or a mixture of two or three of CAL TILs, CAR T cells and CAR NK cells. In alternative examples, the CAR cell(s) are CAR T cells or CAR NK cells or a mixture of two or three of CAL TILs, CAR T cells and CAR NK cells.

[0045] Solid tumors are composed of various components, including malignant cells and endothelial structures and immune cells. Cancer cells can shape the microenvironment to meet their unique metabolic and immunological needs. In contrast, tumor infiltrating lymphocytes (TILs) are recruited into the tumor in an attempt to control its growth. Accumulating evidence shows that the amount of TILs at diagnosis is associated with prognosis. TILs from a patient can be engineered to be used as a therapy for that patient's cancer.

[0046] Adoptive cell therapy (ACT) with TILs is an effective strategy for the treatment of cancers such as metastatic melanoma. This technique involves the generation of TIL cultures from a patient's melanoma biopsy and the rapid expansion of lymphocytes that exhibit high antitumor activity in interleukin-2 (IL-2)-containing medium. The TILs are then reintroduced into the same patient in the presence of high doses of IL-2 after lymphodepletion. Despite being described more than a decade ago, ACT with TILs using lymphodepletion has not been as widely utilized as would be expected given its apparent efficacy. A contributing factor to this may be the toxicity associated with high doses of IL-2, which is generally transient but can be severe.

[0047] Thus, in one embodiment, the immune cells of the invention (e.g., CAL immune cells or CAR immune cells) are TILs. In one example, the invention provides a method of treating or reducing the risk of cancer (e.g., solid tumor or melanoma) in a patient (e.g., a human), comprising administering to the human a CAR or CAR TIL and a crosslinking agent of the invention, and optionally IL-2. In one example, the method comprises administering to the human an autologous or allogeneic TIL graft, the graft comprising a plurality of CAL-TILs or CAR-TILs of the invention. By using such TIL therapy, which has the potential for in vivo cell proliferation and cytotoxicity directed against cancer cells, the invention, in one example, provides for the use of lower doses of IL-2 than previously used. Thus, in one example, a low or intermediate dose of IL-2 (as would be understood by one skilled in the art of trastuzumab testing) is administered to the human. In one example, a low dose of IL-2 is 1 million IU / m(2) or less per day. In one example, the IL-2 is administered subcutaneously (SC). Alternatively, or in addition to administering IL-2, one, two, or all of IL-12, IL-15, and IL-21 are administered to the human (eg, as low doses).For example, preclinical studies with low and intermediate IL-2 doses: Breast cancer Res Treat. 2009 Sep;117(1):83-9. doi:10.1007 / s10549-008-0251-7. Epub 2008 Dec 3, "A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with METASTATIC breast cancer (MBC) who have previously failed trastuzumab", Mani A et al; and J Immunother cancer. 2014;2(Suppl 3): Online Published 2014 Nov See 6. doi:10.1186 / 2051-1426-2-S3-P1, PMCID:PMC4288376, "Adoptive cell therapy with tumour infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma", Rikke Andersen et al. In an embodiment of the TIL-based method of the invention, the method treats or reduces the risk of cancer in a patient (e.g., a human), and the patient has undergone lymphodepletion prior to administration of the immune cell(s) of the invention to the patient.

[0048] Targeting Triple Negative Breast Cancer (TNBC) & HER2 with Crosslinkers Several studies support the suggestion that breast cancer is immunogenic. Data from adjuvant trials in triple-negative breast cancer (TNBC) were used to investigate the prognostic impact of TILs in TNBC and their association with the benefit of trastuzumab in HER2-overexpressing disease. There was a positive correlation between the amount of TILs present at diagnosis and the amount of TILs present at prognosis in TNBC. There was also an interaction between higher levels of TILs and increased benefit from trastuzumab. Thus, in one example, the first antigen is HER2 (or it is the fourth binding moiety of the fifth and sixth configurations). In one example, the first binding site (first binding moiety of the fifth and sixth configurations) comprises a VH / VL binding site of Trastuzumab or Herceptin™, e.g., the binding agent comprises a first scFv, the scFv binds HER2 (the first antigen, or fourth binding moiety) and comprises a VH-linker-VL, where VH and VL are variable domains of Trastuzumab or Herceptin™. In one example, the linker of any scFv herein is (G4S) n linker, where n=2 or more (e.g., 3, 4, 5, or 6). In one example, the immune cells (e.g., CAL cells or CAR-TILs or CAL-TILs of the invention) or the method of the invention are for treating or reducing the risk of breast cancer in a human (e.g., triple-negative breast cancer). In one example, the method includes administering a cell graft to a human, the graft being autologous or allogeneic and comprising a plurality of TILs of the invention and a crosslinker of the invention, the first binding site (first binding moiety) of the crosslinker specifically binds HER2, e.g., the first binding site (first binding moiety) comprises the VH / VL binding site of Trastuzumab or Herceptin™, e.g., provided as an scFv as described above.

[0049] In one example, an embodiment provides a CAL-TIL (or CAL-T or CAL-NK) of the invention for use in a method of treating or reducing the risk of breast cancer (e.g., triple negative breast cancer) in a human, wherein a first antigen is HER2, and optionally a first binding site of the crosslinker comprises a VH / VL binding site of Trastuzumab or Herceptin™, the method comprising administering to the human the CAL cells and the crosslinker, wherein the breast cancer is treated or the risk of breast cancer is reduced.

[0050] In one example, the binding agent comprises an scFv anti-HER2 binding site, optionally wherein the scFv comprises a VH-linker-VL, where VH and VL are variable domains of the binding site of Trastuzumab or Herceptin™. In one example, the second binding site of the binding agent specifically binds the human CD3 extracellular domain or the CD16 (e.g., CD16A) extracellular domain.

[0051] In one example, the CAL cells of the invention are included in a graft comprising a plurality of CAL-TIL (or CAL-T, or CAL-NK) cells of the invention, and the graft is administered to a human to treat or prevent a disease (e.g., cancer, autoimmune disease, transplant rejection for GvHD), or the cells or graft are intended for such use.

[0052] In one example, the human is female or male.

[0053] In one example, the patient or human has undergone lymphodepletion prior to administration of the immune cells (eg, CAL cells) of the invention.

[0054] Techniques for generating CAR and CAR T cells are well known and routine in the art and are generally applicable to the generation of CAL and CAL-cells of the invention (see, for example, WO2012079000A1; J Immunother. 2009 Sep; 32(7): 689-702, doi: 10.1097 / CJI.0b013e3181ac6138, "Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor", James N. Kochenderfer et al.; see also WO 2014012001 for general methods applicable to the present invention). For example, electroporation, the use of retroviral or lentiviral vectors can be used to introduce nucleotide sequences encoding the CAL elements of the invention into T cells, NK cells, TILs or other immune cells to generate the CAL cells of the invention, as known by the skilled artisan. Cells isolated from the patient (autologous cell sample) or from another donor (allogeneic sample) can be used to provide the progenitor cells that are genetically modified to contain the CAL coding sequence. As is known in the art, proliferation of the cells can be used in the process. For example, after modifying the CAL cells, the cell population can be expanded on a large scale using conventional techniques to generate a graft that is administered (e.g., injected) to the patient. The patient can be a human or a non-human animal. One or more nucleotide sequences of the CAL elements (e.g., of the second antigen and / or the first signaling domain) can be cloned or sequenced using cells obtained from the patient or another donor.

[0055] Domain Mutation and Adaptation In embodiments of the fifth and sixth configurations, the second binding moiety is a ligand (e.g., an antigen) and the third moiety is a ligand receptor or binding site (e.g., at a VH / VL binding site), e.g., the immune cell is a CAR cell. In advantageous embodiments, the sequence of the second binding moiety is SNP-matched for one or more non-synonymous SNPs naturally found in humans in the coding sequence of the second moiety.

[0056] In advantageous embodiments of the first to fourth configurations of the CAL, the second antigen sequence is SNP-matched for one or more non-synonymous SNPs found in humans (e.g., with reference to one or more SNPs naturally found in the human CD3 extracellular domain) in the coding sequence of the second antigen.

[0057] Suitable databases for evaluating and identifying SNPs are known to those skilled in the art, such as Ensembl and the 1000 Genomes database. With reference to mutations at a particular nucleotide position in an expressible sequence, the skilled artisan knows that a "non-synonymous SNP" at a particular nucleotide position is a single nucleotide polymorphism at that position where the natural mutation results in a different amino acid residue in the encoded protein sequence. Consideration of one or more SNP mutations or corresponding amino acid changes in the second binding portion of the crosslinker (fifth and sixth configurations of the invention) or the second antigen of the CAL extracellular domain (first to fourth configurations) is useful to tailor this element of the agent or CAL to reflect the natural SNP mutations in the equivalent protein encoded by the immune cell of the invention (or its ancestor cell from which it descends) and / or encoded by the patient's genome. This is particularly useful when the genome of the patient receiving the immune cells (or cell transplant) of the invention encodes such adapted SNP(s), which then increases the compatibility of the crosslinker (in configurations 5 and 6) or the extracellular portion of the CAL (in configurations 1 to 4) with the patient's immune system (and this may be useful to reduce an immune response to the agent or CAL that may otherwise reduce its usefulness). In an advantageous embodiment, the patient expresses a second binding moiety (in configurations 5 and 6) or a second antigen (in configurations 1 to 4), i.e. a protein whose amino acid sequence is identical to the amino acid sequence of the second portion of such agent or the second antigen of the CAL. Thus, for example, the second binding moiety (in configurations 5 and 6) or the second antigen (in configurations 1 to 4) is a CD3 gamma, delta or epsilon domain, and the recipient of the agent and immune cells according to the invention expresses the adapted CD3 gamma, delta or epsilon domain, respectively.

[0058] Similarly, aspects of the invention adapt the intracellular signaling domain(s) of a transmembrane protein (e.g., CAR or CAL) to help optimize performance in an engineered immune cell. In this case, a SNP match is used between (i) the nucleotide sequence (e.g., a non-endogenous sequence introduced in a lentiviral or retroviral vector) encoding the first (or each) signaling domain of the transmembrane protein and (ii) the endogenous nucleotide sequence of the cell encoding such signaling domain. By such matching, the signaling domain is also matched with other components of the endogenous signaling cascade in the cell to optimize performance. "Endogenous" as used herein refers to any naturally occurring material found in, derived from, or generated within an organism, cell, tissue, or system, e.g., found in unmodified cells of a patient having or being administered immune cells (e.g., CAR or CAL cells) according to the invention or from a donor from which the immune cells are derived.

[0059] For example, the first signaling domain is a human CD3 ζ domain, and the cell of the invention is a human cell comprising an endogenous nucleotide sequence encoding said human CD3 ζ domain. In one example, the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO: 24 disclosed in WO2012079000A1, which sequence is expressly incorporated herein for use in the present invention and for inclusion, if possible, in one or more claims herein. In one example, the CD3 zeta signaling domain is encoded by the nucleic acid sequence of SEQ ID NO: 18 disclosed in WO2012079000A1, which sequence is expressly incorporated herein for use in the present invention and for inclusion, if possible, in one or more claims herein.

[0060] For example, the first signaling domain is a human CD28 domain and the cell of the invention is a human cell that comprises an endogenous nucleotide sequence encoding said human CD28 domain.

[0061] For example, the first signaling domain is a human 4-1BB domain and the cell of the invention is a human cell that comprises an endogenous nucleotide sequence encoding said human 4-1BB domain.

[0062] For example, the first signaling domain is a human OX40 domain and the cell of the invention is a human cell that comprises an endogenous nucleotide sequence encoding said human OX40 domain.

[0063] In one example, when the second binding moiety (fifth and sixth configurations) or the second antigen (first through fourth configurations) is a CD3 gamma, delta or epsilon domain and the first signaling domain is a CD3 zeta domain, the moiety / antigen and domain do not naturally occur together in a single cell (e.g., a human wild-type cell or a cell isolated from a patient). In another example, when the second binding moiety or the second antigen is a CD3 gamma, delta or epsilon domain and the first signaling domain is a CD3 zeta domain, the transmembrane protein (e.g., a CAL or CAR) comprises an additional domain that is not a CD3 domain, e.g., the additional domain is a CD28, CD27, OX40 or 4-1BB domain.

[0064] In one example, the first intracellular domain is a CD3 zeta domain, a CD28 domain or a 4-1BB domain disclosed in the sequence listing herein.

[0065] (A): In one example, the CAL is a modified single polypeptide comprising (from N-terminus to C-terminus) a human CD3 extracellular domain; an optional hinge (e.g., a human CD8α hinge); a transmembrane domain (e.g., a human CD8α or CD28 transmembrane domain); and a human CD3ζ domain. In one example, the CAL is a complex of two or more of the above polypeptides. Optionally, the CAL comprises (i) an additional intracellular signaling domain between the transmembrane domain and the CD3ζ domain. Optionally, the CAL comprises an additional intracellular signaling domain, the CD3ζ domain being between the additional signaling domain and the transmembrane domain. In one example, the additional signaling domain is a human CD27 domain, CD28 domain, ICOS domain, OX40 domain, CD40 domain, 4-1BB domain, FcεRIγ domain, CD64 domain, or CD16 domain. In an alternative example, instead of a single polypeptide, the CAL comprises a modified complex of at least two polypeptides comprising the above domains. In an alternative example, when a CAR is used in the present invention, the CAR is identical to such a CAL, except that the CAR has an antigen binding site in place of the CD3 extracellular domain.

[0066] (B): In one example, the CAL is a modified single polypeptide comprising (from N-terminus to C-terminus) a human CD16 (e.g., CD16A) extracellular domain; an optional hinge (e.g., human CD8α hinge); a transmembrane domain (e.g., human CD8α transmembrane domain); and a human CD3ζ domain. In one example, the CAL is a complex of two or more of the above polypeptides. Optionally, the CAL comprises (i) an additional intracellular signaling domain between the transmembrane domain and the CD3ζ domain. Optionally, the CAL comprises an additional intracellular signaling domain, the CD3ζ domain being between the additional signaling domain and the transmembrane domain. In one example, the additional signaling domain is a human CD27 domain, CD28 domain, ICOS domain, OX40 domain, CD40 domain, 4-1BB domain, FcεRIγ domain, CD64 domain, or CD3 domain. In an alternative example, instead of a single polypeptide, the CAL comprises a modified complex of at least two polypeptides comprising the above domains. In an alternative example, when a CAR is used in the present invention, the CAR is identical to such a CAL, except that the CAR has an antigen binding site in place of the CD16 extracellular domain.

[0067] (C): In one embodiment, the CAL is a complex of two or more polypeptides, a first said CAL polypeptide is according to (A) and a second said polypeptide is a CAL polypeptide according to (B). In another embodiment, the CAR is a complex of two or more polypeptides, a first said CAL polypeptide is according to (A) and a second said polypeptide is a CAR polypeptide according to (B).

[0068] In one example, CAL cells do not express the second antigen or its naturally occurring variant from the endogenous nucleotide sequence of the cell. For example, the endogenous sequence is inactivated in the cell, for example, by being knocked out in whole or in part, or by mutation. For example, the mutation is the product of CRISPR / Cas-mediated genome modification. By removing the possibility of expressing an endogenous second antigen (e.g., CD3 extracellular domain), all binding of the second antigen is directed to the induction of CALs (and not to any endogenous receptor complex, such as the endogenous TCR-CD3 complex), which may otherwise compete for binding to the crosslinker.

[0069] In one embodiment, the immune cells (e.g., CAR cells or CAL cells) of the present invention are administered in combination with an immunosuppressant. Any immunosuppressant known in the art may be used. For example, the immunosuppressant may be cyclosporine, azathioprine, rapamycin, mycophenolate mofetil, mycophenolic acid, prednisone, sirolimus, basiliximab, or daclizumab, or any combination thereof.

[0070] Additional or alternative immunosuppressive agents that may be used include, but are not limited to, ORTHOCLONE OKT™3 (muromonab-CD3), SANDIMMUNE™, NEORAL™, SANGDYA™ (cyclosporine), PROGRAF™ (FK506, tacrolimus), CELLCEPT™ (mycophenolate mofetil, whose active metabolite is mycophenolic acid), IMURAN™ (azathioprine), glucocorticoids, corticosteroids such as DELTASONE™ (prednisone) and HYDELTRASOL™ (prednisolone), FOLEX™ and MEXATE™ (methotrexate), OXSORALEN-ULTRA™ (methoxsalen), RITUXAN™ (rituximab), and RAPAMUNE™ (sirolimus).

[0071] The immune cells of the invention can be administered to the patient before, after, or simultaneously with the immunosuppressant agent. For example, the cells of the invention can be administered after the immunosuppressant agent is administered to the patient, or the cells of the invention can be administered before the immunosuppressant agent is administered to the patient. Alternatively, or in addition, the cells of the invention are administered at the same time that the immunosuppressant agent is administered to the patient.

[0072] The immune cells and / or immunosuppressants of the present invention can be administered to a patient after organ or tissue transplantation. Alternatively, or in addition, the immune cells and / or immunosuppressants of the present invention can be administered to a patient prior to transplantation. The immune cells and / or immunosuppressants of the present invention can also be administered to a patient during transplant surgery.

[0073] In some embodiments, the method of the invention of administering immune cells to a patient is performed after immunosuppressive therapy has been initiated. In some embodiments, the method is performed multiple times, e.g., to monitor the transplant recipient over time and, if applicable, under different immunosuppressive therapy regimes. In some embodiments, if the transplant recipient is predicted to tolerate the graft, immunosuppressive therapy is reduced. In some embodiments, if the transplant recipient is predicted to tolerate the graft, immunosuppressive therapy is not administered, e.g., immunosuppressive therapy is stopped. If the transplant recipient exhibits a non-tolerant biomarker signature, immunosuppressive therapy can be resumed or continued at standard levels.

[0074] The organ or tissue transplant can be a heart, heart valve, lung, kidney, liver, pancreas, small intestine, skin, blood vessels, bone marrow, stem cells, bone, or pancreatic islet cells.

[0075] The immune cells of the present invention can be administered either alone or as a pharmaceutical composition in combination with other components or cell populations, such as diluents and / or IL-2 or other cytokines.

[0076] Tumor antigens (TAA) are proteins produced by tumor cells that elicit an immune response, particularly a T cell-mediated immune response. The selection of the first antigen-binding specificity of the crosslinker of the invention depends on the particular type of cancer to be treated. Tumor antigens are known in the art and include, for example, glioma-associated antigen, carcinoembryonic antigen (CEA), beta human chorionic gonadotropin, alpha fetoprotein (AFP), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostase, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-la, p53, prostein, PSMA, Her2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrin B2, CD22, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor and mesothelin. The first antigen (first to fourth configurations of the present invention) or the fourth binding moiety (fifth or sixth configuration) may be any of these TAAs, or may be an antigenic sequence of any of these TAAs.

[0077] In one embodiment, the tumor antigen comprises one or more antigenic cancer epitopes associated with malignant tumors. Malignant tumors express several proteins that can serve as target antigens for immune attack. These molecules include, but are not limited to, tissue-specific antigens such as MART-1, tyrosinase and GP 100 in melanoma and prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) in prostate cancer. Other target molecules belong to the group of transformation-associated molecules such as the oncogene HER-2 / Neu ErbB-2. Yet another group of target antigens are tumor-embryo antigens such as carcinoembryonic antigen (CEA). In B-cell lymphomas, tumor-specific idiotypic immunoglobulins constitute truly tumor-specific immunoglobulin antigens that are unique to individual tumors. B-cell differentiation antigens such as CD 19, CD20 and CD37 are other candidates for target antigens in B-cell lymphomas. Several of these antigens (CEA, HER-2, CD19, CD20, idiotypes) have been used as targets for passive immunotherapy using monoclonal antibodies with limited success. The first antigen or fourth binding moiety may be any of these TAAs or may be an antigenic sequence of any of these TAAs.

[0078] Non-limiting examples of TAA antigens include: differentiation antigens such as MART-I / Melan-A (MART-1), gIOO (Pmel 17), tyrosinase, TRP-1, TRP-2, and tumor-specific multilineage antigens such as MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, pi 5; overexpressed embryonic antigens such as CEA; overexpressed oncogenes and mutated tumor suppressor genes such as p53, Ras, HER-2 / neu; unique tumor antigens resulting from chromosomal translocations; BCR-ABL, E2A-PRL, H4-RET, 1GH-IGK, MYL-RAR, etc.; and viral antigens such as Epstein-Barr virus antigen EBVA and human papillomavirus (HPV) antigens E6 and E7. Other large protein-based antigens include TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, pl85erbB2, pl80erbB-3, c-met, nm-23HI, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, k-ras, β-catenin, CDK4, Mum-1, p15, p16, 43-9F, 5T4(791Tgp72) alpha-fetoprotein, beta-HCG, BCA225, BTAA, CA 125, CA 15-3 / CA 27.29 / BCAA, CA 195, CA 242, CA-50, CAM43, CD68 / I, CO-029, FGF-5, G250, Ga733VEpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV 18, NB / 70K, NY-CO-1, RCAS 1, SDCCAG16, TA-90 / Mac-2 binding protein cyclophilin C binding protein, TAAL6, TAG72, TLP, and TPS.

[0079] In one embodiment, the first antigen or fourth binding moiety is human CD 19 and the first antigen binding site or first binding moiety of the cross-linker is an anti-CD19 scFV, optionally encoded by SEQ ID NO: 14 as disclosed in WO2012079000A1. In one embodiment, the anti-CD 19 scFV comprises the amino acid sequence of SEQ ID NO: 20. The sequences of this paragraph are found in WO2012079000A1 and are expressly incorporated herein for use in the present invention in the cross-linker and for inclusion, where possible, in one or more claims herein.

[0080] In one embodiment, a transmembrane domain that is naturally associated with one of the domains in the CAR or CAL is used. In some instances, the transmembrane domain may be selected or modified by amino acid substitution to avoid binding of such domains to transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.

[0081] The transmembrane domain can be derived from either natural or synthetic sources. If the source is natural, the domain can be derived from any membrane-bound or transmembrane protein. The transmembrane region of particular use in the present invention can be derived from (i.e., including at least the transmembrane region(s) thereof) the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CDS, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 or CD154. Alternatively, the transmembrane domain can be synthetic, in which case it contains mainly hydrophobic residues such as leucine and valine.

[0082] Optionally, a triplet of phenylalanine, tryptophan and valine is found at each end of the synthetic transmembrane domain.

[0083] Optionally, a short oligo- or polypeptide linker, preferably 2-10 amino acids in length, forms the linkage between the transmembrane domain and the intracellular portion of the transmembrane protein (e.g., CAL or CAR). A glycine-serine doublet is a particularly suitable linker (e.g., the (G4S) doublet disclosed herein). n linker).

[0084] Optionally, the transmembrane domain is a CD8 transmembrane domain encoded by the nucleic acid sequence of SEQ ID NO: 16. In one embodiment, the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 22. The sequences in this paragraph are found in WO2012079000A1 and are expressly incorporated herein for use in the present invention as cross-linking agents and for inclusion where possible in one or more claims herein.

[0085] In some cases, the transmembrane domain comprises a CD8 hinge domain encoded by the nucleic acid sequence of SEQ ID NO: 15. In one embodiment, the CD8 hinge domain comprises the amino acid sequence of SEQ ID NO: 21. The sequences in this paragraph are found in WO2012079000A1 and are expressly incorporated herein for use in the present invention as cross-linking agents and for inclusion where possible in one or more claims herein.

[0086] The intracellular portion or otherwise the intracellular signaling domain(s) of the transmembrane protein of the present invention is involved in the activation of at least one of the normal effector functions of immune cells expressing the transmembrane protein (e.g., CAL or CAR). The term "effector function" refers to a specialized function of a cell. The effector function of a T cell can be, for example, cytolytic activity or helper activity, including secretion of cytokines. Thus, the term "intracellular signaling domain" refers to the portion of the protein that transmits the effector function signal and directs the cell to carry out a specialized function. Usually, the entire intracellular signaling domain can be used, but in many cases it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such a truncated portion may be used in place of the intact chain, so long as it transmits the effector function signal. The term "signaling domain" is therefore meant to include any truncated portion of the intracellular signaling domain sufficient to transmit the effector function signal. Examples of intracellular signaling domains for use in the transmembrane proteins of the invention include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen receptor binding, as well as any derivatives or variants of these sequences and any synthetic sequences having the same functional capability.

[0087] It is known that signals generated solely through the TCR are insufficient for full activation of T cells, and that secondary or costimulatory signals are also required. Therefore, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation via the TCR (primary cytoplasmic signaling domains) and those that act antigen-independently to provide secondary or costimulatory signals (secondary cytoplasmic signaling domains). Primary cytoplasmic signaling sequences regulate the primary activation of the TCR complex either stimulatory or inhibitory. Primary cytoplasmic signaling sequences that act in a stimulatory manner may contain signaling motifs known as immunoreceptor tyrosine-based activation motifs or ITAMs.

[0088] In one example, the first signaling domain is a primary cytoplasmic signaling domain (e.g., a CD3 zeta domain). In one example, the first signaling domain is a secondary cytoplasmic signaling domain (e.g., a CD28 or 4-1BB domain).

[0089] In one example, the first signaling domain comprises one or more ITAMs.

[0090] Examples of suitable ITAMs containing primary cytoplasmic signaling domains that are particularly useful in the present invention include those derived from TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CDS, CD22, CD79a, CD79b, and CD66d. It is particularly preferred that the cytoplasmic signaling molecule in the transmembrane protein of the present invention comprises a cytoplasmic signaling sequence derived from CD3 zeta.

[0091] The intracellular portion optionally includes a domain of a costimulatory molecule (e.g., as the first signaling domain or further intracellular domain). A costimulatory molecule is a cell surface molecule other than an antigen receptor or its ligand that is required for an efficient response of lymphocytes (e.g., T cells or NK cells) to antigens. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83. Thus, these and other costimulatory elements are within the scope of the present invention for use in the intracellular portion of a transmembrane protein.

[0092] The domain of the intracellular portion may be linked with one or more linkers, such as those disclosed herein (G4S) n They may be linked to each other by a linker.

[0093] In one embodiment, the intracellular portion comprises the signaling domain of CD3 zeta and the signaling domain of CD28. In another embodiment, the intracellular portion comprises the signaling domain of CD3 zeta and the signaling domain of 4-1BB. In yet another embodiment, the intracellular portion comprises the signaling domain of CD3 zeta and the signaling domains of CD28 and 4-1BB.

[0094] In one embodiment, the intracellular V comprises the signaling domain of 4-1BB and the signaling domain of CD3 zeta, wherein the signaling domain of 4-1BB is encoded by the nucleic acid sequence set forth in SEQ ID NO: 17 and the signaling domain of CD3 zeta is encoded by the nucleic acid sequence set forth in SEQ ID NO: 18. The sequences of this paragraph are found in WO2012079000A1 and are expressly incorporated herein for use in the present invention as cross-linking agents and for inclusion where possible in one or more claims herein.

[0095] In one embodiment, the intracellular portion comprises the signaling domain of 4-1BB and the signaling domain of CD3 Zeta, wherein the signaling domain of 4-1BB comprises the amino acid sequence of SEQ ID NO: 23 and the signaling domain of CD3 Zeta comprises the amino acid sequence of SEQ ID NO: 24. The sequences of this paragraph are found in WO2012079000A1 and are expressly incorporated herein for use in the present invention as cross-linking agents and for inclusion where possible in one or more claims herein.

[0096] In one embodiment, the intracellular portion comprises the signaling domain of 4-1BB and the signaling domain of CD3 Zeta, wherein the signaling domain of 4-1BB comprises the amino acid sequence set forth in SEQ ID NO: 23 and the signaling domain of CD3 Zeta comprises the amino acid sequence set forth in SEQ ID NO: 24. The sequences of this paragraph are found in WO2012079000A1 and are expressly incorporated herein for use in the present invention as cross-linking agents and for inclusion where possible in one or more claims herein.

[0097] The present invention provides a nucleic acid vector comprising an expressible nucleotide sequence encoding a transmembrane protein, e.g., a CAR or CAL of the present invention. The present invention provides a first nucleic acid vector comprising an expressible nucleotide sequence encoding a transmembrane protein of the present invention and a second nucleic acid vector comprising an expressible nucleotide sequence encoding a crosslinker of the present invention. In one embodiment, the present invention (e.g., any method disclosed herein for treating or reducing the risk of a disease or condition in a patient, such as a human) comprises administering to the patient a vector encoding a transmembrane protein, whereby the vector is introduced into one or more first cells of the patient for expression of the transmembrane protein. In one example, the transmembrane protein is expressed in a progeny cell, the cell being progeny of the first cell. In one example, the first cell is a stem cell (e.g., a bone marrow cell, a hematopoietic stem cell and / or a T memory cell) of the patient. As described below, the art already includes suitable vectors and techniques for carrying out this embodiment, e.g., the vector is a lentivirus, adenovirus or retrovirus. In one example, the DNA encoding the transmembrane protein is integrated into the genome of the first cell. This avoids the need to take progenitor cells for ex vivo modification to encode transmembrane proteins and then inject them into the patient. Instead, vector administration is the only step required, and the fitness of the resulting progeny cells is maximized, since the progeny cells are based only on the patient's first cells, without the risk of alterations caused by ex vivo manipulation. Furthermore, the patient's own system (optionally stimulated with agents such as IL-2, which upregulates immune cell proliferation) can be administered to expand the population of progeny cells. Crosslinkers can, for example, be generated ex vivo and administered to the patient after the patient has generated progeny cells, thereby achieving the titration effect of the method of the present invention.

[0098] In one example, the vector is a gene therapy vector for introduction into human cells, such as human T cells, NK cells, TILs, stem cells, bone marrow cells or precursor cells thereof. The invention also provides such cells comprising a nucleotide sequence (e.g., DNA) or vector encoding a transmembrane protein. The invention also includes retroviruses, adenoviruses or lentiviruses comprising an expressible nucleotide sequence encoding a transmembrane protein (e.g., CAL) of the invention. The sequence is expressible when included in an immune cell of the invention, e.g., expressible in human T cells, NK cells or TILs.

[0099] The present invention also provides a vector in which the DNA of the present invention is inserted.Vector derived from retroviruses, such as lentiviruses, are suitable tools for achieving long-term gene transfer, since they allow long-term stable transgene integration and its propagation in daughter cells.Lentivirus vectors have an additional advantage over vectors derived from onco-retroviruses, such as mouse leukemia virus, in that they can transduce non-proliferating cells.They also have the additional advantage of low immunogenicity.

[0100] The constructs and vectors of the present invention can be used for nucleic acid immunization and gene therapy using standard gene delivery protocols. Methods for gene delivery are known in the art. See, for example, U.S. Patent Nos. 5,399,346, 5,580,859, and 5,589,466, which are incorporated herein by reference in their entirety.

[0101] The present invention provides an mRNA encoding a transmembrane protein, for example, a CAL or CAR of the present invention. Those skilled in the art are aware of techniques for delivering mRNA to an organism, such as a human, for expression of the encoded protein in vivo. In one example, the present invention comprises introducing mRNA into a first immune cell or a first immune cell precursor (e.g., a human T cell, a NK cell of a TIL, or a hematopoietic stem cell or a T memory stem cell) for expression of the transmembrane protein in the cell or its progeny. Optionally, the cell or progeny product is administered to a patient (e.g., a human) in a method of treatment or prevention of a disease or condition described herein. In another method, the first cell is included in a patient, for example, a human, when the mRNA is introduced into the cell.

[0102] Sources of T cells and other immune cells, together with methods for their production, activation and expansion, are disclosed in WO2012079000A1, the disclosures of which are hereby incorporated by reference for their possible use in the work of the present invention.

[0103] cancer Cancers that can be treated include non- or substantially non-vascularized tumors, as well as vascularized tumors. Cancers may include non-solid tumors (such as hematological tumors, e.g., leukemias and lymphomas) or may include solid tumors. Cancer types that can be treated with the CALs of the present invention include, but are not limited to, carcinomas, blastomas, and sarcomas, and certain leukemias or lymphoid malignancies, benign and malignant tumors, as well as malignant tumors, e.g., sarcomas, carcinomas, and melanomas. Adult tumors / cancers and pediatric tumors / cancers are also included.

[0104] Hematological cancers are cancers of the blood or bone marrow. Examples of hematological (or hematopoietic) cancers include leukemias, including acute leukemia (such as acute lymphoblastic leukemia, acute myeloid leukemia, acute myelogenous leukemia and myeloblasts, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia and erythroleukemia), chronic leukemia (such as chronic myelogenous (granulocytic) leukemia, chronic myelogenous leukemia and chronic lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (indolent and aggressive forms), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, myelodysplastic syndrome, hairy cell leukemia and myelodysplasia.

[0105] A solid tumor is an abnormal mass of tissue that does not usually contain cysts or liquid areas. Solid tumors can be benign or malignant. Different types of solid tumors are named for the type of cells that form them, such as sarcoma, carcinoma, and lymphoma. Examples of solid tumors, such as sarcoma and carcinoma, include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, and other sarcomas, synovial, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, lymphoid malignancies, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytoma sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatic carcinoma, bile duct carcinoma, ... sebaceous gland carcinoma, sebaceous gland carcinoma, sebaceous gland carcinoma, sebaceous gland carcin carcinoma, choriocarcinoma, Wilms' tumor, cervical cancer, testicular tumor, seminoma, bladder cancer, melanoma, and CNS tumors, such as gliomas (such as brain stem gliomas and mixed gliomas), glioblastomas (also known as glioblastoma multiforme) astrocytomas, CNS lymphomas, germinomas, medulloblastomas, schwannomas, craniopharyngiomas, ependymomas, pinealomas, hemangioblastomas, acoustic neuromas, oligodendroglioma, meningiomas, neuroblastomas, retinoblastomas, and brain metastases.

[0106] In one embodiment, the first binding moiety or first antigen-binding site of the crosslinker of the invention is designed to treat a particular cancer. For example, it specifically binds CD19 and can be used to treat cancers and disorders such as pre-B ALL (pediatric indication), adult ALL, mantle cell lymphoma, diffuse large B-cell lymphoma, or salvage after allogeneic bone marrow transplantation. In another embodiment, the first moiety or first binding site specifically binds CD22 to treat diffuse large B-cell lymphoma.

[0107] In one embodiment, cancers and disorders including, but not limited to, pre-B ALL (pediatric indication), adult ALL, mantle cell lymphoma, diffuse large B-cell lymphoma, and salvage after allogeneic bone marrow transplantation can be treated using a combination of crosslinkers (or binding moieties or sites contained in a single agent) that target two or three of CD19, CD20, CD22, and ROR1 (e.g., CD19 and one of the other targets).

[0108] In one example, the cells of the invention comprise different first and second transmembrane proteins (e.g., CALs or CARs), e.g., CALs whose second antigens are different (and optionally, otherwise the same). Similarly, the invention provides a mixture of immune cells of the invention (e.g., a mixture of CAL cells), e.g., contained in a graft of the invention, the mixture comprises cells that comprise different transmembrane proteins (e.g., separate CALs whose second antigens are different). In one example, the cells of the invention comprise different first and second crosslinkers, e.g., crosslinkers whose specificities of their first moieties / first antigen binding sites are different (and optionally, crosslinkers that are otherwise the same, e.g., first and second crosslinkers that comprise the same second moieties / second antigen binding sites). This can be useful, for example, to reduce resistance to cancer treatment or to more effectively target a cell population, such as cancer cells, whose surface expresses multiple target antigens.

[0109] In one embodiment, the first portion / first antigen binding site of the crosslinker specifically binds to mesothelin to treat or prevent mesothelioma, pancreatic cancer, or ovarian cancer.

[0110] In one embodiment, the first portion / first antigen-binding site of the cross-linker specifically binds to CD33 / IL3Ra to treat or prevent acute myeloid leukemia.

[0111] In one embodiment, the first portion / first antigen binding site of the crosslinker specifically binds to c-Met to treat or prevent triple negative breast cancer or non-small cell lung cancer.

[0112] In one embodiment, the first portion / first antigen binding site of the crosslinker specifically binds to PSMA to treat or prevent prostate cancer.

[0113] In one embodiment, the first portion / first antigen binding site of the cross-linker specifically binds to glycolipid F77 to treat or prevent prostate cancer.

[0114] In one embodiment, the first portion / first antigen binding site of the crosslinker specifically binds to EGFRvIII to treat or prevent glioblastoma.

[0115] In one embodiment, the first portion / first antigen-binding binding site of the cross-linker specifically binds to GD-2 to treat or prevent neuroblastoma or melanoma.

[0116] In one embodiment, the first portion / first antigen binding site of the cross-linker specifically binds to the NY-ESO-1 TCR to treat myeloma, sarcoma, or melanoma.

[0117] In one embodiment, the first portion / first antigen binding site of the cross-linker specifically binds to MAGE A3 TCR to treat myeloma, sarcoma and melanoma.

[0118] In one example, the treatment using the method reduces the progression of the disease or condition or a symptom thereof. In one example, the treatment using the method reduces the incidence of the disease or condition or a symptom thereof, e.g., for at least 1, 2, 3, 4, or 5 years.

[0119] In one example, the methods of the invention are performed ex vivo to generate a graft in which target cells are killed or reduced in number, and the graft is for administration (e.g., injection) to a patient (e.g., a human) to treat or reduce the risk of a disease or condition in the human.

[0120] In one example, the method is in vitro. In another example, the method is in vivo in a mammal, such as a human, male or female, or male or female child, or a human infant (e.g., 1, 2, 3, or 4 years of age or younger). In one example, the patient is an adult human or a pediatric human patient.

[0121] Specific Embodiments The present invention provides specific embodiments in the following numbered paragraphs: 1. A method of targeting immune cells (e.g., T cells, NK cells, or TILs) to a target cell, comprising: A. providing a cross-linking agent, the agent being i. a first antigen-binding site that specifically binds a first target antigen; and ii. a second antigen-binding site that specifically binds a second target antigen. providing a cross-linking agent which is a multispecific antigen-binding fragment comprising: B. Providing a chimeric antigen ligand (CAL)-immune cell, the immune cell comprising a transmembrane ligand, the ligand comprising: iii. an extracellular portion comprising a second antigen linked to the transmembrane domain; iv. an intracellular portion comprising a first signaling domain for intracellular signaling upon binding of the agent to a second antigen; providing a chimeric antigen ligand (CAL)-immune cell comprising an altered combination of: C. Combining the CAL-immune cells and the cross-linking agent with a target cell, the target cell comprising said first target antigen, the first target antigen being an extracellular antigen; v. The cross-linking agent thereby binds the first and second antigens to target immune cells to the target cells; vi. Thereby inducing intracellular signaling in immune cells to regulate immune cell activity Combining The method includes:

[0122] The CAL is modified, i.e., comprises a non-natural combination of moieties and domains. For example, the ligand comprises a single polypeptide (i.e., has only one such polypeptide) comprising the CD3 extracellular domain (second antigen), the CD28 or 4-1BB domain (first signaling domain) and the CD3 zeta domain. In this case, the ligand comprises a modified combination of domains, since the CD3 extracellular domain and the CD28 or 4-1BB domain do not naturally occur in the same receptor (e.g., do not occur in the natural CD3 receptor complex). Thus, in one example, the second antigen and the first signaling domain are not naturally contained in the receptor of the cell or in the people or persons that are the subject of the method of the invention. For example, the immune cell does not comprise an endogenous nucleotide sequence(s) encoding a receptor comprising the above combination.

[0123] The term "specifically binds" as used herein with respect to an antibody or binding site means an antibody or binding site that recognizes a specific antigen with a binding affinity of 1 mM or less as determined by SPR.

[0124] Target binding capacity, specificity and affinity (KD (also called kd), K off and / or K on ) can be determined by any method common in the art, for example, by surface plasmon resonance (SPR). As used herein, the term "KD" is intended to refer to the equilibrium dissociation constant of a particular binding site / ligand, receptor / ligand, or antibody / antigen interaction.

[0125] In one embodiment, surface plasmon resonance (SPR) is performed at 25° C. In another embodiment, SPR is performed at 37° C.

[0126] In one embodiment, SPR is performed at physiological pH, such as about pH 7, or at pH 7.6 (eg, using Hepes buffered saline at pH 7.6 (also called HBS-EP)).

[0127] In one embodiment, SPR is performed at physiological salt levels, for example, 150 mM NaCl.

[0128] In one embodiment, SPR is performed at a detergent level of 0.05% or less by volume, for example, in the presence of 0.05% P20 (Polysorbate 20; e.g., Tween-20™) and 3 mM EDTA.

[0129] In one example, SPR is performed at 25° C. or 37° C. in a buffer of pH 7.6, 150 mM NaCl, 0.05% detergent (e.g., P20), and 3 mM EDTA. The buffer may contain 10 mM Hepes. In one example, SPR is performed in HBS-EP at 25° C. or 37° C. HBS-EP is available from Teknova, Inc. (California; catalog number H8022).

[0130] In one example, affinity (e.g., for an agent that contains a VH / VL binding site) is determined using SPR by using any standard SPR instrument, such as by Biacore™ or using the ProteOn XPR36™ (Bio-Rad®). Binding data can be fitted to a native 1:1 model using standard techniques, for example, using the model native to the ProteOn XPR36™ analysis software.

[0131] A spacer (domain or peptide) is optionally present between the second antigen (which may be a domain or peptide) and the transmembrane domain of the CAL, or between the first signaling domain and the transmembrane domain of the CAL. As used herein, the term "spacer" generally refers to any oligopeptide or polypeptide that functions to link a transmembrane domain to either the second antigen or the signaling domain in the CAL. The spacer may comprise up to 300 amino acids, preferably 10-100 amino acids, and most preferably 25-50 amino acids.

[0132] Optionally, each binding site of the cross-linker comprises an antibody binding site, for example a VH / VL binding site for an antigen.

[0133] Such signaling can upregulate or downregulate immune cell activity, such as cytotoxicity or cell proliferation.

[0134] Fifth and Sixth Configuration Examples In alternative embodiments, paragraph 1 provides the following alternative clauses I-VII. Thus, the features of paragraph 2 et seq. are combinable with any of clauses I-VII. Thus, references to "paragraph 1" below may be read in the alternative as any one of clauses I-VII. A "first antigen-binding site" in any one of paragraphs 2 et seq. may be read as a "first binding moiety" as described in any one of clauses I-VII. A "second antigen-binding site" in any one of paragraphs 2 et seq. may be read as a "second binding moiety" as described in any one of clauses I-VII. A "first antigen" in any one of paragraphs 2 et seq. may be read as a "fourth binding moiety" as described in any one of clauses I-VII. A "second antigen" in any one of paragraphs 2 et seq. may be read as a "third binding moiety" as described in any one of clauses I-VII. A CAL in any one of paragraphs 2 et seq. may be read as a "transmembrane protein", "CAR" or "CAL" in any of clauses I to VII.

[0135] I. A method for targeting immune cells to a target cell, comprising: A. providing a cross-linking agent, the agent being vii. a first binding moiety; and viii. Second binding moiety providing a cross-linking agent which is a multispecific binding fragment comprising: B. Providing immune cells, the immune cells ix. an extracellular portion comprising a third binding moiety linked to the transmembrane domain, wherein the second and third moieties form a specific binding pair (SBP1), such that one moiety specifically binds to the other moiety; x. an intracellular portion comprising a first signaling domain for intracellular signaling when the second and third portions bind together; providing an immune cell expressing a transmembrane protein comprising an altered combination of: C. combining the immune cells and the cross-linking agent with a target cell, the target cell comprising a fourth binding moiety, the fourth binding moiety being extracellular; xi. whereby the first and fourth moieties form a specific binding pair (SBP2), whereby one moiety specifically binds to the other moiety to target the immune cell to the target cell; xii. the second and third portions bind together, thereby inducing intracellular signaling in the immune cell to modulate immune cell activity; and xiii. The molecular weight of the crosslinker is 125 kDa or less; Combining A method comprising:

[0136] II. The method of clause I, wherein the first and second binding moieties are ligand binding sites.

[0137] III. The method of clause II, wherein the first and second binding moieties are first and second antigen binding sites, respectively (e.g., VH / VL antigen binding sites).

[0138] It is well known how an antibody VH domain pairs with an antibody VL domain to form a VH / VL combining site that specifically binds an antigen.

[0139] IV. Each of SBP1 and SB2 is (a) an antigen and an antigen-binding site (e.g., an antigen and a VH / VL antigen-binding site; or a superantigen and an antibody variable or constant domain); and (b) Receptors and Ligands The method according to any one of clauses I-III, selected from the group consisting of:

[0140] Examples of superantigens are protein A (e.g., the ligand binding domain of protein A of Staphylococcus aureus), protein G and protein L (e.g., the ligand binding domain of protein L of Peptostreptococcus magnus) or the ligand binding domain of gp120.

[0141] In one example, each of SB1 and / or SB2 is a growth factor domain-growth factor receptor pair, or a hormone domain-hormone receptor pair. The receptor contains the binding site for the cognate ligand, but need not otherwise be a complete receptor, i.e., it can be a receptor fragment.

[0142] V. The method of any one of clauses I-IV, wherein the transmembrane protein is a chimeric antigen ligand (CAL), the third portion is an antigen and the second portion is an antigen binding site (e.g., an scFv), and optionally the first portion is an antigen binding site (e.g., an scFv) and the fourth portion is an antigen.

[0143] VI. The method of any one of clauses I-IV, wherein the transmembrane protein is a chimeric antigen receptor (CAR), the third portion is an antigen binding site and the second portion is an antigen, and optionally the first portion is an antigen binding site (e.g., an scFv) and the fourth portion is an antigen.

[0144] VII. The method of any one of clauses I-VI, wherein the molecular weight of the crosslinker is 115 kDa or less, for example, 55-115 kDa or 60-100 kDa.

[0145] The following features are applicable to all configurations.

[0146] In one example, the binding agent is a ligand trap whose molecular weight is less than or equal to 125, 120, 115, 110, 100 or 50 kDa. In one example, the first binding portion of the trap comprises a ligand binding site, e.g., a binding site of a ligand receptor, the second binding portion comprises an antibody Fc region (e.g., the Fc region of human IgG1), the third binding portion comprises a binding site of an Fc receptor (e.g., CD16, CD16A or CD16B), and the fourth binding portion comprises said ligand. Such binding agents of the invention advantageously have a shorter half-life than antibodies as described above. In one example, the ligand is human IL-1A, IL-1β, IL-1RN, IL-6, BLys, APRIL, activin A, TNF alpha, BMP, BMP2, BMP7, BMP9, BMP10, GDF8, GDF11, RANKL, TRAIL, VEGFA, VEGFB or PGF. In one example, the first binding moiety comprises an IL-1R domain, a gp130 domain, an ActRIIA domain, an ActRIIB domain, an Alk1 domain, an OPG domain, and a VEGFR1 and / or a VEGFR2 domain. In one example, the first binding moiety comprises a ligand binding site of human IL-1R, gp130, an ActRIIA domain, ActRIIB, Alk1, OPG, VEGFR1, or VEGFR2.

[0147] In one example, the agent is selected from the group consisting of aflibercept, Zaltrap™, or Eylea™ (and the fourth binding moiety is VEGFA, VEGFB, or PGF), ranibizumab or Lucentis™ (and the fourth binding moiety is VEGFA, VEGFB, or PGF), etanercept or Enbrel™ (and the fourth binding moiety is TNF-alpha), certolizumab (i.e., certolizumab pegol or Cimzia™ Fab excluding PEG) (and the fourth binding moiety is TNF-alpha), atacicept (and the fourth binding moiety is BLys), rilonacept or Arcalyst™ (and the fourth binding moiety is IL-1), or the first binding moiety of the crosslinker of the invention comprises a ligand binding site of an agent selected from the above groups.

[0148] In one example, each binding moiety is human or derived from a human moiety, such as a human ligand or a human binding site.

[0149] 2. The method of clause 1, wherein the cross-linking agent has a human serum half-life that is shorter than the human serum half-life of IgG.

[0150] Optionally, the crosslinker has a human serum half-life shorter than that of IgA. Optionally, the crosslinker has a human serum half-life shorter than that of IgM. Optionally, the crosslinker has a human serum half-life shorter than that of IgD. Optionally, the crosslinker has a human serum half-life shorter than that of IgE.

[0151] 3. The method of clause 2, wherein the crosslinker has a human serum half-life of 15, 10, or 5 days or less.

[0152] Those of skill in the art know how to routinely determine such half-lives. The serum half-lives of many prior art fragments, including the fragments disclosed herein, are known in the art.

[0153] 4. The method of clause 3, wherein the half-life is less than 1 day.

[0154] 5. The method of any of clauses 1-4, wherein the first binding site is a VH / VL binding site.

[0155] 6. The method of any of clauses 1-5, wherein the second binding site is a VH / VL binding site.

[0156] 7. The method of any of clauses 1-6, wherein the binding affinity (KD) of the first binding site for the first antigen is at least 5-fold, 10-fold or 20-fold lower than the affinity of the second binding site for the second antigen.

[0157] In this way, binding to the first antigen is stronger than to the second antigen, which can help control the switching behavior of the crosslinker.

[0158] For example, blinatumomab highly specifically targets malignant B cells (1.6 × 10 -9 M affinity). Blinatumomab also has a lower affinity interaction with CD3 (8.7 × 10 -8 M) to recruit and activate T cells. In one example, the cross-linking agent is or includes blinatumomab. The sequence of blinatumomab is shown below in SEQ ID NO: 19. In one embodiment, the agent therefore includes SEQ ID NO: 19.

[0159] 8. The method of any of clauses 1-7, wherein the first binding site has a binding affinity (KD) for the first antigen of 10 nM or less as determined by surface plasmon resonance (SPR), and the second binding site has a binding affinity (KD) for the second antigen of 50 nM or more (e.g., up to 1 mM) as determined by SPR.

[0160] This is useful for producing preferential binding to target cells over immune cells to help mitigate immune cell activity in vivo.

[0161] The binding affinity of the native TCR peptide / MHC interaction is a KD of about 0.1-500 μM. In one example, the KD for binding of the second binding site to the second antigen (first to fourth configurations) / binding of the second moiety to the third moiety of the invention (fifth or sixth configuration) is less than 100 nM, e.g., a KD of 50 nM or more and less than 100 nM, e.g., 50 nM to 95, 90, 85, or 80 nM. Affinity lower than 100 nM is useful to promote preferential binding to the engineered transmembrane protein (e.g., CAL or CAR) rather than native TCR binding on the surface of the immune cell of the invention. In one example, the immune cell is a CAL-T or CAR-T cell, and the binding affinity of the crosslinker for the first antigen is higher than the affinity of the crosslinker for the second antigen / third moiety, and the affinity for the second antigen / third moiety is less than 100, 90, or 85 nM. Thus, by selecting the relative binding affinities in this way, when a TCR and a second antigen or a third moiety are co-expressed on an immune cell of the invention, the cell may be preferentially bound to the engineered transmembrane protein (e.g., a CAL or CAR) of the invention rather than through any endogenous TCR of the T cell, which is useful for promoting signaling through the transmembrane protein.

[0162] 9. The method of any of clauses 1-8, wherein the first binding site has a binding affinity (KD) for the first antigen of 2 nM or less as determined by SPR, and the second binding site has a binding affinity (KD) for the second antigen of 60 nM or more (e.g., up to 1 mM) as determined by SPR.

[0163] 10. The method of any of clauses 1-9, wherein the first binding site has a binding affinity (KD) for the first antigen of 100 nM or less as determined by surface plasmon resonance (SPR).

[0164] 11. The first binding site has a K determined by SPR off =10 -3 11. The method according to any one of clauses 1 to 10, wherein the antibody has a binding / dissociation rate for the first antigen of 0.1 to 0.5 / second or less.

[0165] 12. The method of any of clauses 1-11, wherein the second binding site has a binding affinity (KD) for the second antigen of 100 nM or less as determined by surface plasmon resonance (SPR).

[0166] 13. The second binding site has a K determined by SPR off =10 -3 13. The method according to any one of clauses 1 to 12, wherein the antibody has a binding / dissociation rate for the second antigen of at least 100 / second.

[0167] The present invention includes any of the following embodiments with respect to the crosslinker.

[0168] First binding site kinetics (a) the first antigen-binding site specifically binds human FA (FA = said first antigen) with a dissociation constant (KD) of 0.1 (or about 0.1) to 10000 (or about 10000) nM, optionally 1 (or about 1) to 6000 (or about 6000) nM, as determined by surface plasmon resonance; (b) The first antigen-binding site has a density of 1.5×10 as determined by surface plasmon resonance. -4 (or about 1.5×10 -4 ) ~0.1 (or about 0.1) / sec, 3×10 -4 (or about 3×10 -4 ) ~0.1 (or about 0.1) / sec off-rate constant (K d ) specifically binds human FA; and (c) The first antigen-binding site has a density of 2×10 as determined by surface plasmon resonance. 6 (or about 2×10 6 )~1×10 4 (or about 1×10 4 ) / M / sec, 1×10 6 (or about 1×10 6 )~2×10 4 (or about 2×10 4 On-rate constant (K) / M / sec a ) specifically binds human FA; Optionally, also: (d) the first antigen-binding site specifically binds cynomolgus monkey FA with a dissociation constant (KD) of 0.1 (or about 0.1) to 10000 (or about 10000) nM, optionally 1 (or about 1) to 6000 (or about 6000) nM, as determined by surface plasmon resonance; (e) The first antigen-binding site has a density of 1.5×10 as determined by surface plasmon resonance. -4 (or about 1.5×10 -4 ) ~0.1 (or about 0.1) / sec, 3×10 -4 (or about 3×10 -4 ) ~0.1 (or about 0.1) / sec off-rate constant (K d ) specifically binds cynomolgus monkey FA; (f) The first antigen binding site has a density of 2×10 as determined by surface plasmon resonance. 6 (or about 2×10 6 )~1×10 4 (or about 1×10 4 ) / M / sec, 1×10 6 (or about 1×10 6 )~5×10 3 (or about 5×10 3 On-rate constant (K) / M / sec a ) specifically binds cynomolgus monkey FA.

[0169] Optionally, the first binding site comprises a KD according to (a) and (d), a KD according to (b) and (e), d , and K under (c) and (f) a has.

[0170] Dynamics of the second binding site (a') the second antigen-binding site specifically binds human SA (SA = said second antigen) with a dissociation constant (KD) of 0.1 (or about 0.1) to 10000 (or about 10000) nM, optionally 1 (or about 1) to 6000 (or about 6000) nM, as determined by surface plasmon resonance; (b') The second antigen-binding site is 1.5 x 10 as determined by surface plasmon resonance. -4 (or about 1.5×10 -4) ~0.1 (or about 0.1) / sec, 3×10 -4 (or about 3×10 -4 ) ~0.1 (or about 0.1) / sec off-rate constant (K d ) specifically binds human SA; and (c') The second antigen binding site is 2 x 10 as determined by surface plasmon resonance. 6 (or about 2×10 6 )~1×10 4 (or about 1×10 4 ) / M / sec, 1×10 6 (or about 1×10 6 )~2×10 4 (or about 2×10 4 On-rate constant (K) / M / sec a ) specifically binds human SA; Optionally, also: (d') the second antigen-binding site specifically binds cyno SA with a dissociation constant (KD) of 0.1 (or about 0.1) to 10,000 (or about 10,000) nM, optionally 1 (or about 1) to 6,000 (or about 6,000) nM, as determined by surface plasmon resonance; (e') The second antigen binding site is 1.5 x 10 determined by surface plasmon resonance. -4 (or about 1.5×10 -4 ) ~0.1 (or about 0.1) / sec, 3×10 -4 (or about 3×10 -4 ) ~0.1 (or about 0.1) / sec off-rate constant (K d ) specifically binds cynomolgus SA; (f') The second antigen binding site is 2 x 10 as determined by surface plasmon resonance. 6 (or about 2×10 6 )~1×10 4 (or about 1×10 4 ) / M / sec, 1×10 6 (or about 1×10 6 )~5×10 3 (or about 5×10 3 On-rate constant (K) / M / sec a ) specifically binds cynomolgus SA.

[0171] Optionally, the second binding site is a KD according to (a') and (d'), a KD according to (b') and (e'), d , and K according to (c') and (f') a has.

[0172] 14. The method of any of clauses 1 to 13, wherein each of the first and second antigen binding sites is selected from the group consisting of an scFv, a Nanobody™, a dAb, a Duocalin, a DARpin, an avimer, an adnectin and a Finomer.

[0173] 15. The method according to any one of clauses 1 to 14, wherein the size of the cross-linking agent is 125 kDa or less.

[0174] In one example, the size is less than 115, 110, 100, 90, 80, 70 or 60 kDa.

[0175] This has the advantage of providing a human serum half-life that has useful advantages in accordance with the present invention, as discussed above.

[0176] 16. The method of any of clauses 1 to 15, wherein the size of the cross-linker is 80 kDa or less (e.g., 50 or 55 kDa or less).

[0177] 17. The method of any of clauses 1-16, wherein the crosslinking agent is or comprises a BiTE™ antibody, a bispecific scFv, a trispecific scFv, a tandab™, a dAb nanobody (e.g. a dimer or trimer), a dAb multimer (e.g. a dimer or trimer), a diabody, a tetrabody or a DART™.

[0178] In one example, the cross-linker contains one, two or more Fabs to provide binding sites.

[0179] antigen binding site In one example, the or each antigen-binding site (or ligand-binding moiety in the case of the fifth or sixth configuration) may be an antibody variable domain (e.g. VL or VH, an antibody single variable domain (domain antibody or dAb), a camelid VHH antibody single variable domain, a shark immunoglobulin single variable domain (NAV), a Nanobody™ or a camelized VH single variable domain); a T cell receptor binding domain; an immunoglobulin superfamily domain; an agana variable lymphocyte receptor (J Immunol; 2010 Aug 1; 185(3):1367-74; "Alternative adaptive immunity in jawless vertebrates; Herrin BR & Cooper M D.); fibronectin domains (e.g., Adnectins™); scFv (scFv)2; sc-diabodies; scFab; antigen binding sites derived from scaffolds selected from centrin and CTLA-4 (Evibody™); lipocalin domains; protein A such as the Z domain of protein A (e.g., Affibody™ or SpA); A domains (e.g., Avimer™ or Maxibody™); heat shock proteins (epitope binding domains from GroEI and GroES); transferrin domains (e.g., trans-forms); ankyrin repeat proteins (e.g., DARpin™); peptide aptamers; C-type lectin domains (e.g., Tetranectin™); human gamma-crystallin or human ubiquitin (Affilin); PDZ domains; scorpion toxins; and Kunitz-type domains of human protease inhibitors.

[0180] Further sources of antigen-binding sites are the variable domains and antibody VH / VL pairs disclosed in WO2007024715, p. 40, line 23 to p. 43, line 23. This particular disclosure is incorporated herein by reference as if expressly set forth herein, to provide the basis for epitope-binding moieties for use in the present invention and as may be included within the scope of the claims herein. A "domain" is a folded protein structure that has a tertiary structure independent of the rest of the protein. In general, domains are responsible for distinct functional properties of a protein, and can often be added, removed, or transferred to other proteins without loss of function of the remainder of the protein and / or domain. A "single antibody variable domain" is a folded polypeptide domain that contains sequences characteristic of antibody variable domains. Single antibody variable domains therefore include complete antibody variable domains and modified variable domains, for example in which one or more loops have been replaced by sequences not characteristic of antibody variable domains, or antibody variable domains which are truncated or contain N-terminal or C-terminal extensions, as well as folded fragments of variable domains which retain at least the binding activity and specificity of the full-length domain.

[0181] The phrase "immunoglobulin single variable domain" refers to an antibody variable domain (VH, VHH, VL) that specifically binds an antigen or epitope independently of a different V region or domain. Immunoglobulin single variable domains may exist in formats (e.g., homo- or hetero-multimers) with other, different variable regions or variable domains, where the other regions or domains are not required for antigen binding by the single immunoglobulin variable domain (i.e., the immunoglobulin single variable domain binds antigen independently of additional variable domains). The term "domain antibody" or "dAb" as used herein is the same as an "immunoglobulin single variable domain" capable of binding to an antigen. Immunoglobulin single variable domains may be human antibody variable domains, but also include single antibody variable domains from other species, such as rodent (e.g., as disclosed in WO 00 / 29004), nurse shark and camelid VHH immunoglobulin single variable domains. Camelid VHHs are immunoglobulin single variable domain polypeptides derived from species including camel, llama, alpaca, dromedary, and guanaco that produce heavy chain antibodies naturally devoid of light chains. Such VHH domains may be humanized according to standard techniques available in the art, and such domains are still considered to be "domain antibodies" according to the present invention. "VH" as used herein includes camelid VHH domains. NA V is another type of immunoglobulin single variable domain identified in cartilaginous fishes, including the nurse shark. These domains are also known as novel antigen receptor variable regions (commonly abbreviated as V(NAR) or NARV). For further details, see Mol. Immunol. 44, 656-665 (2006) and US20050043519A. CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) is a CD28 family receptor expressed primarily on CD4+ T cells. Its extracellular domain has a folded Ig-like variable domain. Loops corresponding to the CDRs of an antibody can be replaced with heterologous sequences to confer different binding properties. CTLA-4 molecules engineered to have different binding specificities are also known as Evibodies.For further details, see Journal of Immunological Methods 248(1-2), 31-45(2001). Lipocalins are a family of extracellular proteins that transport hydrophobic small molecules such as steroids, bilin, retinoids and lipids. Lipocalins have a rigid beta-sheet secondary structure with several loops at the open end of a cone-shaped structure that can be modified to bind different target antigens. Anticalins are 160-180 amino acids in size and are derived from lipocalins. For further details, see Biochim Biophys Acta 1482:337-350(2000), US7250297B1 and US20070224633. Affibodies are scaffolds derived from protein A of Staphylococcus aureus that can be modified to bind antigens. The domain consists of a triple-helical bundle of about 58 amino acids. Libraries have been generated by randomization of surface residues. For further details, see Protein Eng. Des. Sel. 17, 455-462 (2004) and EP1641818A1. Avimers™ are multi-domain proteins derived from the A-domain scaffold family. A native domain of about 35 amino acids adopts a defined disulfide bond structure. Diversity is generated by shuffling the natural mutations exhibited by the family of A-domains. For further details, see Nature Biotechnology 23(12), 1556-1561 (2005) and Expert Opinion on Investigational Drugs 16(6), 909-917 (June 2007). Transferrin is a monomeric serum transport glycoprotein. Transferrin can be modified to bind different target antigens by the insertion of peptide sequences in permissive surface loops. Examples of modified transferrin scaffolds include the trans form. For further details, see J. Biol. Chem 274, 24066-24073 (1999). Designed ankyrin repeat proteins (DARPins™) are derived from ankyrins, a family of proteins that mediate the attachment of integral membrane proteins to the cytoskeleton.A single ankyrin repeat is a 33-residue motif consisting of two α-helices and a β-turn. They can be engineered to bind different target antigens by randomizing residues in the first α-helix and β-turn of each repeat. Their binding interface can be increased by increasing the number of modules (a method of affinity maturation). For further details, see J. Mol. Biol. 332, 489-503 (2003), PNAS 100(4), 1700-1705 (2003) and J. Mol. Biol. 369, 1015-1028 (2007) and US20040132028. Fibronectin is a scaffold that can be engineered to bind antigens. Adnectins™ consist of a backbone of the natural amino acid sequence of the 10th domain of the 15 repeat units of human fibronectin type III (FN3). Three loops at one end of the beta sandwich can be engineered to allow the adnectin to specifically recognize a therapeutic target of interest. For further details, see Protein Eng. Des. Sel. 18, 435-444 (2005), US20080139791, WO2005056764 and US6818418A1. Peptide aptamers are combinatorial recognition molecules that consist of a constant scaffold protein, typically thioredoxin (TrxA), which contains a restricted variable peptide loop that is inserted into the active site. For further details, see Expert Opin. Biol. Ther. 5, 783-797 (2005). Microbodies are derived from naturally occurring microproteins of 25-50 amino acids in length that contain 3-4 cysteine ​​bridges, examples of which include KalataBI and conotoxins and knottins. The microproteins have loops that can be modified to contain up to 25 amino acids without affecting the overall folding of the microprotein. For further details of modified knottin domains see WO2008098796.Other epitope binding moieties and domains include proteins that have been used as scaffolds to engineer different target antigen binding properties, including human gamma crystallin and human ubiquitin (affilin), Kunitz-type domains of human protease inhibitors, the PDZ-domain of the Ras binding protein AF-6, scorpion toxin (charybdotoxin), and C-type lectin domains (tetranectin) are reviewed in Chapter 7 - Non-Antibody Scaffolds from the Handbook of Therapeutic Antibodies (2007, ed. Stefan Dubel) and Protein Science 15:14-27 (2006). The antigen binding site or ligand binding moiety of the crosslinker of the invention may be derived from any of these alternative protein domains.

[0182] 18. The method of any of clauses 1-17, wherein the CAL comprises a hinge region and / or a linker between the second antigen and the transmembrane domain.

[0183] 19. The method of any one of clauses 1 to 18, wherein the target cell is a human cell.

[0184] 20. The method of any of clauses 1-19, wherein the cross-linking agent comprises a third antigen-binding site.

[0185] 21. The method of clause 20, wherein the third antigen is different from the first antigen.

[0186] 22. The method of clause 20 or 21, wherein the third antigen is a tumor-associated antigen (TAA), such as a cell surface TAA contained in the target cell.

[0187] 23. The method of any of clauses 1 to 22, wherein the first and / or third antigen is more prevalent on cancer cells than on normal cells.

[0188] 24. The method of any of clauses 1 to 23, wherein the target cell is a tumor cell and the signaling upregulates cytotoxic activity (e.g., ADCC) or immune cell proliferation.

[0189] 25. The method of clause 24, wherein signaling upregulates said cytotoxicity resulting in tumor cell death or downregulation of tumor cell proliferation.

[0190] 26. The method according to any one of clauses 1 to 25, wherein the target cell is a leukemia cell, a lymphoma cell, an adenocarcinoma cell or a cancer stem cell.

[0191] 27. The method of any of clauses 1-26, wherein the first antigen is a tumor-associated antigen (TAA).

[0192] 28. The first antigen is human CD19 (and optionally, the target cell is a leukemia or lymphoma cell), EpCAM (and optionally, the target cell is a lung cancer cell, a gastrointestinal cancer cell, an adenocarcinoma, a cancer stem cell), CD20 (and optionally, the target cell is a leukemia cell), MCSP (and optionally, the target cell is a melanoma cell), CEA, EGFR, EGFRvIII, sialyl-Tn, CD133, CD33 (and optionally, the target cell is a leukemia cell, e.g., an AML cell), PMSA, WT1, CD22, L1CAM, ROR-1, MUC-16, CD30, CD47, CD52, gpA33, TAG-72, mucin, CIX, GD2, GD3, GM2, CD123, VEGFR, integrin, cMET, Her1, Her2, Her3, MAGE1, MAGE A3 28. The method according to any one of clauses 1 to 27, wherein the target molecule is TCR, NY-ESO-1, IGF1R, EPHA3, CD66e, EphA2, TRAILR1, TRAILR2, RANKL, FAP, angiopoietin, mesothelin, glycolipid F77 or tenascin.

[0193] 29. The first antigen-binding site is a CD19-binding site of blinatumomab or antibody HD37; an EpCAM-binding site of catumaxomab; a CD19-binding site of AFM11; a CD20-binding site of Lymphomun; a Her2-binding site of ertumaxomab; a CEA-binding site of AMG211 (MEDI-565, MT111); a PSMA-binding site of pasotuxizumab; an EpCAM-binding site of solitomab; a VEGF- or angiopoietin-2-binding site of RG7221 or RG7716. 29. The method of any of clauses 1 to 28, comprising a variable domain of an antibody selected from the group consisting of: a Her1 or Her3 binding site of RG7597; a Her2 or Her3 binding site of MM111; an IGF1R or Her3 binding site of MM141; a CD123 binding site of MGD006; a gpa33 binding site of MGD007; a CEA binding site of TF2; a CD30 binding site of AFM13; a CD19 binding site of AFM11; and a Her1 or cMet binding site of LY3164530.

[0194] 30. The method of any of clauses 1-29, wherein the crosslinking agent is Blinatumomab or a CD3 / CD19-binding derivative thereof (optionally, the target cell is an acute lymphoblastic leukemia (ALL) B cell); AMG211 or a CD3 / CEA-binding derivative thereof (MEDI-565, MT111; optionally, the target cell is a gastrointestinal cancer cell); Pasotuxizumab or a CD3 / PMSA-binding derivative thereof (optionally, the target cell is a prostate cancer cell); Solitomab or a CD3 / EpCAM-binding derivative thereof (optionally, the target cell is a cancer cell); or AFM11 or a CD3 / CD19-binding derivative thereof (and optionally, the target cell is an ALL cell or a non-Hodgkin's lymphoma cell).

[0195] 31. The first antigen-binding site is selected from the group consisting of LeoPro(trademark); abciximab; Rituxan(trademark); rituximab; Zenapax(trademark); daclizumab; Simulect(trademark); basiliximab; Synagis(trademark); palivizumab; Remicade(trademark); infliximab; Herceptin(trademark); trastuzumab; Mylotarg(trademark); gemtuzumab; Cambus(trademark); Alemtuz Mab;Zevalin(trademark);Ibritumomab;Humira(trademark);Adalimumab;Xolair(trademark);Omalizumab;Bexar(trademark);Tositumomab;Raptiva(trademark);Efalizumab;Erbitux(trademark);Cetuximab;Avastin(trademark);Bevacizumab;Tysabri(trademark);Natalizumab;Actemra(trademark);Tocilizumab;Vectibix(trademark);Panitum The method of any one of clauses 1 to 27, comprising a variable domain of the antigen-binding site of an antibody selected from the group consisting of: Mab; Lucentis™; Ranibizumab; Soliris™; Eculizumab; Cimzia™; Certolizumab; Simponi™; Golimumab, Ilaris™; Canakinumab; Stelara™; Ustekinumab; Arzera™; Ofatumumab; Prolia™; Denosumab; Numax™; Motavizumab; ABThrax™; Raxibacumab; Benlysta™; Belimumab; Yervoy™; Ipilimumab; Adcetris™; Brentuximab; Vedotin™; Perjeta™; Pertuzumab; Kadcyla™; Adotrastuzumab; Gazyva™ and obinutuzumab.

[0196] 32. The method of any one of clauses 1 to 31, wherein the target cells are blood cells.

[0197] Alternatively, the target cells are human or animal stem cells or bone marrow cells.

[0198] 33. The method of any of clauses 1 to 32, wherein the target cell is a B cell or a T cell.

[0199] 34. The method of any one of clauses 1-21 and 31-33, wherein the first antigen is a target of an autoimmune disease and the signaling downregulates cytotoxic activity or proliferation of immune cells.

[0200] The term "autoimmune disease" as used herein is defined as a disease resulting from an autoimmune response. Autoimmune disease is the result of an inappropriate and excessive response to self-antigens. Examples of autoimmune diseases include, but are not limited to, Addison's disease, alopecia areata, ankylosing spondylitis, autoimmune hepatitis, autoimmune parotitis, Crohn's disease, diabetes mellitus (type I), dystrophic epidermolysis bullosa, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathy, thyroiditis, vasculitis, vitiligo, myxedema, pernicious anemia, and ulcerative colitis, among others.

[0201] 35. The method of any of clauses 1-34, wherein the second antigen is an extracellular antigen of an immune cell (e.g., a human T cell or a NK cell).

[0202] In one example, the antigen is contained in a cell type that is the same as the type of cell of the invention, e.g., the CAL cell of the invention is a T cell, NK cell, or TIL, and the second antigen is a cell surface antigen of a T cell, NK cell, or TIL, respectively.

[0203] 36. The method of any of clauses 1-35, wherein the second antigen is a protein antigen and the immune cell comprises a first nucleotide sequence that is an endogenous sequence that expresses an amino acid sequence (e.g., a CD3 extracellular domain sequence) that is identical to an amino acid sequence of the second antigen contained in the CAL.

[0204] Thus, the second antigen is self and is recognized by the cross-linking agent. When a human patient receives the cells, this reduces the risk of immune rejection of the CAL cells by the human, provided that the patient also expresses the second antigen.

[0205] In one example, the second antigen is provided by a synthetic protein sequence.

[0206] 37. The method of any of clauses 1-36, wherein the second antigen is provided by a human CD3 or human CD16 (e.g., CD16A) extracellular domain sequence.

[0207] In one example, the second binding site comprises a variable domain of the CD16A binding site of AFM12 or AFM13 of TANDAV™.

[0208] In one example, the CAL cell does not express the second antigen from an endogenous nucleotide sequence, e.g., the sequence is knocked out or inactivated in the cell genome. In one example, the second antigen is provided by a CD3 or CD16 (e.g., CD16A) extracellular domain sequence, and the endogenous genome of the CAL-T cell includes a modification that renders TCR signaling non-functional. For example, the exon sequence of the endogenous corresponding CD3 or CD16A extracellular domain is knocked out or inactivated. In one example, the CD3 extracellular domain is a CD3γ, CD3δ, or CDε domain. The skilled artisan knows the usual methods for precisely knocking out or modifying sequences in a cell genome, e.g., by using homologous recombination and / or CRISPR / Cas (e.g., Cas9) nuclease cleavage.

[0209] 38. The method of any of clauses 37, wherein the CD3 extracellular domain is a CD3γ, CD3δ or CDε domain.

[0210] Optionally, the CD3 extracellular domain is a CD3 gamma domain. Optionally, the CD3 extracellular domain is a CD3 delta domain. Optionally, the CD3 extracellular domain is a CD3 epsilon domain.

[0211] 39. The method of any of clauses 1-38, wherein the second target binding site comprises a variable domain of an anti-CD3 binding site of an antibody selected from the group consisting of antibody L2K-07, antibody OKT3™, muromonab-CD3, otelixizumab, teplizumab, visilizumab, catumaxomab, ertumaxomab and foralumab.

[0212] 40. The method of any of clauses 1 to 39, wherein the extracellular portion does not contain non-self epitopes.

[0213] This can reduce the risk of rejection if the recipient patient also expresses the domain of the extracellular portion. In one example, "self" is determined by the phenotype of the patient, e.g., the human recipient of the immune cells and crosslinkers of the invention, and / or the phenotype of the ancestral cells from which the immune cells are derived (e.g., ancestral cells obtained from the patient).

[0214] 41. A. A second antigen of the CAL is encoded in the cell by a non-endogenous nucleotide (S1) sequence that contains a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of the antigen; B. The genome of the cell comprises a second nucleotide sequence (S2) that contains SNP1 and encodes an amino acid sequence that is identical to the amino acid sequence of the second antigen and comprises R1; or that is a naturally occurring variant of the amino acid sequence of the second antigen and encodes an amino acid sequence that comprises R1; and C. S2 is an endogenous genomic sequence of the cell and SNP1 is a non-synonymous SNP; 41. The method according to any one of clauses 1 to 40.

[0215] This provides the advantage of meeting an increased chance of compatibility between the cell and the modified transmembrane proteins of the invention (eg, CALs), as further described herein.

[0216] In one example, the amino acid sequence of the variant is at least 80, 90, or 95% identical to the sequence of the second antigen.

[0217] The term "nonsynonymous" SNPs is explained above.

[0218] 42. A. A second antigen of CAL is encoded in the cell by a non-endogenous nucleotide (S1) sequence that contains a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of the antigen; and B. The method of any of clauses 1-40, wherein the CAL cells are comprised in an allograft, and the method comprises administering the graft to a human in step (c), wherein the CAL cells and the target cells are combined, and wherein the human genome comprises said SNP1 prior to said administration.

[0219] This provides the advantages of adaptation as described herein.

[0220] As used herein, "graft" refers to cells, tissues, or organs that are introduced into an individual. The source of the graft material can be cultured cells, cells from another individual, or cells from the same individual (e.g., after the cells have been cultured in vitro).

[0221] 43. The method according to clause 41 or 42, wherein the second antigen of the CAL is the CD3γ extracellular domain and R1 is selected from the group consisting of I53, N53 and T53 (position numbers correspond to positions in SEQ ID NO:1).

[0222] 44. The method of clause 43, wherein the second antigen comprises I53.

[0223] The inventors have found that this position exhibits natural mutations in humans, with the I53 mutation being the most common mutation as shown by Ensembl, and therefore, the inventors have realized that this embodiment provides an embodiment that is compatible with most patients receiving the CAL cells of the present invention.

[0224] 45. The method according to clause 41 or 42, wherein the second antigen of the CAL is the CD3 delta extracellular domain and R1 is selected from the group consisting of N38 and K38 (position numbers correspond to positions in SEQ ID NO:3).

[0225] 46. ​​The method of clause 45, wherein the second antigen comprises N38.

[0226] The inventors have found that this position exhibits natural mutations in humans, with the N38 variant being the most common mutation as shown by Ensembl, and therefore, the inventors have realized that this embodiment provides an embodiment that is compatible with most patients receiving the CAL cells of the present invention.

[0227] 47. The method according to clause 41 or 42, wherein the second antigen of the CAL is the CD3ε extracellular domain and is selected from the group consisting of A108, E108 and V108 (position numbers correspond to positions in SEQ ID NO:5).

[0228] 48. The method of clause 47, wherein the second antigen comprises A108.

[0229] The inventors have found that this position exhibits natural mutations in humans, with the A108 variant being the most common mutation as shown by Ensembl, and therefore, the inventors have realized that this embodiment provides an embodiment that is compatible with most patients receiving the CAL cells of the present invention.

[0230] 49. The method of any one of clauses 42-48, wherein the CAL cells are comprised in an allograft, and the method comprises administering the graft to the human in step (c), and the CAL cells and target cells are combined, and the human comprises said SNP1 prior to administration of the graft.

[0231] 50. The method of any one of clauses 1-48, wherein the CAL cells are modified descendants of ancestral cells from a human, and the method comprises administering the modified CAL cells to the human in step (c), and the CAL cells and the target cells are combined.

[0232] 51. A. a first signaling domain (SD1) is encoded in the cell by a third nucleotide sequence (S3) that contains a human single nucleotide polymorphism (SNP2) that encodes an amino acid residue (R2) in the signaling domain; B. the genome of the cell comprises a fourth nucleotide sequence (S4) that comprises SNP2 and encodes a signaling domain (SD2), where SD2 is identical to SD1 and comprises R2, or (ii) is a naturally occurring variant of SD1 and comprises R2; and C. S4 is an endogenous genomic sequence of the cell and SNP2 is a non-synonymous SNP; 51. The method according to any one of clauses 1 to 50.

[0233] 52. The method of clause 51, wherein each of SD1 and SD2 comprises an immunoreceptor tyrosine-based activation motif (ITAM) that includes R2.

[0234] Given the importance of ITAMs in cell signaling, this aspect of the invention adapts SNPs in ITAMs to fit their natural context to function in the cell's endogenous signaling machinery.

[0235] 53. The method according to clause 52, wherein the ITAMs of the signalling domains are identical.

[0236] 54. The method of any of clauses 1-53, wherein the intracellular portion comprises a further intracellular signalling domain (SD3) encoded in the cell by a fifth nucleotide sequence (S5), wherein S5 comprises a human single nucleotide polymorphism (SNP3) encoding an amino acid residue (R3) of SD3, the genome of the cell comprises a sixth nucleotide sequence (S6) encoding a signalling domain (SD4), wherein SD4 is identical to SD3 and comprises R3 or is a naturally occurring variant of SD3 and comprises R3, S6 is an endogenous genomic sequence of the cell, and SNP3 is a non-synonymous SNP.

[0237] 55. The method according to clause 54, wherein SD1 and SD3 of the receptor are different.

[0238] 56. The method of clause 54 or 55, wherein each of SD3 and SD4 comprises an ITAM that includes R3.

[0239] 57. The method according to clause 56, wherein the ITAMs of SD3 and SD4 are identical.

[0240] 58. The method according to any one of clauses 54 to 57, wherein SD3 and SD4 are identical.

[0241] 59. The method of any one of clauses 54 to 58, wherein SD3 is human.

[0242] 60. The method of any one of clauses 54 to 59, wherein each of SD3 is a CD3ζ (CD3 zeta) domain, a CD3η, (CD3 eta) domain, an FcεRIγ domain, a CD64 domain, a CD16 domain, a CD27 domain, a CD28 domain, an ICOS domain, an OX40 domain, a CD40 domain or a 4-1BB domain.

[0243] CD137 is a member of the tumor necrosis factor (TNF) receptor family, also known as tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB, and is induced by lymphocyte activation (ILA), which is currently of interest to immunologists as a costimulatory immune checkpoint molecule.

[0244] 61. The method of any of clauses 1-60, wherein the first signaling domain is a CD3 intracellular domain selected from a CD3ζ (CD3 zeta) domain (wherein the second antigen is not a CD3 domain), a CD3η (CD3 eta) domain (wherein the second antigen is not a CD3 domain), an FcεRIγ domain, a CD64 domain, a domain of CD16 (wherein the second antigen is not a CD16 domain), a CD27 domain, a CD28 domain, an ICOS domain, an OX40 domain, a CD40 domain, or a 4-1BB domain.

[0245] In any of the embodiments herein, the first signaling domain is selected from the group consisting of CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds CD83.

[0246] 62. The method of clause 61, wherein the first signaling domain is a CD3 intracellular domain selected from a CD3ζ (CD3 zeta) domain and a CD3η (CD3 eta) domain and comprises one, two or three amino acid motifs selected from: (a) SEQ ID NO: 10, optionally with up to 10, 9, 8, 7, 6 or 5 (e.g., up to 5) amino acid differences, but in which tyrosine is conserved; (b) SEQ ID NO: 11, optionally with up to 10, 9, 8, 7, 6 or 5 (e.g., up to 5) amino acid differences, but in which tyrosine is conserved; and (c) SEQ ID NO: 12, optionally with up to 10, 9, 8, 7, 6 or 5 (e.g., up to 5) amino acid differences, but in which tyrosine is conserved.

[0247] 63. The method of clause 62, wherein the first signaling domain comprises motif (a), and the motif differs from SEQ ID NO: 10 by up to five changes at residues selected from the group consisting of A61, P62, A63, Q66, G67, N69, Q70, N73, R79, E82, D84, V85, D87 and K88 (positions numbered according to positions in SEQ ID NO: 7).

[0248] This is based on the inventors' analysis of natural human genomic polymorphisms in the CD3 zeta sequence and their realization that these positions are naturally occurring variants and therefore tolerant of alterations. Using a similar analysis, the inventors have also devised other possible variations and compatible embodiments as set forth in the following clauses and examples.

[0249] 64. The method of clause 63, wherein the alteration is selected from the group consisting of A61V, A61P, P62S, P62A, A63P, Q66H, G67S, N69T, Q70Y, Q70L, Q70P, Q70W, N73Y, R79L, R79G, E82K, D84G, D84A, D84Y, V85I, D87G and K88R (positions numbered according to SEQ ID NO:7).

[0250] The inventors have found that these are naturally occurring mutations (and therefore tolerated in humans).

[0251] 65. The method of any one of clauses 62 to 64, wherein the first signaling domain comprises motif (b), and the motif differs from SEQ ID NO: 11 by up to five changes at residues selected from the group consisting of P100, Q101, R103, K104, N105, P106, E108, L110, A120, A122 and M128 (positions numbered according to positions in SEQ ID NO: 7).

[0252] 66. The method according to clause 65, wherein the alteration is selected from the group consisting of P100L, Q101L, Q101P, R103K, K104E, N105K, P106R, E108A, L110Q, A120V, A122V and M128T (positions numbered according to SEQ ID NO:7).

[0253] 67. The method of any one of clauses 62-66, wherein the first signaling domain comprises motif (c), and the motif differs from SEQ ID NO: 12 by up to five changes at residues selected from the group consisting of E131, R132, R133, K136, G137, G140, L145, A148, T152, A155, L156 (positions numbered according to positions in SEQ ID NO: 7).

[0254] 68. The method of clause 67, wherein the alterations are selected from the group consisting of E131K, R132H, R132C, R133Q, R133W, K136N, G137E, G140D, L145F, A148D, T152I, A155T, L156P (positions numbered according to SEQ ID NO:7).

[0255] 69. The method of any one of clauses 61-68, wherein the first signaling domain is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3 eta) domain and comprises one, more or all amino acid residues selected from the group consisting of S58, Y64, Y72, Y83, Y111, Y123, Y142 and Y153 (positions numbered according to the positions in SEQ ID NO:7).

[0256] The inventors have realized that such residues are involved in signal transduction and recognition in intracellular pathways and therefore, conservation of these residues is useful for successful signal transduction using the transmembrane proteins (e.g., CALs) of the invention.

[0257] 70. The first signaling domain is a CD3 intracellular domain selected from the group consisting of the CD3 zeta domain and the CD3 eta domain, and is selected from the group consisting of rs368651001, rs372651048, rs767112686, rs765877580, rs751145956, rs772867144, rs55893506, rs761710510, rs776601547, rs768607376, rs193922741, rs193922740, rs193922739, rs s780188126, rs772128174, rs757978223, rs779397562, rs749926653, rs181746205, rs181746205, rs753572867, rs371709798, rs145407 267, rs143180729, rs148513413, rs367690333, rs144963570, rs367690333, rs144963570, rs770320255, rs139926301, rs56297636, rs76 0895755, rs112890541, rs370910340, rs145505909, rs754935006, rs751583971, rs766541481, rs763074967, rs745871212, rs37266546 1, rs764185491, rs756340039, rs773572491, rs201594815, rs781510519, rs147527561, rs751981677, rs763532939, rs753278244, rs771 873949, rs186004179, rs186004179, rs762773775, rs748158220, rs776703680, rs561262982, rs758846009, rs746262183, rs376046446, rs201937405 and rs752198795, and wherein the genome of the immune cell comprises an endogenous nucleotide sequence comprising said selected SNP.

[0258] The inventors have noted that these SNPs code for residues at positions in naturally occurring CD3 zeta and CD3 eta that are tolerant to alteration, which is useful, for example, when the endogenous genome of the cell also contains SNPs to provide adaptive advantages as described herein.

[0259] 71. The method of any of clauses 1 to 70, wherein the first or third signaling domain is a CD28 intracellular domain comprising at least 13 amino acid residues selected from the group consisting of R180, S181, K182, R183, S184, R185, L186, D190, Y191, N193, P196, P199, T202, K204, Q207, F215, A217 and Y218 (position numbers correspond to positions in SEQ ID NO: 13).

[0260] The inventors realised that these are naturally occurring mutations in the CD28 intracellular domain and therefore form the basis for tailoring in accordance with tailoring aspects of the invention, which is useful, for example, when the endogenous genome of the cell also encodes selected residues to provide tailoring advantages as described herein.

[0261] 72. The method of clause 71, wherein the CD28 domain comprises all of the residues in the above groups.

[0262] 73. The method according to clause 71 or 72, wherein the CD28 domain comprises amino acid residues Y191 and Y209 (position numbers corresponding to positions in SEQ ID NO: 13).

[0263] As further described in the Examples, the inventors have noted that these locations are found in conserved CD28 intracellular motifs (YMNM and PYAP) that are important for intracellular signaling.

[0264] 74. The method according to any one of clauses 71 to 73, wherein the CD28 domain comprises a YMNM motif (corresponding to Y191-M192-N193-M194 of SEQ ID NO: 13) and / or a PYAP motif (corresponding to P208-Y209-A210-P211 of SEQ ID NO: 13).

[0265] 75. CAL-immune cells are CAL-T cells (e.g., CD8 + T cells or CD4 + T cells, e.g., activated T cells), NK cells, tumor infiltrating lymphocytes (TILs, e.g., pre-REP TILs), memory T cells, T SCM , T CM Or T EM 75. The method according to any one of clauses 1 to 74,

[0266] Within the overall memory T cell population, several distinct subpopulations have been described and can be recognized by differential expression of the chemokine receptors CCR7 and L-selectin (CD62L). Memory T, like naive cells, SCM Stem cells are CD45RO-, CCR7+, CD45RA+, CD62L+ (L-selectin), CD27+, CD28+, and IL-7Rα+, but they also express large amounts of CD95, IL-2Rβ, CXCR3, and LFA-1, and display many of the functional attributes characteristic of memory cells. CM The effector memory T cells express L-selectin and CCR7, and they secrete IL-2 but not IFNγ or IL-4. EM The cells, however, do not express L-selectin or CCR7, but do produce effector cytokines such as IFNγ and IL-4. SCM Memory T cells such as may be particularly useful for establishing persistent populations of modified immune cells in humans.

[0267] Any stem cell may be referred to herein in one example as a T SCM , T CM Or T EM Cells, such as human T SCM , T CM Or TEM It may be a cell.

[0268] 76. The method of any of clauses 1-75, wherein the CAL immune cells are descendants of cells from a human suffering from an autoimmune disease, an inflammatory disease, a viral infection or cancer, for example, the human suffering from lymphoblastic leukemia, ALL (e.g., T-ALL), CLL (e.g., B-cell chronic lymphocytic leukemia) or non-Hodgkin's lymphoma.

[0269] 77. The method of any of clauses 1-76, wherein the CAL immune cells have been modified to enhance signaling, and the signaling is selected from CD28, 4-1BB, OX40, ICOS and CD40 signaling.

[0270] 78. The method of any of clauses 1-77, wherein step (c) comprises mixing the cells together prior to combining the mixed cells with the cross-linking agent.

[0271] 79. The method of any one of clauses 1-77, comprising mixing the target cells and a crosslinking agent together prior to combining the target cells and the agent with the immune cells.

[0272] 80. The method of any of clauses 1 to 79, wherein the method is carried out using a plurality of said target cells, a plurality of said CAL-immune cells and a plurality of copies of said crosslinking agent, and in step (C) the target cells, CAL cells and drug copies are combined and activity of said immune cells is modulated thereby.

[0273] 81. The method according to clause 80, wherein the amount of drug is reduced after step (c).

[0274] 82. The method of clause 80, wherein more of the agent is combined after step (c).

[0275] 83. The method according to any one of clauses 80 or 82, carried out on a human or animal.

[0276] 84. The method of any one of clauses 80 to 82, carried out in vitro with target cells and CAL cells.

[0277] 85. A method for treating or reducing the risk of a disease or condition in a human involving a target cell, the method of any one of clauses 80-84, wherein step (c) comprises administering simultaneously or sequentially to the human a crosslinker copy and a CAL cell (or a progenitor cell thereof), wherein the crosslinker binds to the first and second antigens to target the CAL cell to the target cell, thereby inducing intracellular signaling in the CAL cell to modulate CAL cell activity, thereby treating the disease or condition or reducing the risk of the disease or condition.

[0278] 86. The method according to clause 85, wherein the disease or condition is cancer, an inflammatory disease, an autoimmune disease or a viral infection in a human.

[0279] 87. The method of clause 85 or 86, wherein the target cell (e.g., tumor cell) is killed.

[0280] 88. The method of clause 86 or 87, wherein each target cell is a tumor cell and the method treats or reduces the risk of cancer, or treats or reduces the risk of cancer progression in a human.

[0281] 89. The method of any one of clauses 85-88, wherein the human has cancer.

[0282] In one example, the cancer is a hematological cancer. In one example, the human has a cancer of B cell origin. In one example, the human has a cancer of T cell origin.

[0283] For example, the cancer is lung cancer, melanoma, breast cancer, prostate cancer, colon cancer, renal cell carcinoma, ovarian cancer, neuroblastoma, rhabdomyosarcoma, leukemia and lymphoma. Preferred cancer targets for use in the present invention are cancers of B-cell origin, including in particular acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia or B-cell non-Hodgkin's lymphoma.

[0284] 90. The method of clause 89, wherein the cancer is a cancer of T-cell or B-cell origin, such as lymphoblastic leukemia, ALL (e.g., T-ALL), CLL (e.g., B-cell chronic lymphocytic leukemia), or non-Hodgkin's lymphoma.

[0285] 91. The method of any one of clauses 85-90, wherein the CAL cell is a progeny of said human immune cell, for example, the human has lymphoblastic leukemia, diffuse large B-cell lymphoma (DLBCL), ALL (e.g., T-ALL or B-ALL), CLL (e.g., B-cell chronic lymphocytic leukemia), or non-Hodgkin's lymphoma.

[0286] 92. The method of any one of clauses 85-91, wherein each said cell is an autologous cell (e.g., a T cell) of said human, or is the progeny of such an autologous cell.

[0287] The term "autologous" as used herein is meant to refer to any material derived from the same individual that is subsequently reintroduced into that individual.

[0288] "Allogeneic" refers to graft tissue derived from a different animal of the same species.

[0289] 93. The method of clause 92, wherein each CAL cell is derived from a human blood or tumor sample and is activated and expanded in vitro prior to step (c).

[0290] As used herein, "activation" refers to a state of T cells that have been stimulated sufficiently to induce detectable cell proliferation. Activation may also be associated with the induction of cytokine production and detectable effector function. The term "activated T cells" refers, inter alia, to T cells that are undergoing cell division.

[0291] 94. The method of clause 80, wherein the human has an autoimmune disease and the CAL cells are anergic or have reduced proliferation and / or cytotoxic activity when bound to target cells by the crosslinker, whereby the CAL cells compete with endogenous immune cells of said human to upregulate said autoimmune disease.

[0292] 95. The method of any one of clauses 85 to 94, wherein administration is by infusion of CAL cells into the patient's blood.

[0293] 96. The method of any one of clauses 85-95, comprising expanding the CAL-immune cells to generate an expanded immune cell population that is combined with the target cells in step (c).

[0294] 97. The method of any of clauses 85-96, comprising activating the modified immune cell(s) to generate an activated immune cell population that is combined with the target cell(s) in step (c).

[0295] 98. Chimeric antigen ligand (CAL)-immune cells for targeted binding to antigen-specific agents, A. The drug is i. a first antigen-binding site that specifically binds a first target antigen; and ii. a second antigen-binding site that specifically binds a second target antigen. a multispecific antigen-binding fragment comprising: B. The CAL-immune cell contains a transmembrane ligand, the ligand being iii. an extracellular portion comprising a second antigen linked to the transmembrane domain; iv. an intracellular portion comprising a first signaling domain for intracellular signaling upon binding of the agent to a second antigen; including modified combinations of; C. When the CAL-immune cells and the crosslinking agent are combined with the target cells, the target cells contain the first target antigen, the first antigen being an extracellular antigen; v. A cross-linking agent binds the first and second antigens to target immune cells to the target cells; vi. Thereby inducing intracellular signaling in immune cells to regulate immune cell activity; Chimeric antigen ligand (CAL)-immune cells.

[0296] The features of methods 1 to 97 may be applied mutatis mutandis to the features of clauses 98 et seq.

[0297] In alternative embodiments, clause 98 provides the following alternative clauses VIII-XV. Thus, the features of clause 99 et seq. below are combinable with any of clauses VIII-XV. References to "clause 98" below may be read in alternative embodiments as any of clauses VIII-XV. The "first antigen binding site" in any of clauses 99 et seq. may be read as the "first binding moiety" as listed in any of clauses VIII-XV. The "second antigen binding site" in any of clauses 99 et seq. may be read as the "second binding moiety" as listed in any of clauses VIII-XV. The "first antigen" in any of clauses 99 et seq. may be read as the "fourth binding moiety" as listed in any of clauses VIII-XV. The "second antigen" in any of clauses 99 et seq. may be read as the "third binding moiety" as listed in any of clauses VIII-XV. And a CAL according to any one of clauses 99 et seq. can be read as a "transmembrane protein", a "CAR" or a "CAL" according to any one of clauses VIII to XV.

[0298] VIII. Immune cells for targeted binding to antigen-specific agents, A. The drug is i. a first binding moiety; and ii. a second binding moiety; a multispecific binding fragment comprising: B. Immune cells iii. an extracellular portion comprising a third binding moiety linked to the transmembrane domain, the second and third moieties forming a specific binding pair (SBP1), one moiety specifically binding to the other moiety; iv. an intracellular portion comprising a first signaling domain for intracellular signaling when the second and third portions bind together. expressing a transmembrane protein comprising an engineered combination of: C. when the immune cell and the crosslinking agent are combined with the target cell, the target cell comprises a fourth binding moiety, the fourth binding moiety being extracellular; v. the first and fourth moieties form a specific binding pair (SBP2), where one moiety specifically binds to the other moiety to target the immune cell to the target cell; vi. the second and third portions bind together, thereby inducing intracellular signaling in the immune cell to modulate immune cell activity; and D. The molecular weight of the crosslinker is 125 kDa or less; immune cells.

[0299] IX. The immune cell of clause VIII in combination with a crosslinking agent.

[0300] X. The immune cell of clauses VIII-IX, wherein the first and second binding moieties are ligand binding sites.

[0301] XI. The immune cell of clause X, wherein the first and second binding moieties are first and second antigen-binding sites, respectively (e.g., VH / VL antigen-binding sites).

[0302] XII. Each of SBP1 and SB2 is (a) an antigen and an antigen-binding site (e.g., an antigen and a VH / VL antigen-binding site, or a superantigen and an antibody variable domain); and (b) Receptors and Ligands The immune cell according to any one of clauses VIII to XI, selected from the group consisting of:

[0303] XIII. The immune cell of any one of clauses VIII-XII, wherein the transmembrane protein is a chimeric antigen ligand (CAL), the third portion is an antigen and the second portion is an antigen binding site (e.g., scFv), and optionally the first portion is an antigen binding site (e.g., scFv) and the fourth portion is an antigen.

[0304] XIV. The immune cell of any one of clauses VIII-XII, wherein the transmembrane protein is a chimeric antigen receptor (CAR), the third portion is an antigen binding site and the second portion is an antigen, and optionally the first portion is an antigen binding site (e.g., an scFv) and the fourth portion is an antigen.

[0305] XV. The immune cell of any one of clauses VIII-XIV, wherein the molecular weight of the crosslinker is 115 kDa or less, for example, 55-115 kDa, or 60-100 kDa.

[0306] Generally applicable features: 99. The CAL cell of clause 98, wherein the CAL comprises a hinge region and / or a linker between the second antigen and the transmembrane domain.

[0307] 100. The CAL cell of clause 99, wherein the hinge region is a CD8α hinge region.

[0308] In one example, the transmembrane domain is a CD8α transmembrane domain. In one example, the second antigen and / or the first signaling domain are human. Optionally, the transmembrane domain and / or the hinge are human.

[0309] 101. A CAL cell according to any one of clauses 98 to 100, wherein the signal transduction upregulates CAL cytotoxicity.

[0310] 102. The CAL cell of any one of clauses 98-101, wherein the signaling upregulates ADCC activity of the CAL cell.

[0311] 103. The CAL cell of any one of clauses 98-102, wherein the first antigen is a tumor-associated antigen (TAA).

[0312] 104. The first antigen is human CD19 (and optionally, the target cell is a leukemia cell or lymphoma cell), EpCAM (and optionally, the target cell is a lung cancer cell, a gastrointestinal cancer cell, an adenocarcinoma, a cancer stem cell), CD20 (and optionally, the target cell is a leukemia cell), MCSP (and optionally, the target cell is a melanoma cell), CEA, EGFR, EGFRvIII, HER2, sialyl Tn, CD133, CD33 (and optionally, the target cell is a is a leukemic cell, e.g., an AML cell), PMSA, CD30, CD47, CD52, gpA33, TAG-72, mucin, CIX, GD2, GD3, GM2, CD123, VEGFR, integrin, cMET, Her1, Her2, Her3, IGF1R, EPHA3, CD66e, EphA2, TRAILR1, TRAILR2, RANKL, FAP, angiopoietin, or tenascin.

[0313] 105. The first antigen-binding site is a CD19-binding site of blinatumomab or antibody HD37; an EpCAM-binding site of catumaxomab; a CD19-binding site of AFM11; a CD20-binding site of Lymphomun; a Her2-binding site of ertumaxomab; a CEA-binding site of AMG211 (MEDI-565, MT111); a PSMA-binding site of pasotuxizumab; an EpCAM-binding site of solitomab; a VEGF or angiopoietin 2-binding site of RG7221 or RG7716. 105. The CAL cell of any one of clauses 98 to 104, comprising a variable domain of an antibody selected from the group consisting of: a Her1 or Her3 binding site of RG7597; a Her2 or Her3 binding site of MM111; an IGF1R or Her3 binding site of MM141; a CD123 binding site of MGD006; a gpa33 binding site of MGD007; a CEA binding site of TF2; a CD30 binding site of AFM13; a CD19 binding site of AFM11; and a Her1 or cMet binding site of LY3164530.

[0314] 106. CAL cells according to any one of clauses 98 to 105, wherein the crosslinking agent is Blinatumomab or a CD3 / CD19-binding derivative thereof (optionally, the target cell is an acute lymphoblastic leukemia (ALL) B cell); AMG211 or a CD3 / CEA-binding derivative thereof (MEDI-565, MT111; optionally, the target cell is a gastrointestinal cancer cell); Pasotuxizumab or a CD3 / PMSA-binding derivative thereof (optionally, the target cell is a prostate cancer cell); Solitomab or a CD3 / EpCAM-binding derivative thereof (optionally, the target cell is a cancer cell); or AFM11 or a CD3 / CD19-binding derivative thereof (and optionally, the target cell is an ALL cell or a non-Hodgkin's lymphoma cell).

[0315] 107. The first antigen-binding site is selected from the group consisting of LeoPro(trademark); abciximab; Rituxan(trademark); rituximab; Zenapax(trademark); daclizumab; Simulect(trademark); basiliximab; Synagis(trademark); palivizumab; Remicade(trademark); infliximab; Herceptin(trademark); trastuzumab; Mylotarg(trademark); gemtuzumab; Cambus(trademark); alemtuzumab ;Zevalin(trademark);Ibritumomab;Humira(trademark);Adalimumab;Xolair(trademark);Omalizumab;Bexar(trademark);Tositumomab;Raptiva(trademark);Efalizumab;Erbitux(trademark);Cetuximab;Avastin(trademark);Bevacizumab;Tysabri(trademark);Natalizumab;Actemra(trademark);Tocilizumab;Vectibix(trademark);Panitumumab ;Lucentis(TM);Ranibizumab;Soliris(TM);Eculizumab;Cimzia(TM);Certolizumab;Simponi(TM);Golimumab, Ilaris(TM);Canakinumab;Stelara(TM);Ustekinumab;Arzera(TM);Ofatumumab;Prolia(TM);Denosumab;Numax(TM);Motavizumab;ABThrax(TM);Raxibacumab;Benlysta(TM);Belimumab;Yervoy(TM);Ipilimumab;Adcetris(TM);Brentuximab;Vedotin(TM);Perjeta(TM);Pertuzumab;Kadcyla(TM);Adotrastuzumab;Gazyva(TM) and obinutuzumab. A CAL cell according to any one of clauses 98 to 106, comprising a variable domain of the antigen binding site of an antibody selected from the group consisting of:

[0316] 108. The CAL cell of any one of clauses 98-102, wherein the first antigen is an autoimmune disease target and the signaling downregulates immune cell cytotoxic activity or proliferation.

[0317] 109. The CAL cell of any one of clauses 98 to 108, wherein the second antigen is an extracellular antigen of an immune cell (e.g., a human T cell or a NK cell).

[0318] 110. The CAL cell of any one of clauses 98-109, wherein the second antigen is a protein antigen and the immune cell comprises a first nucleotide sequence that is an endogenous sequence (e.g., a CD3 extracellular domain sequence) that expresses an amino acid sequence that is identical to an amino acid sequence of the second antigen contained in the CAL.

[0319] 111. The CAL cell of any one of clauses 98-110, wherein the second antigen is provided by an extracellular domain sequence of human CD3 or human CD16.

[0320] 112. The CAL cell according to clause 111, wherein the CD3 extracellular domain is a CD3γ, CD3δ or CDε domain.

[0321] 113. The CAL cell of any one of clauses 98-112, wherein the second target binding site comprises a variable domain of an anti-CD3 binding site of an antibody selected from the group consisting of antibody L2K-07, antibody OKT3™, muromonab-CD3, otelixizumab, teplizumab, visilizumab, catumaxomab, ertumaxomab and foralumab.

[0322] 114. The CAL cell of any one of clauses 98-113, wherein the extracellular portion does not contain non-self epitopes.

[0323] 115. a. A second antigen of the CAL is encoded in the cell by a non-endogenous nucleotide (S1) sequence that contains a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of the antigen; b. the genome of the cell comprises a second nucleotide sequence (S2) that contains SNP1 and encodes an amino acid sequence identical to the amino acid sequence of the second antigen and comprises R1; or that encodes an amino acid sequence that is a naturally occurring variant of the amino acid sequence of the second antigen and comprises R1; and c. S2 is an endogenous genomic sequence of the cell and SNP1 is a nonsynonymous SNP; The CAL cell of any one of clauses 98 to 114.

[0324] 116. The CAL cell of any one of clauses 98-115, wherein the CAL cell is for use in a method of treating or reducing the risk of a disease or condition (e.g., cancer) in a human, the method comprising administering to the human the CAL cell and said crosslinking agent, wherein the CAL cell and the human target cell are combined and crosslinked by the crosslinking agent, thereby upregulating signaling in the CAL cell to increase target cell cytotoxicity (e.g., ADCC-mediated killing activity) of the CAL cell, thereby treating or reducing the risk of said disease or condition in the human.

[0325] In the methods herein, an effective amount of the CAL cells and crosslinking agent is administered. As used herein, "effective amount" means an amount that provides a therapeutic or prophylactic benefit.

[0326] In an embodiment of the method of the invention, the method treats or reduces the risk of cancer in a patient (e.g., a human), and the patient has undergone lymphodepletion prior to administration of the immune cells of the invention to the patient.

[0327] 117. The CAL cell of any one of clauses 98-115, wherein the CAL cell is for use in a method of treating or reducing the risk of a disease or condition in a human (e.g., an autoimmune disease, GvHD, or allograft rejection), the method comprising administering to the human the CAL cell and said crosslinking agent, wherein the CAL cell and the human target cell are combined and crosslinked by the crosslinking agent, thereby upregulating signaling in the CAL cell to reduce the cytotoxicity (e.g., ADCC-mediated killing activity) of the CAL cell, thereby treating or reducing the risk of said disease or condition in the human.

[0328] 118. The CAL cells according to clause 117, wherein said cross-linking induces CAL cell anergy in humans.

[0329] 119. A graft (e.g., an allograft) comprising a plurality of CAL-cells according to clause 117 or 118, wherein the graft is intended to treat or reduce a disease or condition in a human by competing with immune cells that mediate the disease or condition (e.g., mediated by T cell activity).

[0330] For example, CAL cells effectively "dilute" the prevalence or other disease activity of disease-mediating endogenous immune cells at the site of tissue damage. By thus reducing the local concentration of such disease-mediating endogenous immune cells, undesirable activity of endogenous immune cells such as T cells (e.g., autoimmune, GvHD or rejection activity) may be suppressed in humans. In this case, in one embodiment, CAL cells (e.g., CAL-T cells) become anergy, whereby such anergic cells "dilute" the activity of endogenous T cells, thereby suppressing or reducing the risk of a disease or condition in humans.

[0331] In another example, the immune cells of the invention become activated to kill target cells (eg, T cells) in a patient to treat or prevent a disease or condition.

[0332] As used herein, the term "treating" a disease means reducing the frequency or severity of at least one sign or symptom of the disease or condition experienced by a subject.

[0333] 120. A CAL cell or graft according to any one of clauses 116 to 119, subject to clause 115, in which the genome of the human comprises said SNP1 prior to said administration.

[0334] In this way, the cells or grafts are adapted in their extracellular portion to enhance compatibility with the recipient human.

[0335] 121. A CAL cell or graft according to any one of clauses 98 to 120, wherein the target cell is a human cell.

[0336] 122. The CAL cell or graft of any one of clauses 98-121, wherein the target cell is a tumor cell and the signaling upregulates immune cell cytotoxic activity (e.g., ADCC) or proliferation.

[0337] 123. A CAL cell or graft according to any one of clauses 98 to 122, wherein the target cell is a leukemia cell, a lymphoma cell, an adenocarcinoma cell or a cancer stem cell.

[0338] 124. CAL cells or grafts according to any one of clauses 98 to 123, wherein the target cells are blood cells.

[0339] 125. The CAL cell or graft according to any one of clauses 98 to 123, wherein the target cell is a B cell or a T cell.

[0340] 126. CAL cell or graft according to any one of clauses 116 to 125 when dependent on clause 115 or clause 115, wherein the second antigen of the CAL is the CD3 gamma extracellular domain and R1 is selected from the group consisting of I11, M11, A22, T22, I53, N53, T53, V131, F131, R166, G166, Y171 and H171 (position numbers correspond to positions in SEQ ID NO: 1).

[0341] As with the above embodiment, the inventors have noted that such positions are permissive for naturally occurring CD3γ mutations in humans and therefore have identified them as candidate positions for adaptation in accordance with the present invention.

[0342] 127. The CAL cell or graft according to clause 126, wherein the second antigen comprises I11, A22, I53, N53, V131, R166 and Y171.

[0343] The inventors realised that these mutations are the most common in humans (as shown by Ensembl) and therefore this signature is likely to be compatible with most humans and most human cells.

[0344] 128. A CAL cell or graft according to any one of clauses 116 to 125 when subordinate to clause 115 or clause 115, wherein the second antigen of the CAL is the CD3δ extracellular domain and R1 is selected from the group consisting of Q18, K18, N38 and K38 (position numbers corresponding to positions in SEQ ID NO: 3).

[0345] As with the above embodiment, the inventors have noted that such positions are permissive for naturally occurring CD3δ mutations in humans and therefore have identified these as candidate positions for fitting in accordance with the present invention.

[0346] 129. The CAL cell or graft according to clause 128, wherein the second antigen comprises Q18 and N38.

[0347] The inventors realised that these mutations are the most common in humans (as shown by Ensembl) and therefore this signature is likely to be compatible with most humans and most human cells.

[0348] 130. CAL cell or graft according to any one of clauses 116 to 125 when subordinate to clause 115 or clause 115, wherein the second antigen of the CAL is the CD3ε extracellular domain and R1 is selected from the group consisting of D71, N71, H71, Y71, A108, E108, V108, A157 and V157 (position numbers correspond to positions in SEQ ID NO: 5).

[0349] As with the above embodiment, the inventors have noted that such positions are permissive for naturally occurring CD3ε mutations in humans and therefore have identified them as candidate positions for adaptation in accordance with the present invention.

[0350] 131. The CAL cell or graft according to clause 130, wherein the second antigen comprises D71, A108 and A157.

[0351] The inventors realised that these mutations are the most common in humans (as shown by Ensembl) and therefore this signature is likely to be compatible with most humans and most human cells.

[0352] 132. A CAL cell or graft according to any one of clauses 116 to 131, wherein each CAL cell is a modified descendant of a human ancestral cell, and the method comprises administering the modified CAL cell or graft to a human, wherein the CAL cell(s) and the target cell are combined.

[0353] 133.a. a first signaling domain (SD1) is encoded in each CAL cell by a third nucleotide sequence (S3) that includes a human single nucleotide polymorphism (SNP2) that encodes an amino acid residue (R2) of the signaling domain; b. the genome of the cell comprises SNP2 and comprises a fourth nucleotide sequence (S4) encoding a signaling domain (SD2), where SD2 is identical to SD1 and comprises R2, or (ii) is a naturally occurring variant of SD1 and comprises R2; and c. S4 is an endogenous genomic sequence of the cell and SNP2 is a nonsynonymous SNP; CAL cells or grafts according to any one of clauses 98 to 132.

[0354] 134. A CAL cell or graft according to clause 133, wherein each of SD1 and SD2 comprises an immunoreceptor tyrosine-based activation motif (ITAM) that includes R2.

[0355] 135. A CAL cell or graft according to clause 134, wherein the ITAMs of the signalling domains are identical.

[0356] 136. The CAL cell or graft of any one of clauses 98-135, wherein the intracellular portion comprises a further intracellular signalling domain (SD3) encoded in the cell by a fifth nucleotide sequence (S5), wherein S5 comprises a human single nucleotide polymorphism (SNP3) encoding an amino acid residue (R3) of SD3, and the genome of the cell comprises a sixth nucleotide sequence (S6) encoding a signalling domain (SD4), wherein SD4 is identical to SD3 and comprises R3; or is a naturally occurring variant of SD3 and comprises R3, and S6 is an endogenous genomic sequence of the cell, and SNP3 is a non-synonymous SNP.

[0357] 137. CAL cells or grafts according to clause 136, in which the recipient's SD1 and SD3 are different.

[0358] 138. A CAL cell or graft according to clause 136 or 137, wherein each of SD3 and SD4 comprises an ITAM comprising R3.

[0359] 139. CAL cells or grafts according to clause 138, wherein the ITAMs of SD3 and SD4 are identical.

[0360] 140. CAL cells or grafts according to any one of clauses 136 to 139, wherein SD3 and SD4 are identical.

[0361] 141. A CAL cell or graft according to any one of clauses 136 to 140, wherein SD3 is human.

[0362] 142. The CAL cell or graft according to any one of clauses 136 to 141, wherein each of SD3 is a CD3ζ (CD3 zeta) domain, a CD3η (CD3 eta) domain, an FcεRIγ domain, a CD64 domain, a CD16 (e.g., CD16A) domain, a CD27 domain, a CD28 domain, an ICOS domain, an OX40 domain, a CD40 domain or a 4-1BB domain.

[0363] 143. The CAL cell or graft of any one of clauses 98-142, wherein the first signaling domain is a CD3 intracellular domain selected from a CD3ζ (CD3 zeta) domain (wherein the second antigen is not a CD3 domain), a CD3η (CD3 eta) domain (wherein the second antigen is not a CD3 domain), an FcεRIγ domain, a CD64 domain, a CD16 domain (wherein the second antigen is not a CD16 domain), a CD27 domain, a CD28 domain, an ICOS domain, an OX40 domain, a CD40 domain, or a 4-1BB domain.

[0364] 144. The CAL cell or graft of clause 143, wherein the first signaling domain is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3 eta) domain and comprises one, two or three amino acid motifs selected from: (a) SEQ ID NO: 10, optionally with up to 10, 9, 8, 7, 6 or 5 (e.g., up to 5) amino acid differences, but in which tyrosine is conserved; (b) SEQ ID NO: 11, optionally with up to 10, 9, 8, 7, 6 or 5 (e.g., up to 5) amino acid differences, but in which tyrosine is conserved; and (c) SEQ ID NO: 12, optionally with up to 10, 9, 8, 7, 6 or 5 (e.g., up to 5) amino acid differences, but in which tyrosine is conserved.

[0365] 145. The CAL cell or graft according to clause 144, wherein the first signalling domain comprises motif (a), and the motif differs from SEQ ID NO: 10 by up to five changes at residues selected from the group consisting of A61, P62, A63, Q66, G67, N69, Q70, N73, R79, E82, D84, V85, D87 and K88.

[0366] The CAL cell or graft of clause 145, wherein the alteration is selected from the group consisting of A61V, A61P, P62S, P62A, A63P, Q66H, G67S, N69T, Q70Y, Q70L, Q70P, Q70W, N73Y, R79L, R79G, E82K, D84G, D84A, D84Y, V85I, D87G and K88R.

[0367] The CAL cell or graft of any one of clauses 144 to 146, wherein the first signaling domain comprises motif (b), and the motif differs from SEQ ID NO: 12 by up to five changes at residues selected from the group consisting of P100, Q101, R103, K104, N105, P106, E108, L110, A120, A122 and M128.

[0368] 148. The CAL cell or graft according to clause 147, wherein the alteration is selected from the group consisting of P100L, Q101L, Q101P, R103K, K104E, N105K, P106R, E108A, L110Q, A120V, A122V and M128T.

[0369] 149. The CAL cell or graft of any one of clauses 144-148, wherein the first signaling domain comprises motif (c), and the motif differs from SEQ ID NO: 13 by up to five changes at residues selected from the group consisting of E131, R132, R133, K136, G137, G140, L145, A148, T152, A155, L156.

[0370] 150. The CAL cell or graft according to clause 149, wherein the alteration is selected from the group consisting of E131K, R132H, R132C, R133Q, R133W, K136N, G137E, G140D, L145F, A148D, T152I, A155T, L156P.

[0371] 151. The CAL cell or graft according to any one of clauses 98 to 150, wherein the first signalling domain is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3 eta) domain and comprises one, more or all of the amino acid residues selected from the group consisting of S58, Y64, Y72, Y83, Y111, Y123, Y142 and Y153 (position numbers correspond to positions in SEQ ID NO: 7).

[0372] 152. The first signaling domain is a CD3 intracellular domain selected from the group consisting of the CD3 zeta domain and the CD3 eta domain, and is selected from the group consisting of rs368651001, rs372651048, rs767112686, rs765877580, rs751145956, rs772867144, rs55893506, rs761710510, rs776601547, rs 768607376, rs193922741, rs193922740, rs193922739, rs780188126, rs772128174, rs757978223, rs7793975 62, rs749926653, rs181746205, rs181746205, rs753572867, rs371709798, rs145407267, rs143180729, rs148 513413, rs367690333, rs144963570, rs367690333, rs144963570, rs770320255, rs139926301, rs56297636, r s760895755, rs112890541, rs370910340, rs145505909, rs754935006, rs751583971, rs766541481, rs7630749 67, rs745871212, rs372665461, rs764185491, rs756340039, rs773572491, rs201594815, rs781510519, rs14 7527561, rs751981677, rs763532939, rs753278244, rs771873949, rs186004179, rs186004179, rs762773775, 152. The CAL cell or graft of any one of clauses 98 to 151, comprising a residue encoded by a SNP selected from the group consisting of rs748158220, rs776703680, rs561262982, rs758846009, rs746262183, rs376046446, rs201937405 and rs752198795, and wherein the genome of the immune cell comprises an endogenous nucleotide sequence comprising said selected SNP.

[0373] 153. The CAL cell or graft according to any one of clauses 98 to 152, wherein the first or third signalling domain is a CD28 intracellular domain comprising at least 13 amino acid residues selected from the group consisting of R180, S181, K182, R183, S184, R185, L186, D190, Y191, N193, P196, P199, T202, K204, Q207, F215, A217 and Y218.

[0374] 154. A CAL cell or graft according to clause 153, wherein the CD28 domain comprises all residues of the above groups.

[0375] 155. A CAL cell or graft according to clause 153 or 154, wherein the CD28 domain comprises amino acid residues Y191 and Y209 (position numbers corresponding to positions in SEQ ID NO: 13).

[0376] 156. CAL cell or graft according to any one of clauses 153 to 155, wherein the CD28 domain comprises a YMNM motif (corresponding to SEQ ID NO: Y191-M192-N193-M194 of the full length CD28 sequence) and / or a PYAP motif (corresponding to P208-Y209-A210-P211 of SEQ ID NO: 13).

[0377] 157. Each CAL-immune cell is a CAL-T cell (e.g., CD8 + T cells or CD4 + The CAL cell or graft of any one of clauses 98-156, which is a T cell, e.g., an activated T cell), a NK cell, a tumor infiltrating lymphocyte (TIL, e.g., a pre-REP TIL), a memory T cell, a TSCM, a TCM or a TEM.

[0378] 158. The CAL cell or graft of any one of clauses 98-157, wherein each CAL immune cell is a descendant of a cell of a human suffering from an autoimmune disease, an inflammatory disease, a viral infection or cancer, for example, the human suffering from lymphoblastic leukemia, ALL (e.g., T-ALL), CLL (e.g., B-cell chronic lymphocytic leukemia) or non-Hodgkin's lymphoma.

[0379] In one embodiment, the human is resistant to at least one chemotherapeutic agent.

[0380] In one embodiment, the chronic lymphocytic leukemia is refractory CD19+ leukemia and lymphoma.

[0381] The invention also includes a method of generating a persistent population of genetically modified T cells in a human diagnosed with cancer. In one embodiment, the method includes administering T cells of the invention (e.g., CAL T cells) to the human, and the persistent population of genetically modified T cells persists in the human for at least one month after administration. In one embodiment, the persistent population of genetically modified T cells includes memory T cells. In one embodiment, the persistent population of genetically modified T cells persists in the human for at least three months after administration. In another embodiment, the persistent population of genetically modified T cells persists in the human for at least four, five, six, seven, eight, nine, ten, eleven, twelve months, two, or three years after administration.

[0382] In one embodiment, chronic lymphocytic leukemia is treated. The present invention also provides a method of expanding a population of modified T cells or NK cells in a human diagnosed with cancer.

[0383] Optionally, autologous lymphocyte infusion is used in the treatment: autologous PBMCs are obtained from a patient in need of treatment, T cells are engineered to express a transmembrane protein of the invention, activated and expanded using methods known in the art, and then infused back into the patient, either simultaneously with or consecutively with administration of the cross-linking agent.

[0384] 159. The CAL cell or graft of any one of clauses 98 to 158, wherein each CAL-immune cell has been modified to enhance signaling, the signaling being selected from CD28, 4-1BB, OX40, ICOS and CD40 signaling.

[0385] 160. A CAL cell or graft according to any one of clauses 98 to 159, wherein each CAL cell is derived from a blood or tumor sample of a human (eg a cancer patient), and the cells are activated cells.

[0386] 161. A CAL cell or graft according to any one of clauses 98 to 160, combined with a cross-linking agent.

[0387] 162. CAL cells or grafts according to clause 161, wherein the cross-linking agent has a human serum half-life shorter than the human serum half-life of IgG.

[0388] 163. CAL cells or grafts according to clause 161 or 162, wherein the crosslinking agent has a human serum half-life of 5 days or less.

[0389] 164. A CAL cell or graft according to clause 163, having a half-life of less than 1 day.

[0390] 165. The CAL cell or graft according to any one of clauses 161-164, wherein the first binding site is a VH / VL binding site of an antibody.

[0391] 166. The CAL cell or graft according to any one of clauses 161-165, wherein the second binding site is a VH / VL binding site of an antibody.

[0392] 167. A CAL cell or graft according to any one of clauses 161 to 166, wherein the binding affinity (KD) of the first binding site for the first antigen is at least 5, 10 or 20 times lower than the affinity of the second binding site for the second antigen.

[0393] 168. A CAL cell or graft according to any one of clauses 161 to 167, wherein the first binding site has a binding affinity (KD) for a first antigen of 10 nM or less as determined by surface plasmon resonance (SPR), and the second binding site has a binding affinity (KD) for a second antigen of 50 nM or more (e.g., up to 1 mM) as determined by SPR.

[0394] 169. A CAL cell or graft according to any one of clauses 161 to 168, wherein the first binding site has a binding affinity (KD) for a first antigen of 2 nM or less as determined by SPR, and the second binding site has a binding affinity (KD) for a second antigen of 60 nM or more (e.g., up to 1 mM) as determined by SPR.

[0395] 170. A CAL cell or graft according to any of clauses 161-169, wherein the first binding site has a binding affinity (KD) for the first antigen of 100 nM or less as determined by surface plasmon resonance (SPR).

[0396] 171. The first binding site has a Koff of 10 as determined by SPR. -3 171. The CAL cell or graft of any one of clauses 161 to 170, having a binding dissociation rate to the first antigen of 1 / sec or less.

[0397] 172. The CAL cell or graft according to any one of clauses 161-172, wherein the second binding site has a binding affinity (KD) for the second antigen of 100 nM or less as determined by surface plasmon resonance (SPR).

[0398] 173. A CAL cell or graft according to any one of clauses 161 to 172, wherein the binding affinity (KD) of the first binding site for the first antigen is higher than the affinity (KD) of the second binding site for the second antigen, and the affinity for the second antigen is less than 100 nM.

[0399] 174. The second binding site has a Koff of 10 as determined by SPR. -3 174. The CAL cell or graft of any one of clauses 161 to 173, having a binding dissociation rate to the first antigen of 1 / sec or less.

[0400] 175. The CAL cell or graft according to any one of clauses 161 to 174, wherein each of the first and second antigen binding sites is selected from the group consisting of scFv, Nanobody™, dAb, Duocalin, DARpin, Avimer, Adnectin and Finomer.

[0401] 176. CAL cells or grafts according to any one of clauses 161 to 175, wherein the size of the cross-linking agent is 100 kDa or less.

[0402] 177. A CAL cell or graft according to any one of clauses 161 to 176, wherein the size of the cross-linking agent is 80 kDa or less (eg 50 or 55 kDa or less).

[0403] 178. The CAL cell or graft of any one of clauses 161-177, wherein the crosslinking agent is or comprises a BiTE™ antibody, a bispecific scFv, a trispecific scFv, a tandab™, a dAb nanobody (e.g., a dimer or trimer), a dAb multimer (e.g., a dimer or trimer), a diabody, a tetrabody or a DART™.

[0404] 179. A CAL cell or graft according to any one of clauses 161 to 178, wherein the cross-linking agent comprises a third antigen-binding site.

[0405] 180. A CAL cell or graft according to clause 179, wherein the third antigen is different from the first antigen.

[0406] 181. The CAL cell or graft according to clause 179 or 180, wherein the third antigen is a tumor-associated antigen (TAA), for example a cell surface TAA contained on the target cell.

[0407] 182. CAL cells or grafts according to any one of clauses 161-180, wherein the first and / or third antigen is more prevalent on cancer cells than on normal cells.

[0408] 183. A CAL-immune cell, a CAL-T cell, a CAL-NK cell or a CAL-TIL, wherein the CAL is as defined in any one of clauses 98 to 182.

[0409] A CAR-immune cell, a CAR-T cell, a CAR-NK cell or a CAR-TIL, wherein the CAR is as defined in any one of clauses 98 to 182 (with reference to any one of clauses VIII to XV).

[0410] 184. A population of CAL-immune cells, a population of CAL-T cells, a population of CAL-NK cells or a population of CAL-TILs, wherein the cells are as described in clause 183.

[0411] A population of CAR-immune cells, a population of CAR-T cells, a population of CAR-NK cells or a population of CAR-TILs, wherein the cells are as described in clause 183.

[0412] 185. A cell or population of clause 183 or 184 for use in a method for treating or reducing the risk of a human disease or condition, wherein the method is in accordance with any one of clauses 116 to 120.

[0413] 186. A cell or population according to any one of clauses 98 to 185 contained in a medical IV container, infusion device or syringe.

[0414] 187. A mammalian stem cell comprising a nucleotide sequence encoding a modified transmembrane protein according to any one of clauses 1 to 186.

[0415] 188. The cell according to clause 187, wherein the modified protein is a CAL.

[0416] 189. The cell according to clause 187, wherein the modified protein is CAR.

[0417] 190. The cell according to any one of clauses 187 to 189, wherein the cell is pluripotent or multipotent.

[0418] The stem cells are incapable of developing into a human being. In one embodiment, the stem cells are incapable of developing into a human embryo or zygote.

[0419] 191. The cell according to any one of clauses 187 to 190, wherein the cell is a bone marrow stem cell.

[0420] 192. The cell according to any one of clauses 187 to 191, wherein the cell is a hematopoietic stem cell.

[0421] 193. The cell according to any one of clauses 187 to 192, wherein the cell is a non-human stem cell.

[0422] 194. The cell according to any one of clauses 187 to 193, wherein the cell is ex vivo.

[0423] 195. A population of cells comprising a plurality of stem cells according to any one of clauses 187 to 194.

[0424] 196. The method of any one of clauses 1-97, wherein step (c) comprises administering to a human a crosslinking agent and stem cells of any one of clauses 187-194, wherein the stem cells develop into said immune cells expressing the modified transmembrane protein (e.g., CAL or CAR), and wherein the immune cells are combined with target cells in the human.

[0425] 197. The method of claim 196, wherein the method comprises administering the population of claim 195, wherein said stem cells develop into a plurality of immune cells expressing the modified transmembrane protein, and the immune cells are combined with target cells in a human.

[0426] 198. A cell or population according to any one of clauses 187 to 195 for use in the method of clause 196 or 197 for treating or reducing the risk of a disease or condition in a human, such as cancer or an autoimmune disease or condition.

[0427] Precision immunotherapy: Domain mutations & further adaptation aspects It is recognized that individual humans have different sequences and recently some, for example James Watson and Craig Venter, have had their genomes sequenced. Comparison of genome sequences of individuals has revealed differences in their sequences, both in coding and non-coding parts of the genome. Some of these variations in humans are significant and contribute to phenotypic differences between individuals. In extreme cases, they result in inherited diseases. The 1000 Genomes Project aims to catalog the sequences in the human genome and involves sequencing a very large sample of genomes from individuals from diverse human ethnic groups as recognized in the art.

[0428] There is accumulating evidence regarding polymorphisms in intracellular signaling proteins with various disease states that are applicable to the present invention. For example, Genes Immun.2015 Mar;16(2):142-50.doi: 10.1038 / gene.2014.73.Epub 2015 Jan 8, "Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study", Martins M et al.; Rheumatology(Oxford).2013 Sep;52(9):1551-5.doi:10.1093 / rheumatology / ket119.Epub 2013 Mar 22, "CD247 variants and single-nucleotide polymorphisms observed in systemic lupus erythematosus patients", Takeuchi T & Suzuki K; "Polymorphisms in CD28,CTLA-4,CD80 and CD86 genes may influence the risk of multiple sclerosis and its age of onset",Wagner M et al.,J Neuroimmunol.2015 Nov 15;288:79-86.doi:10.1016 / j.jneuroim.2015.09.004.Epub 2015 Sep 18; "CTLA-4 and CD28 genes' polymorphisms and renal cell Carcinoma susceptibility in the Polish population-a prospective study",Tupikowski K et al.,Tissue Antigens.2015 Nov;86(5):353-61.doi:10.1111 / tan.12671.Epub 2015 Sep 25; and "CTLA-4,CD28,and ICOS gene polymorphism associations with non-small-cell lung cancer", Karabon L,Hum Immunol.2011 Oct;72(10):947-54.doi:10.1016 / j.humimm.2011.05.010.Epub 2011 May 24.

[0429] Through the application of human gene mutation analysis and rationally designed sequence selection, the present invention provides improved human patient treatments based on human mutations in the protein components of CAR and CAL. Importantly, the present invention enables tailored medicines that address the genotype or phenotype of individual human patients.

[0430] The inventors' analysis of a large number of naturally occurring genomic human sequences reveals that there is significant variation between various human populations, providing the ability to correlate between individual human patients and targeted tailored drug approaches. The technical application of these findings, according to the present invention, therefore contributes to better treatment and prevention in humans, providing benefits to patients by enabling personalized medicine and therapy. This provides the benefits of better prescriptions, less drug waste and improved chances of efficacy in patients.

[0431] This has led the inventors to realise that there are important industrial and medical applications for the present invention in guiding the selection of CAR and CAL protein domains for administration to human patients for the treatment and / or prevention of diseases and conditions. In this way, patients receive immunotherapy tailored to their needs, as determined by the genetic or phenotypic makeup of the patient. In line with this, the present invention provides genotyping and / or phenotyping of patients relevant to such treatment, thereby enabling proper matching of drugs to patients. This increases the chances of medical efficacy, reduces the likelihood of inferior treatment (e.g. poor efficacy and / or side effects) with drugs that are not compatible with the patient, and avoids misprescription and waste of medicines.

[0432] As mentioned above and further explained in Example 1, an embodiment of the present invention provides for the adaptation of the sequences used to modify a transmembrane protein (e.g., CAL or CAR) with the endogenous (i.e., naturally occurring) genotype of a recipient cell or human patient. In this aspect, the inventors have adapted the engineered protein domain(s) to reflect the natural mutations found in the human population and found in the genome of the recipient human cells and patients. This is based in part on the recognition that the naturally tolerated amino acid mutations (and corresponding non-synonymous SNPs) in humans have co-evolved to operate efficiently with other components of the intracellular signaling machinery. As shown by the publication immediately above, mutations in signaling proteins can lead to undesirable effects, possibly in part through poor signaling. The present invention aims to adapt the engineered proteins to more closely reflect the endogenous proteins and genotypes of human cells and patients used in the present invention.

[0433] Similar to matching with intracellular signaling mechanisms, in another aspect the invention provides that the extracellular portion of the engineered transmembrane protein is exposed to the recipient patient's immune system on the surface of immune cells. Thus, matching embodiments of the invention also provide for the desirability of making the extracellular portion of the transmembrane protein appear as "self" as possible to the recipient human patient. Thus, in aspects, one or more polymorphisms in the extracellular portion (e.g., in the second antigen or hinge of the CAL) are matched to polymorphisms naturally found in the patient. In the examples, the inventors have identified common individual polymorphisms or groups of polymorphisms that should be useful for matching human cell populations and patients with such common polymorphisms.

[0434] As an extension of this, the present invention identifies "universal frameworks" for the domains of the transmembrane proteins of the present invention. This is based on identifying groups of residues in particular domains that are naturally tolerated for variation in the human population. The present invention identifies a collection of such mutations, each of which represents the most common polymorphisms in humans, and therefore the inventors believe that they will be useful in generating "universal CARs" and "universal CALs" that can be used in many human cells and human patients, as they are compatible with many naturally occurring polymorphisms in such cells and patients.

[0435] Therefore, the present invention provides the following specific aspects of this embodiment of the invention that utilize genomic and phenotypic matching:

[0436] 1. A human immune cell comprising a modified transmembrane protein, Protein, A. an extracellular portion comprising one or more ligand binding domains or one or more ligand domains; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain (SD1); Includes; D. the variant protein SD1 is encoded in the cell by a first nucleotide sequence (S1) that includes a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of SD1; E. the genome of the cell comprises SNP1 and comprises a second nucleotide sequence (S2) encoding a second signaling domain (SD2), the second signaling domain being (i) identical to SD1 and comprising R1, or (ii) a variant of a naturally occurring SD1 and comprising R1; and F. S2 is an endogenous genomic sequence of the cell, and SNP1 is a non-synonymous SNP; Human immune cells.

[0437] Additionally or alternatively, clause 1 provides: 1. A human immune cell comprising a modified transmembrane protein, Protein, A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain Includes; D. a first antigen or ligand domain of the variant protein is encoded in the cell by a first nucleotide sequence (S1) that includes a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of the antigen or ligand domain; E. the genome of the cell comprises SNP1 and comprises a second nucleotide sequence (S2) encoding a second antigen or ligand domain, the second antigen or ligand domain being (i) identical to the first antigen or ligand domain, respectively, and comprising R1, or (ii) a variant of a naturally occurring first antigen or ligand domain, respectively, and comprising R1; and F. S2 is an endogenous genomic sequence of the cell, and SNP1 is a non-synonymous SNP; Human immune cells.

[0438] Additionally or alternatively, clause 1 provides: 1. A human immune cell for use in a method of treating or reducing the risk of a disease or condition (e.g., cancer or an autoimmune disease, e.g., as disclosed herein), the method comprising administering an immune cell to a human patient, the immune cell comprising a modified transmembrane protein; Protein, A. an extracellular portion comprising one or more ligand binding domains or one or more ligand domains; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain (SD1); Includes; D. the variant protein SD1 is encoded in the cell by a first nucleotide sequence (S1) that includes a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of SD1; E. the human genome comprises SNP1 and a second nucleotide sequence (S2) encoding a second signaling domain (SD2), where SD2 is (i) identical to SD1 and comprises R1 or (ii) a naturally occurring variant of SD1 and comprises R1; F. S2 is a human endogenous genomic sequence and SNP1 is a non-synonymous SNP; and G. the human genome comprises S2 prior to said administration of immune cells; and H. The method treats the risk of a disease or condition in a human. Human immune cells.

[0439] Additionally or alternatively, clause 1 provides: 1. A human immune cell for use in a method of treating or reducing the risk of a disease or condition (e.g., cancer or an autoimmune disease, e.g., as disclosed herein), the method comprising administering an immune cell to a human patient, the immune cell comprising a modified transmembrane protein; Protein, A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. an intracellular portion comprising the first signaling domain; Includes; D. a first antigen or ligand domain of the variant protein is encoded in the cell by a first nucleotide sequence (S1) that includes a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of the antigen or ligand domain; E. the human genome comprises SNP1 and a second nucleotide sequence (S2) encoding a second antigen or ligand domain, the second antigen or ligand domain being (i) identical to the first antigen or ligand domain, respectively, and comprising R1, or (ii) a variant of a naturally occurring first antigen or ligand domain, respectively, and comprising R1; F. S2 is a human endogenous genomic sequence and SNP1 is a non-synonymous SNP; and G. the human genome comprises S2 prior to said administration of immune cells; and H. The method treats the risk of a disease or condition in a human. Human immune cells.

[0440] In one example, S1 is at least 80, 90, or 95% identical to S2.

[0441] In one example, the extracellular portion comprises an antigen binding domain. In one example, the transmembrane protein is a CAR, such as any CAR disclosed herein.

[0442] In one example, the extracellular portion comprises an antigen or a ligand (e.g., a receptor ligand). In one example, the transmembrane protein is a CAL, e.g., any CAL disclosed herein.

[0443] In one example, the immune cells are used in a method of treating or reducing the risk of a disease or condition (e.g., as disclosed herein), the method comprising administering the immune cells to a human patient, the patient's genome comprising S2 and / or SNP1 prior to said administration, and the disease or condition is treated or prevented in the human. In one example, the immune cells of the invention are for use in such a method.

[0444] As the transmembrane proteins of the present invention are "modified" herein, this means that they are not naturally found in humans or human cells, or in the cell or mammal into which they are introduced.

[0445] 2. The cell of aspect 1, wherein each of said signaling domains is a CD3 intracellular domain selected from the group consisting of the CD3ζ (CD3 zeta) domain, the CD3η (CD3 eta) domain, the FcεRIγ domain, the CD64 domain, the CD16 domain, the CD27 domain, the CD28 domain, the ICOS domain, the OX40 (CD134) domain, the CD40L domain, and the 4-1BB (CD137) domain.

[0446] 3. The first signaling domain is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3 eta) domain, and is selected from V53, K54, F55, R57, S58, D60, Y64, Q65, Q68, L71, E74, L75, N76, L77, G78, R80, E81, Y83, L86, R89, G91, P94, E95, G98, K99, R102, Q107, G109, Y111, N112, E113, L114, Q115, K116 3. The cell according to any one of aspects 1 to 2, comprising at least 50 amino acid residues selected from the group consisting of: D117, K118, M119, E121, A122, Y123, S124, E125, I126, G127, G130, R134, G135, H138, D139, L141, Y142, Q143, G144, S146, T147, T149, K150, D151, D154, H157, M158, Q159, L161 and P162 (position numbers correspond to positions in SEQ ID NO: 7).

[0447] 4. The cell of embodiment 3, wherein the first signaling domain is a CD3ζ (CD3 zeta) domain that comprises all of the residues in the above group.

[0448] 5. The cell of aspect 3 or 4, wherein the first signaling domain comprises amino acid residues Y64, Y72, and Y83; Y64 and Y72; Y72 and Y83; Y111 and Y123; Y142 and Y153; Y64, Y72, Y83, Y111, Y123, Y142 and Y153; or Y64, Y72, Y111, Y123, Y142 and Y153; or Y72, Y83, Y111, Y123, Y142, and Y153 (position numbers correspond to positions in SEQ ID NO: 7).

[0449] 6. The cell of any of aspects 1 to 5, wherein the first signaling domain is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3-eta) domain, and comprises SEQ ID NO:9.

[0450] This is the universal framework according to the present invention (described above and further in Example 1).

[0451] 7. A human immune cell comprising a modified transmembrane protein, Protein, A. an extracellular portion comprising one or more ligand binding domains or one or more ligand domains; B. A transmembrane portion; and C. an intracellular portion comprising the first signaling domain; Includes; D. The first signaling domain is a CD3 intracellular domain selected from a CD3 ζ (CD3 zeta) domain and a CD3 η (CD3 eta) domain, and is selected from V53, K54, F55, R57, S58, D60, Y64, Q65, Q68, L71, E74, L75, N76, L77, G78, R80, E81, Y83, L86, R89, G91, P94, E95, G98, K99, R102, Q107, G109, Y111, N112, E113, L114, Q1 15, K116, D117, K118, M119, E121, A122, Y123, S124, E125, I126, G127, G130, R134, G135, H138, D139, L141, Y142, Q143, G144, S146, T147, T149, K150, D151, D154, H157, M158, Q159, L161 and P162 (position numbers correspond to positions in SEQ ID NO: 1); E. the genome of the cell comprises an endogenous nucleotide sequence encoding a second signaling domain, the second domain being a CD3 ζ (CD3 zeta) domain or a CD3 η (CD3 eta) domain that comprises at least 40 (e.g., 45 or all) of the selected residues; Human immune cells.

[0452] This is based on the inventors' identification of groups of residues in the CD3 ζ and CD3 η domains that are naturally tolerated for mutation in the human population. The present invention identifies a collection of such mutations, each representing the most common polymorphisms in humans, and therefore the inventors believe they can be used in many human cells and human patients, as they are compatible with many naturally occurring polymorphisms in such cells and patients.

[0453] Additionally or alternatively, aspect 7 provides: 1. A human immune cell for use in a method of treating or reducing the risk of a disease or condition (e.g., cancer or an autoimmune disease, e.g., as disclosed herein), the method comprising administering an immune cell to a human patient, the immune cell comprising a modified transmembrane protein; Protein, A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. an intracellular portion comprising the first signaling domain; Includes; D. The first signaling domain is a CD3 intracellular domain selected from a CD3 ζ (CD3 zeta) domain and a CD3 η (CD3 eta) domain, and is selected from V53, K54, F55, R57, S58, D60, Y64, Q65, Q68, L71, E74, L75, N76, L77, G78, R80, E81, Y83, L86, R89, G91, P94, E95, G98, K99, R102, Q107, G109, Y111, N112, E113, L114, Q1 15, K116, D117, K118, M119, E121, A122, Y123, S124, E125, I126, G127, G130, R134, G135, H138, D139, L141, Y142, Q143, G144, S146, T147, T149, K150, D151, D154, H157, M158, Q159, L161 and P162 (position numbers correspond to positions in SEQ ID NO: 1); E. the human genome comprises an endogenous nucleotide sequence encoding a second signaling domain, the second domain being a CD3ζ (CD3 zeta) domain or a CD3η (CD3 eta) domain that comprises at least 40 (e.g., 45 or all) of the selected residues; F. The method treats the risk of a disease or condition in a human. Human immune cells.

[0454] 8. The cell of aspect 7, wherein the first signaling domain comprises amino acid residues Y64, Y72, and Y83; Y64 and Y72; Y72 and Y83; Y111 and Y123; Y142 and Y153; Y64, Y72, Y83, Y111, Y123, Y142 and Y153; or Y64, Y72, Y111, Y123, Y142 and Y153; or Y72, Y83, Y111, Y123, Y142, and Y153 (position numbers correspond to positions in SEQ ID NO: 7).

[0455] 9. The cell of aspect 7 or 8, wherein the first signaling domain is a CD3ζ (CD3 zeta) domain comprising SEQ ID NO:9, and the second domain is a CD3ζ (CD3 zeta) domain comprising SEQ ID NO:9.

[0456] 10. The cell of any one of clauses 7-9, wherein the first and second signaling domains are CD3ζ (CD3 zeta) domains, and optionally each domain comprises at least the 50 selected residues described above.

[0457] 11. The cell of any of clauses 1-10, wherein each of the first and second signaling domains comprises an immunoreceptor tyrosine-based activation motif (ITAM) that comprises R1.

[0458] 12. The cell of embodiment 11, wherein the ITAMs of the signaling domains are identical.

[0459] 13. The cell according to any of aspects 1 to 12, wherein the first and second signalling domains are identical.

[0460] 14. The cell according to any one of aspects 1 to 13, wherein the signalling domain of 1 is human.

[0461] 15. The cell according to any of aspects 1-14, wherein the intracellular portion comprises an additional intracellular signalling domain (third signalling domain, SD3) encoded in the cell by a third nucleotide sequence (S3), wherein S3 comprises a human single nucleotide polymorphism (SNP2) encoding an amino acid residue (R2) of SD3, and the genome of the cell comprises a fourth nucleotide sequence (S4) encoding a fourth signalling domain (SD4), wherein SD4 is (iii) identical to SD3 and comprises R2, or (iv) a variant of SD3 and comprises R3, wherein S4 is an endogenous genomic sequence of the cell, and wherein SNP2 is a non-synonymous SNP.

[0462] In further or alternative embodiments, the intracellular portion comprises an additional intracellular signaling domain (third signaling domain, SD3) encoded in the human genome by a third nucleotide sequence (S3), wherein S3 comprises a human single nucleotide polymorphism (SNP2) that encodes an amino acid residue (R2) of SD3, wherein the human genome comprises a fourth nucleotide sequence (S4) that encodes a fourth signaling domain (SD4), wherein SD4 is (iii) identical to SD3 and comprises R2 or (iv) a variant of SD3 and comprises R3, wherein S4 is a human endogenous genomic sequence, and wherein SNP2 is a non-synonymous SNP.

[0463] 16. The cell according to aspect 15, wherein the SD1 and SD3 domains are distinct.

[0464] 17. The cell of aspect 15 or 16, wherein each of SD3 and SD4 comprises an ITAM comprising R2.

[0465] 18. The cell of aspect 17, wherein the ITAMs of SD3 and SD4 are identical.

[0466] 19. The cell according to any one of aspects 15 to 18, wherein SD3 and SD4 are identical.

[0467] 20. The cell according to any one of aspects 15 to 19, wherein SD3 is human.

[0468] 21. The cell according to any one of aspects 15 to 20, wherein each of SD3 and SD4 is a CD3ζ (CD3 zeta) domain, a CD3η (CD3-eta) domain, an FcεRIγ domain, a CD64 domain, a CD16 domain, a CD27 domain, a CD28 domain, an ICOS domain, an OX40 domain, a CD40 domain, or a 4-1BB domain.

[0469] 22. The cell according to any one of aspects 15 to 21, wherein SD1 is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3-eta) domain, and the third domain is an FcεRIγ domain, a CD64 domain, a CD16 domain, a CD27 domain, a CD28 domain, an ICOS domain, an OX40 domain, a CD40 domain, or a 4-1BB domain.

[0470] 23. The cell according to any of aspects 1 to 22, wherein SD1 is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3-eta) domain, and is a C-terminal domain of a transmembrane protein.

[0471] 24. The cell according to any of aspects 1 to 23, wherein SD1 is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3-eta) domain and comprises one, two or three amino acid motifs selected from: (a) SEQ ID NO: 10, optionally with up to 10, 9, 8, 7, 6 or 5 (e.g. up to 5) amino acid differences, but in which tyrosine is conserved; (b) SEQ ID NO: 11, optionally with up to 10, 9, 8, 7, 6 or 5 (e.g. up to 5) amino acid differences, but in which tyrosine is conserved; and (c) SEQ ID NO: 12, optionally with up to 10, 9, 8, 7, 6 or 5 (e.g. up to 5) amino acid differences, but in which tyrosine is conserved.

[0472] 25. The cell of aspect 24, wherein SD1 comprises motif (a), and the motif differs from SEQ ID NO: 10 by alteration of up to five residues selected from the group consisting of A61, P62, A63, Q66, G67, N69, Q70, N73, R79, E82, D84, V85, D87 and K88.

[0473] 26. The cell of aspect 25, wherein the alteration is selected from the group consisting of A61V, A61P, P62S, P62A, A63P, Q66H, G67S, N69T, Q70Y, Q70L, Q70P, Q70W, N73Y, R79L, R79G, E82K, D84G, D84A, D84Y, V85I, D87G and K88R.

[0474] 27. The cell according to any one of aspects 24 to 26, wherein SD1 comprises motif (b), and the motif differs from SEQ ID NO: 11 by alteration of up to five residues selected from the group consisting of P100, Q101, R103, K104, N105, P106, E108, L110, A120, A122 and M128.

[0475] 28. The cell of aspect 27, wherein the alteration is selected from the group consisting of P100L, Q101L, Q101P, R103K, K104E, N105K, P106R, E108A, L110Q, A120V, A122V and M128T.

[0476] 29. The cell according to any one of aspects 24 to 28, wherein SD1 comprises motif (c), and the motif differs from SEQ ID NO: 12 by alteration of up to five residues selected from the group consisting of: E131, R132, R133, K136, G137, G140, L145, A148, T152, A155, L156.

[0477] 30. The cell of aspect 29, wherein the alteration is selected from the group consisting of E131K, R132H, R132C, R133Q, R133W, K136N, G137E, G140D, L145F, A148D, T152I, A155T, L156P.

[0478] 31. The cell according to any of aspects 1-30, wherein SD1 is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3 eta) domain, the first signalling domain comprises multiple (e.g. 3) ITAMs, and the second signalling domain comprises the same corresponding ITAMs.

[0479] 32. The cell according to any one of aspects 1 to 31, wherein SD1 is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3 eta) domain and comprises one, more or all amino acid residues selected from the group consisting of S58, Y64, Y72, Y83, Y111, Y123, Y142 and Y153 (position numbers correspond to positions in SEQ ID NO: 7).

[0480] 33. The cell of aspect 32, wherein SD1 comprises one or both of C72 and N153.

[0481] 34. SD1 is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3Η (CD3-eta) domain, and is selected from R52, S56, A59, A61, P62, A63, Q66, G67, N69, Q70, Y72, N73, R79, E82, D84, V85, D87, K88, R90, R92, D93, M96, G97, P100, Q101, R103, K104, 34. The cell according to any one of aspects 1 to 33, comprising a residue (R1 above) selected from the group consisting of N105, P106, E108, L110, A120, A122, M128, K129, E131, R132, R133, K136, G137, G140, L145, A148, T152, Y153, A155, L156, A160, P163 and R164 (position numbers correspond to positions in SEQ ID NO: 7).

[0482] 35. The cell according to any one of aspects 1 to 34, wherein SD1 is a CD3 intracellular domain selected from the CD3ζ (CD3 zeta) domain and the CD3η (CD3-eta) domain, and comprises a residue (R1 above) that is Y72 or Y153 (position numbers correspond to positions in SEQ ID NO: 7).

[0483] 36. SD1 is a CD3 intracellular domain selected from the CD3 zeta domain and the CD3 eta domain, and is selected from rs368651001, rs372651048, rs767112686, rs765877580, rs751145956, rs772867144, rs55893506, rs761710510, rs776601547, rs768607376, rs193922741, rs193922740, rs193922739, rs s780188126, rs772128174, rs757978223, rs779397562, rs749926653, rs181746205, rs181746205, rs753572867, rs371709798, rs 145407267, rs143180729, rs148513413, rs367690333, rs144963570, rs367690333, rs144963570, rs770320255, rs139926301, rs56 297636, rs760895755, rs112890541, rs370910340, rs145505909, rs754935006, rs751583971, rs766541481, rs763074967, rs7458 71212, rs372665461, rs764185491, rs756340039, rs773572491, rs201594815, rs781510519, rs147527561, rs751981677, rs763532 36. The cell according to any one of aspects 1 to 35, comprising a residue (R1) encoded by a SNP (SNP1) selected from the group consisting of rs376046446, rs201937405 and rs752198795.

[0484] 37. SD1 is a CD3 intracellular domain selected from the CD3 ζ (CD3 zeta) domain and the CD3 η (CD3-eta) domain, and is R52, S56, A59, A61, P62, A63, Q66, G67, N69, Q70, Y72, N73, R79, E82, D84, V85, D87, K88, R90, R92, D93, M96, G97, P100, Q101, R103, K104, N105, P106, E108 37. The cell according to any one of aspects 1 to 36, comprising a residue (R1 above) selected from the group consisting of: L110, A120, A122, M128, K129, E131, R132, R133, K136, G137, G140, L145, A148, T152, Y153, A155, L156, A160, P163 and R164 (position numbers correspond to positions in SEQ ID NO: 7), and optionally SD2 also comprises the selected residue (R1).

[0485] 38. The cell according to any one of aspects 1 to 36, wherein SD1 or SD3 is a CD28 intracellular domain comprising at least 13 amino acid residues selected from the group consisting of R180, S181, K182, R183, S184, R185, L186, D190, Y191, N193, P196, P199, T202, K204, Q207, F215, A217 and Y218 (position numbers correspond to positions in SEQ ID NO: 13).

[0486] 39. The cell according to embodiment 38, wherein the CD28 domain comprises all of the residues in the above group.

[0487] 40. The cell according to aspect 38 or 39, wherein the CD28 domain comprises amino acid residues Y191 and Y209 (position numbers corresponding to positions in SEQ ID NO: 13).

[0488] 41. The cell according to any one of aspects 38 to 40, wherein the CD28 domain comprises a YMNM motif (corresponding to Y191-M192-N193-M194 of SEQ ID NO: 13) and / or a PYAP motif (corresponding to P208-Y209-A210-P211 of SEQ ID NO: 13).

[0489] 42. The cell according to any of aspects 1-41, wherein the CD domain comprises SEQ ID NO: 15.

[0490] 43. A human immune cell comprising a modified transmembrane protein, Protein, A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain (SD1); Includes; D. SD1 is a CD28 intracellular domain comprising at least 13, 14, 15, 16, 17 or 18 amino acid residues selected from the group consisting of R180, S181, K182, R183, S184, R185, L186, D190, Y191, N193, P196, P199, T202, K204, Q207, F215, A217 and Y218 (position numbers correspond to positions in SEQ ID NO: 13); and E. The genome of the cell comprises an endogenous nucleotide sequence encoding a second signaling domain (SD2), wherein SD2 is a CD28 intracellular domain that comprises at least 10 (or 11, 12, or 13) of the selected residues. Human immune cells.

[0491] Additionally or alternatively, aspect 7 provides: 1. A human immune cell for use in a method of treating or reducing the risk of a disease or condition (e.g., cancer or an autoimmune disease, e.g., as disclosed herein), the method comprising administering an immune cell to a human patient, the immune cell comprising a modified transmembrane protein; Proteins are A. an extracellular portion comprising a first antigen or ligand domain; B. A transmembrane portion; and C. The intracellular portion containing the first signaling domain (SD1); Includes; D. SD1 is a CD28 intracellular domain comprising at least 13, 14, 15, 16, 17 or 18 amino acid residues selected from the group consisting of R180, S181, K182, R183, S184, R185, L186, D190, Y191, N193, P196, P199, T202, K204, Q207, F215, A217 and Y218 (position numbers correspond to positions in SEQ ID NO: 13); E. the human genome comprises an endogenous nucleotide sequence encoding a second signaling domain (SD2), wherein SD2 is a CD28 intracellular domain that comprises at least 10 (or 11, 12, or 13) of the selected residues; and F. A human immune cell, wherein the method treats the risk of a disease or condition in a human.

[0492] 44. The cell according to aspect 43, wherein SD1 comprises amino acid residues Y191 and Y209 (position numbers correspond to positions in SEQ ID NO: 13).

[0493] 45. The cell according to aspect 43 or 44, wherein SD1 comprises SEQ ID NO: 15 and the second domain is a CD28 domain comprising SEQ ID NO: 15.

[0494] 46. ​​The cell according to any one of aspects 43, 44 or 45, wherein each of the SD1 and SD2 domains comprises at least the 13 selected residues as described above.

[0495] 47. The cell according to any one of aspects 43-46, wherein the intracellular portion comprises a further intracellular signalling domain (third signalling domain, SD3) encoded in the cell by a third nucleotide sequence (S3), wherein S3 comprises a human single nucleotide polymorphism (SNP2) encoding an amino acid residue (R2) of SD3, and wherein the genome of the cell or human comprises a fourth nucleotide sequence (S4) encoding a fourth signalling domain (SD4), wherein SD4 is (iii) identical to SD3 and comprises R2 or (iv) a variant of SD3 and comprises R2, and wherein SD4 is an endogenous genomic sequence of the cell or human, respectively.

[0496] 48. The cell according to aspect 47, wherein the SD1 and SD3 domains are distinct.

[0497] 49. The cell according to aspect 47 or 48, wherein SD3 and SD4 are identical.

[0498] 50. The cell according to any one of aspects 47 to 49, wherein SD3 is human.

[0499] 51. The cell according to any one of aspects 47 to 50, wherein each of SD3 and SD4 is an intracellular domain selected from the group consisting of a CD3ζ (CD3 zeta) domain, a CD3η (CD3-eta) domain, an FcεRIγ domain, a CD64 domain, a CD16 domain, a CD27 domain, an ICOS domain, an OX40 domain, a CD40 domain, and a 4-1BB domain.

[0500] 52. A cell according to any one of aspects 47 to 51, wherein SD1 is the C-terminal domain of the receptor or the most N-terminal intracellular domain of the receptor.

[0501] 53. The cell according to any of aspects 1 to 52, wherein the SD1 or SD3 domain is a CD28 intracellular domain comprising a residue (R1 or R2 above) selected from the group consisting of L187, H188, S189, M192, M194, T195, R197, R198, G200, P201, R203, H205, Y206, P208, Y209, A210, P211, P212, R213, D214, A216, R219, and S220 (position numbers correspond to positions in SEQ ID NO: 13).

[0502] 54. The cell according to any one of aspects 1 to 53, wherein SD1 or SD3 is a CD28 intracellular domain comprising a residue (R1 or R2 above) that is M192, M194, P208, Y209, A210 or P211 (position numbers correspond to positions in SEQ ID NO: 13).

[0503] 55. SD1 or SD3 is the CD28 intracellular domain, and rs139881881, rs139881881, rs751945323, rs753396357, rs754453810, rs200221759, rs562969933, rs765515314, rs145761335, rs199647272, rs200751829, rs201547332, rs200642723, rs367908475, rs199549636, rs199549636, rs74968888 55. The cell according to any one of aspects 1 to 54, comprising a residue (R1 or R2) encoded by a SNP (SNP1 or SNP2) selected from the group consisting of rs769098383, rs572738990, rs200606770, rs371850110, rs201773411, rs762144222, rs770610915, rs199777674, rs201909740, rs200016310, rs200936737, rs201598596 and rs762747357.

[0504] 56. A cell according to any of aspects 1 to 55 dependent on aspect 15 and / or 47, wherein SD3 and SD4 are human 4-1BB domains and R2 is selected from the group consisting of R215, Q215, W215, R217, G217, K218, N218, Y222, C222, P227, S227, M229, 1229, V232, A232, Q236, H236, D239, C241, Y241, R244, Q244, E247, G247, E250, G250, G252, E252, V252, R252, C253 and S253 (position numbers correspond to positions in SEQ ID NO: 16).

[0505] 57. The cell according to aspect 56, wherein SD3 comprises at least 10, 11, 12, 13, 14 or all of the residues selected from the group consisting of R215, R217, K218, Y222, P227, M229, V232, Q236, D239, C241, R244, E247, E250, G252 and C253 (position numbers correspond to positions in SEQ ID NO: 16).

[0506] 58. The cell according to any one of aspects 1 to 57 dependent on aspect 15 and / or 47, wherein SD3 and SD4 are human 4-1BB domains and SD3 comprises Q236 and D239 (position numbers corresponding to positions in SEQ ID NO: 16).

[0507] These are the conserved TRAF binding residues, as explained in Example 1.

[0508] 59. The cell according to any one of aspects 1 to 58 dependent on aspect 15 and / or 47, wherein SD3 comprises SEQ ID NO: 18.

[0509] This is the universal 4-1BB framework of the present invention that retains conserved, naturally occurring residues and TRAF binding motifs.

[0510] 60. A human immune cell comprising a modified transmembrane protein, Protein, F. an extracellular portion comprising the first antigen or ligand domain; G. A transmembrane portion; and H. An intracellular portion containing the first signaling domain (SD1); Includes; I. SD1 is a 4-1BB intracellular domain that includes at least 10, 11, 12, 13, 14 or all of the residues selected from the group consisting of R215, R217, K218, Y222, P227, M229, V232, Q236, D239, C241, R244, E247, E250, G252 and C253 (position numbers correspond to positions in SEQ ID NO: 16); and J. The genome of the cell comprises an endogenous nucleotide sequence encoding a second signaling domain (SD2), wherein SD2 is a 4-1BB intracellular domain that comprises at least 8 (or 9 or 10) of the selected residues. Human immune cells.

[0511] Additionally or alternatively, aspect 7 provides: 1. A human immune cell for use in a method of treating or reducing the risk of a disease or condition (e.g., cancer or an autoimmune disease, e.g., as disclosed herein), the method comprising administering an immune cell to a human patient, the immune cell comprising a modified transmembrane protein; Proteins are G. an extracellular portion comprising the first antigen or ligand domain; H. A transmembrane portion; and I. An intracellular portion containing the first signaling domain (SD1); Includes; J. SD1 is a 4-1BB intracellular domain that includes at least 10, 11, 12, 13, 14 or all of the residues selected from the group consisting of R215, R217, K218, Y222, P227, M229, V232, Q236, D239, C241, R244, E247, E250, G252 and C253 (position numbers correspond to positions in SEQ ID NO: 16); and K. the human genome comprises an endogenous nucleotide sequence encoding a second signaling domain (SD2), wherein SD2 is a 4-1BB intracellular domain that comprises at least 8 (or 9 or 10) of the selected residues; L. The method treats the risk of a disease or condition in a human. Human immune cells.

[0512] 61. The cell according to embodiment 60, wherein SD1 comprises amino acid residues Q236, D239, E247 and E250 (position numbers correspond to positions in SEQ ID NO: 16).

[0513] 62. The cell according to aspect 60 or 61, wherein SD1 comprises SEQ ID NO: 18 and the second domain is a 4-1BB domain comprising SEQ ID NO: 18.

[0514] 63. The cell according to any one of aspects 60, 61 or 62, wherein each of the SD1 and SD2 domains comprises at least the 13 selected residues as described above.

[0515] 64. The cell according to any one of aspects 60-63, wherein the intracellular portion comprises a further signalling domain (third signalling domain, SD3) encoded in the cell by a third nucleotide sequence (S3), wherein S3 comprises a human single nucleotide polymorphism (SNP2) encoding an amino acid residue (R2) of SD3, and wherein the genome of the cell or human comprises a fourth nucleotide sequence (S4) encoding a fourth signalling domain (SD4), wherein SD4 is (iii) identical to SD3 and comprises R2, or (iv) a variant of SD3 and comprises R2, and wherein SD4 is an endogenous genomic sequence of the cell or human, respectively.

[0516] 65. The cell according to embodiment 64, wherein the SD1 and SD3 domains are distinct.

[0517] 66. The cell according to aspect 64 or 65, wherein SD3 and SD4 are identical.

[0518] 67. The cell according to any one of aspects 64 to 66, wherein SD3 is human.

[0519] 68. The cell according to any one of aspects 64 to 67, wherein each of SD3 and SD4 is an intracellular domain selected from the group consisting of a CD3ζ (CD3 zeta) domain, a CD3η (CD3-eta) domain, an FcεRIγ domain, a CD64 domain, a CD16 domain, a CD27 domain, an ICOS domain, an OX40 domain, a CD40 domain and a CD28 domain.

[0520] 69. A cell according to any one of aspects 60-68, wherein SD1 is the C-terminal domain of the receptor or the most N-terminal intracellular domain of the receptor.

[0521] 70. The cell according to any one of aspects 1 to 69, wherein the SD1 or SD3 domain is a 4-1BB intracellular domain comprising a residue (R1 or R2 above) selected from the group consisting of R215, R217, K218, Y222, P227, M229, V232, Q236, D239, C241, R244, E247, E250, G252 and C253 (position numbers correspond to positions in SEQ ID NO: 16).

[0522] 71. The cell according to any one of aspects 1 to 70, wherein SD1 or SD3 is a 4-1BB intracellular domain comprising a residue (R1 or R2 above) that is Q236, D239, E247 or E250 (position numbers correspond to positions in SEQ ID NO: 16).

[0523] 72. SD1 or SD3 is a 4-1BB intracellular domain, and rs753016242, rs143524950, rs780812476, rs755927735, rsL44908104, rs533883433, rs367584804, rsL41498457, rs751542955, rs764017912, rs75219141 6. The cell according to any one of aspects 1 to 71, comprising a residue (R1 or R2 above) encoded by a SNP (SNP1 or SNP2) selected from the group consisting of rs554909019, rs759184548, rs776878260, rsLL3310001, rsLL3310001, rs761088691 and rs772691718.

[0524] 73. The cell according to any of aspects 1 to 72, wherein the extracellular portion comprises an antigen-binding site comprising an antibody VH domain, wherein the VH domain is derived from recombination of a human VH gene segment with a D and a JH gene segment, and wherein the VH gene segment comprises a SNP (SNP3) contained in the genome of the cell or human.

[0525] 74. The cell according to any of aspects 1 to 73, wherein the extracellular portion comprises an antigen-binding site comprising an antibody VL domain, the VL domain being derived from recombination of a human VL gene segment and a JL gene segment, and the VL gene segment comprises a SNP (SNP4) contained in the genome of the cell or human.

[0526] 75. The cell according to any one of aspects 1 to 73, wherein the extracellular portion comprises an antigen-binding site comprising a TCR Vα domain, the Vα domain being derived from recombination of a human Vα gene segment with a Jα gene segment, and the Vα gene segment comprises a SNP (SNP5) contained in the genome of the cell or human.

[0527] 76. The cell according to any one of aspects 1 to 73 and 74, wherein the extracellular portion comprises an antigen-binding site comprising a TCR Vβ domain, the Vβ domain being derived from recombination of a human Vβ gene segment with a Dβ and a Jβ gene segment, and the Vβ gene segment comprises a SNP (SNP6) contained in the genome of the cell or human.

[0528] 77. The cell according to any of aspects 1 to 76, wherein the extracellular portion comprises a TCR Cα sequence encoded by a Cα gene segment sequence, the Cα gene segment comprising a SNP (SNP7) contained in the genome of a cell or human, SNP7 encoding a Cα extracellular amino acid residue (R3), and R3 being contained in the Cα sequence of the extracellular portion.

[0529] 78. The cell of any of aspects 1-77, wherein the extracellular portion comprises a TCR Cβ sequence encoded by a Cβ gene segment sequence, and the Cβ gene segment comprises a SNP (SNP8) contained in the genome of a cell or human, and SNP8 encodes a Cβ extracellular amino acid residue (R4), and R4 is contained in the Cβ sequence of the extracellular portion.

[0530] 79. The cells are T cells (e.g., CD8 +T cells, e.g., activated T cells), NK cells, tumor infiltrating lymphocytes (TILs, e.g., pre-REP TILs), stem cells, memory stem cells, bone marrow cells, bone marrow stem cells, hematopoietic stem cells, memory T cells, T SCM , T CM Or T EM The cell according to any one of aspects 1 to 78,

[0531] 80. The cell according to any of aspects 1-79, wherein the cell has been modified for improved signaling, and the signaling is selected from CD28, 4-1BB, OX40, ICOS and CD40 signaling.

[0532] 81. A population of immune cells comprising a plurality of cells according to any one of aspects 1 to 80.

[0533] 82. A cell or population according to any of aspects 1 to 81 for treating cancer, an inflammatory disease, an autoimmune disease or a viral infection in a human.

[0534] In one embodiment, the cancer, disease or condition is any cancer, disease or condition disclosed herein.

[0535] 83. The cell or population according to aspect 82, wherein the cancer is a cancer of T-cell or B-cell origin, such as lymphoblastic leukemia, ALL (e.g. T-ALL), CLL (e.g. B-cell chronic lymphocytic leukemia) or non-Hodgkin's lymphoma.

[0536] 84. A cell or population according to aspect 82 or 89, wherein each said cell is an autologous cell (e.g. a T cell) of said human, or is the progeny of such an autologous cell.

[0537] 85. The cell or population according to aspect 84, wherein each autologous cell is derived from a human blood or tumor sample and activated and expanded in vitro.

[0538] 86. A method for producing a cell according to any one of aspects 1 to 85, comprising: i. Obtaining human immune cells (e.g., memory T cells, NK cells, bone marrow cells, stem cells, or TILs); ii. obtaining an expressible nucleotide sequence encoding the modified transmembrane protein, the protein comprising the residue (R1) encoded by a SNP (SNP1) contained in the genome of the cell; and iii. introducing a nucleotide sequence into the cell for expression of the receptor; The method includes:

[0539] 87. The method of embodiment 86, further comprising culturing, differentiating and / or activating the cells produced by step (iii), thereby producing a population of cells expressing the receptor.

[0540] 88. The method according to aspect 86 or 87, wherein the cells of step (i) are obtained from a human suffering from cancer, an inflammatory disease, an autoimmune disease or a viral infection.

[0541] 89. A method for treating cancer, an inflammatory disease, an autoimmune disease or a viral infection in a human, comprising administering to a human a cell or population according to any of aspects 1 to 88, or produced by the method according to aspect 87 or 88, wherein cell death is achieved and the cancer, disease or condition is treated.

[0542] In one example, the severity or progression of a cancer, disease or infection in a human is reduced.

[0543] 90. The method according to embodiment 89, wherein the administered cells are descendants of cells obtained from a human and used in step (i) of the method according to embodiment 86, 87 or 88.

[0544] 91. A cell or population according to any of aspects 1 to 90 for use in a method according to aspect 89 or 90 for treating or reducing the risk or progression of cancer, an inflammatory disease, an autoimmune disease or a viral infection in a human.

[0545] 92. A medical V-bag or injection device comprising the cell or population according to any one of aspects 1 to 85 and 91.

[0546] 93. A mammalian stem cell comprising a nucleotide sequence encoding a modified transmembrane protein according to any one of aspects 1 to 92.

[0547] 94. The cell according to embodiment 93, wherein the modified protein is a CAL.

[0548] 95. The cell according to embodiment 93, wherein the modified protein is CAR.

[0549] 96. The cell according to any one of aspects 93 to 95, wherein the cell is pluripotent or multipotent.

[0550] The stem cells are incapable of developing into a human being. In one embodiment, the stem cells are incapable of developing into a human embryo or zygote.

[0551] 97. The cell according to any one of aspects 93 to 96, wherein the cell is a bone marrow stem cell.

[0552] 98. The cell according to any one of aspects 93 to 97, wherein the cell is a hematopoietic stem cell.

[0553] 99. The cell according to any one of aspects 93 to 98, wherein the cell is a non-human stem cell.

[0554] 100. The cell according to any one of aspects 93 to 99, wherein the cell is ex vivo.

[0555] 101. A population of cells comprising a plurality of stem cells according to any one of aspects 93 to 100.

[0556] 102. The method of any of aspects 1-101, wherein the method comprises administering immune cells and a crosslinking agent to a human to treat or prevent a disease or condition in the human.

[0557] 103. The method of embodiment 102, comprising administering to a human the stem cell of any one of embodiments 93 to 100, wherein the stem cell develops into said immune cell expressing a modified transmembrane protein (e.g., a CAL or a CAR), and wherein the immune cell combines with a target cell in the human, and wherein the modified immune cell is activated and the target cell is killed.

[0558] 104. The method of aspect 103, wherein the method comprises administering the population of clause 101, wherein the stem cells develop into a plurality of immune cells expressing the modified transmembrane protein, and the immune cells combine with target cells in a human, activating the modified immune cells and killing the target cells, thereby treating or preventing a disease or condition.

[0559] 105. A cell or population according to any one of aspects 93 to 101 for use in a method according to aspect 103 or 104 for treating or reducing the risk of a disease or condition in a human, such as cancer or an autoimmune disease or condition.

[0560] As described in the Examples, the inventors have designed universal intracellular signaling domain frameworks: SEQ ID NOs: 9, 15 and 18. To this end, the present invention also provides the following aspects: 1. The genome is: (i)-(iii): (i) an endogenous nucleotide sequence encoding a CD3 zeta intracellular domain comprising SEQ ID NO:9; and a nucleotide sequence encoding the CD3 zeta intracellular domain of a CAL or CAR comprising SEQ ID NO:9; (ii) an endogenous nucleotide sequence encoding the CD28 intracellular domain comprising SEQ ID NO: 15; and a nucleotide sequence encoding the CD28 intracellular domain of a CAL or CAR comprising SEQ ID NO: 15; and / or (iii) an endogenous nucleotide sequence encoding a 4-1BB intracellular domain comprising SEQ ID NO: 18; and a nucleotide sequence encoding a 4-1BB intracellular domain of a CAL or CAR comprising SEQ ID NO: 18; CAL immune cells or CAR immune cells comprising one, more or all of:

[0561] 2. An autologous or allogeneic cell graft for administration to a human patient to treat or prevent a disease or condition (e.g., cancer), comprising a plurality of CAL or CAR immune cells, the cells being progeny of one or more ancestral cells obtained from a human donor, and the genome of each of said cells of the graft comprising: (i)-(iii): (i) a nucleotide sequence encoding a CD3 zeta intracellular domain of a CAL or CAR comprising SEQ ID NO:9; wherein the genome(s) of the ancestor cell(s) comprises an endogenous nucleotide sequence encoding a CD3 zeta intracellular domain comprising SEQ ID NO:9; (ii) a nucleotide sequence encoding the CD28 intracellular domain of a CAL or CAR comprising SEQ ID NO: 15; wherein the genome(s) of the ancestor cell(s) comprises an endogenous nucleotide sequence encoding the CD28 intracellular domain comprising SEQ ID NO: 15; or (iii) a nucleotide sequence encoding a 4-1BB intracellular domain of a CAL or CAR comprising SEQ ID NO: 18; wherein the genome(s) of the ancestor cell(s) comprises an endogenous nucleotide sequence encoding a 4-1BB intracellular domain comprising SEQ ID NO: 18; Autologous or allogeneic cell grafts, including one, more or all of the following:

[0562] 3. The graft of aspect 2, wherein each said cell of the graft comprises said endogenous sequence(s).

[0563] In one example, the CAL or CAR comprises SEQ ID NO:9 and the graft comprises an endogenous CD3 zeta intracellular domain sequence encoding SEQ ID NO:9, and / or the CAL or CAR comprises SEQ ID NO:15 and the graft comprises an endogenous CD28 intracellular domain sequence encoding SEQ ID NO:15, and / or the CAL or CAR comprises SEQ ID NO:18 and the graft comprises an endogenous 4-1BB intracellular domain sequence encoding SEQ ID NO:18.

[0564] In alternative examples, one or more of such endogenous sequences can be knocked out (i.e., rendered non-functional or non-expressible) in the graft cell or immune cell(s). However, the cells still express signaling machinery that functions in the donor with the intracellular domain of a CAR or CAL comprising one or more of SEQ ID NOs: 9, 15, and 18. Such knockouts can be used to focus signaling to the CAR or CAL of the cell, rather than the endogenous signaling domain.

[0565] 4. The cell or graft of any one of aspects 1-3, for use in a method of treating or preventing a disease or condition (e.g. cancer) in a human patient, wherein the patient's germline genome comprises said intracellular domain endogenous sequence(s), optionally wherein the germline genome encodes CD3 zeta, CD28 and 4-1BB intracellular domains comprising SEQ ID NOs: 9, 15 and 18, respectively.

[0566] In one example, a CAL or CAR comprises SEQ ID NO:9, and the germline genome comprises an endogenous CD3 zeta intracellular domain sequence that encodes SEQ ID NO:9, and / or a CAL or CAR comprises SEQ ID NO:15, and the germline genome comprises an endogenous CD28 intracellular domain sequence that encodes SEQ ID NO:15, and / or a CAL or CAR comprises SEQ ID NO:18, and the germline genome comprises an endogenous 4-1BB intracellular domain sequence that encodes SEQ ID NO:18.

[0567] 5. A graft according to aspect 2, 3 or 4 for treating or preventing a disease or condition (e.g. cancer) in said donor human patient.

[0568] 6. The cell or graft of any one of aspects 1-5, wherein the CAL or CAR comprises an extracellular CD3 (e.g., CD3 delta) or CD16 (e.g., CD16A) extracellular domain. Optionally, the CD3 extracellular domain is a CD3 gamma, CD3 delta or CD epsilon domain.

[0569] The present invention also provides the following concept: 1. A chimeric antigen ligand (CAL), wherein the CAL comprises a modified polypeptide comprising (in an N-terminal to C-terminal direction): a CD3 extracellular domain (e.g., a CD3δ or CD3ε extracellular domain); an optional hinge (e.g., a CD8α hinge); a transmembrane domain (e.g., a CD8α or CD28 transmembrane domain); and a CD3ζ intracellular signaling domain, wherein when the CAL is contained in an immune cell membrane and the CAL associates with a crosslinking agent, intracellular signaling is elicited in the immune cell to modulate the activity of the immune cell.

[0570] Optionally, the transmembrane domain is not a CD3 domain.

[0571] In one example, the CAL comprises a human CD3δ extracellular domain. In one example, the CAL comprises a human CD8α hinge. In one example, the CAL comprises a human CD8α or CD28 transmembrane domain. In one example, the CAL comprises a human CD3ζ domain. Provision of the CD3 extracellular domain in a modified polypeptide that also comprises a CD3ζ intracellular signaling domain is a non-natural configuration.

[0572] Optionally, each of the above CD3 domains may be according to any of the CD3 domains described herein, for example including one or more CD3 domain SNPs described herein.

[0573] In the alternative, Concept 1 provides: A CAL polypeptide complex comprising at least a first and a second polypeptide, (i) the first polypeptide comprises (in the N-terminal to C-terminal direction) a CD3 extracellular domain (e.g., a CD3δ or CD3ε extracellular domain); an optional hinge (e.g., a CD8α hinge) and a transmembrane domain (e.g., a CD3δ, CD3ε, CD8α or CD28 transmembrane domain); and (ii) the second polypeptide comprises (in an N-terminal to C-terminal direction) a transmembrane domain (e.g., a CD3ζ, CD8α or CD28 transmembrane domain); and a CD3ζ intracellular signaling domain; or one or both of the above polypeptides comprises an intracellular signaling domain that is not a CD3 domain (e.g., a 4-1BB and / or CD28 intracellular signaling domain), and when the CAL is contained in the immune cell membrane and the CAL binds to the crosslinking agent, intracellular signaling is induced in the immune cell to modulate the activity of the immune cell. CAL Polypeptide Complex.

[0574] In one example, the CAL comprises (a) a CD3δ, CD3ε or CD3γ chain, and (b) a CD3ζ chain, where one or both or said chains comprise an intracellular signaling domain that is not a CD3 domain (e.g., 4-1BB and / or CD28 intracellular signaling domain). For example, one or both chains each comprise one or more intracellular signaling domains selected from the group consisting of a CD27 domain, a CD28 domain, an ICOS domain, an OX40 domain, a CD40 domain, a 4-1BB domain, an FcεRIγ domain, a CD64 domain and a CD16 domain, e.g., a CD28 intracellular signaling domain and an intracellular signaling 4-1BB domain. In one example, the CAL comprises a CD3δ chain (e.g., one of said chains), optionally the CAL also comprises a CD3ε chain (e.g., two of said chains), and / or the CAL comprises a CD3γ chain (e.g., one of said chains), optionally the CAL comprises a CD3ζ chain (e.g., two of said chains). In one example, the (a) chain comprises a human extracellular CD3 domain (e.g., a CD3δ domain). In one example, a CAL comprises a complex of one CD3δ chain, two CD3ε chains, one CD3γ chain, and two CD3ζ chains, where at least one of the chains (e.g., both CD3ζ chains) comprises a respective intracellular signaling domain that is not a CD3 domain (e.g., a 4-1BB and / or CD28 intracellular signaling domain). A CAL may comprise a naturally occurring CD3 chain complex, including, for example, a complex of CD3γ, δ, ε, and ζ chains, where one or more chains (e.g., one or more ζ or δ chain(s)) comprise a non-CD3 intracellular signaling domain (e.g., a 4-1BB or CD28 intracellular signaling domain).

[0575] In one aspect, the invention provides a modified CD3 ζ chain comprising one or more intracellular signaling domains that are not CD3 domains (e.g., each of 4-1BB and / or CD28 intracellular signaling domains). For example, each non-CD3 domain is selected from the group consisting of CD27 domain, CD28 domain, ICOS domain, OX40 domain, CD40 domain, 4-1BB domain, FcεRIγ domain, CD64 domain and CD16 domain, e.g., comprising a CD28 intracellular signaling domain and an intracellular signaling 4-1BB domain. Optionally, the CD3 ζ chain comprises a CD3 (e.g., CD3δ or CD3ε) extracellular domain or a CD16 (e.g., CD16A) extracellular domain. The extracellular domains may be human.

[0576] In one example, all CD3 chains or domains are human, e.g., derived from the same human genome (e.g., the genome of the patient or future recipient of the CAL), e.g., derived from a human donor cell or tissue (e.g., a bone marrow or hematopoietic stem cell sample).

[0577] In one example, a CAL of the invention is contained in an immune cell (eg, a T cell, NK cell, or TIL cell) membrane.

[0578] 2. The CAL of concept 1, wherein the CD3 ectodomain is a human CD3 ectodomain.

[0579] 3. The CAL of concept 1 or 2, comprising one or more additional intracellular signaling domains, each selected from the group consisting of a CD27 domain, a CD28 domain, an ICOS domain, an OX40 domain, a CD40 domain, a 4-1BB domain, an FCεRIγ domain, a CD64 and a CD16 domain, e.g., a CD28 intracellular signaling domain and an intracellular signaling 4-1BB domain.

[0580] In one example, the modified polypeptide comprises, from N-terminal to C-terminal, the CD3ζ intracellular signaling domain and one or more of the additional intracellular signaling domains (eg, 4-1BB and / or CD28).

[0581] In one example, the modified polypeptide comprises, from N-terminal to C-terminal direction, one or more of the additional intracellular signaling domains described above (eg, 4-1BB and / or CD28) and the CD3ζ intracellular signaling domain described above.

[0582] In one example, the modified polypeptide comprises, from N-terminus to C-terminus, one or more of the additional intracellular signaling domain (e.g., 4-1BB and / or CD28), the CD3ζ intracellular signaling domain, and the additional intracellular signaling domain (e.g., 4-1BB and / or CD28).

[0583] 4. A chimeric antigen ligand (CAL)-immune cell (e.g., a human T cell, NK cell or TIL cell), wherein the cell expresses a CAL according to any one of concepts 1-3.

[0584] 5. A nucleic acid encoding a CAL according to any one of concepts 1 to 3.

[0585] 6. A method for producing a CAL, comprising expressing a CAL described in any one of concepts 1-3 in a cell (e.g., a human T cell, a NK cell or a TIL cell).

[0586] In certain embodiments of the invention, the crosslinking agent is a multispecific agent that can bind a first target antigen (e.g., a TAA expressed on a cancer cell, e.g., CD19) and also bind a second target antigen that is naturally surface expressed by cells of a human or patient to which the crosslinking agent may be administered. In this case, for example, when the cell is an immune cell (e.g., a T cell, a NK cell, or a TIL cell), the crosslinking agent can bind to a wild-type (i.e., endogenous) immune cell of the human or patient when not bound to a CAL immune cell of the invention. For example, the crosslinking agent can bind the CD3 extracellular domain (e.g., CD3 delta extracellular domain), and the crosslinking agent can induce intracellular signaling when bound to the extracellular domain (second target antigen) of a CAL-immune cell of the invention, or the crosslinking agent can induce intracellular signaling in an endogenous T cell of the patient when bound to an endogenous T cell of the patient. For example, the crosslinking agent can be BiTE™. For example, the crosslinking agent is blinatumomab or catumaxomab. In these aspects of the invention, the invention therefore advantageously comprises two methods of inducing immune cell signaling in a patient to which CAL immune cells (eg, T cells) have been administered.

[0587] Working Example Example 1: Analysis of domain mutations Based on information from Ensembl, an analysis of naturally occurring mutations in human immune cell proteins and domains was performed. This provided information to support SNP and amino acid mutations of interest that match between the modified protein (e.g., CAR or CAL) and the human cell, recipient or donor. The advantages of such matching according to the present invention are discussed in more detail above. The inventors have identified the following non-synonymous SNP mutations that have utility in the present invention:

[0588] (a) Human CD3 mutations [Table 2] * See product of transcript ENST00000532917.

[0589] [Table 3] * See product of transcript ENST00000300692.

[0590] [Table 4] * See product of transcript ENST00000361763.

[0591] [Table 5] TIFF0007577430000006.tif230162TIFF0007577430000007.tif198162

[0592] Positions referenced below are amino acid and nucleotide sequences, which are incorporated herein by reference. [Table 6]

[0593] [Table 7] * See the protein identified by Ensembl transcript ID ENST00000392122 and Uniprot number P20963, the sequences of which are incorporated by reference in their entirety.

[0594] At the following location: (chemical 1) S58, Y64, Y72, Y83, Y111, Y123, Y142 and Y153 is phosphorylated following T cell receptor triggering. Bold = ITAM residues: In a preferred embodiment of the invention, the CD3 zeta signaling domain of the engineered protein, CAR or CAL, comprises at least Y72 and Y152, and preferably all six tyrosines.

[0595] ITAM (29 amino acids each) Positions 61 to 89 (positions with reference to SEQ ID NO: 7) APAYQQGQNQLYNELNLGRREEYDVLDKR Position 100~128 PQRRKNPQEGLYNELQKDKMAEAYSEIGM Position 131~159 ERRRGKGHDGLYQGLSTATKDTYDALHMQ

[0596] See position number in protein product of Ensembl transcript number ENST00000392122: The inventors have identified the following mutation positions (numbered according to position in SEQ ID NO:7) for one or more of these possible adaptations according to the invention: (chemical 2) R52, S56, A59, A61, P62, A63, Q66, G67, N69, Q70, Y72 , N73, R79, E82, D84, V85, D87, K88, R90, R92, D93, M96, G97, P100, R102, R103, K104, N105, E107, L109, A119, A121, M127, K128, E130, R131, R132, K135, G136, G139, L144, A147, T151, Y152 , A154, L155, A159, P162, and R163.

[0597] Based on this, the inventors have identified a framework for a universal human CD3 zeta intracellular domain, where certain positions are constant for universal compatibility with most human patients and human cells, and the tyrosine of the ITAM is retained for use in intracellular signaling cascades. In this regard, see SEQ ID NO: 9, which shows the universal CD3 zeta framework intracellular domain of the invention (X = any amino acid). The present invention therefore provides an engineered protein, a CAR or CAL, comprising an intracellular CD3 zeta domain comprising SEQ ID NO: 9. In one example, the engineered protein, a CAR or CAL, is expressed by an immune cell, e.g., a T cell, a NK cell, or a TIL. In one example, the present invention provides a method of treating or reducing the risk of a disease or condition (e.g., as disclosed herein) in a human, the method comprising administering an immune cell (e.g., a CAR cell or a CAL cell) to the human, the human comprising a CD3 zeta intracellular domain nucleotide sequence encoding SEQ ID NO: 9. Thus, the protein (e.g., a CAR or CAL) is adapted for compatibility with the patient.

[0598] (b) Human CD28 mutations CD28 (cluster of differentiation 28; Uniprot P10747) is one of the proteins expressed on T cells that provides a costimulatory signal required for T cell activation and survival. In addition to the T cell receptor (TCR), stimulation of T cells through CD28 can provide a strong signal for the production of various interleukins, especially IL-6. CD28 is the receptor for the CD80 (B7.1) and CD86 (B7.2) proteins.

[0599] topology: Transmembrane = position 153~179; Intracellular domain = positions 180-220 (positions numbered with reference to SEQ ID NO:13).

[0600] CD28 possesses an intracellular domain with several residues important for its effective signal transduction. The YMNM motif starting at tyrosine 170 is particularly important for the recruitment of SH2 domain-containing proteins, especially PI3K, Grb2, and Gad. The Y170 residue is important for the induction of Bcl-xL via mTOR and for enhancing IL-2 transcription via PKCθ, but does not affect proliferation and results in a slight decrease in IL-2 production. The N172 residue (as part of the YMNM) is important for binding Grb2 and Gad and appears to be able to induce IL-2 mRNA stability but not NF-κB translocation. Induction of NF-κB seems to be much more dependent on Gad binding to both the YMNM and the two proline-rich motifs within the molecule. However, mutation of the last amino acid of the motif, M173, which cannot bind PI3K but can bind Grb2 and Gad, gives little NF-κB or IL-2, suggesting that Grb2 and Gad cannot compensate for the loss of PI3K. IL-2 transcription appears to have two phases; an early Y170-dependent, PI3K-dependent phase that allows transcription, and a PI3K-independent second phase that depends on the formation of an immune synapse, which leads to enhanced IL-2 mRNA stability. Both are required for full production of IL-2.

[0601] CD28 also contains two proline-rich motifs that can bind SH3-containing proteins. Itk and Tec can bind the N-terminus of these two motifs immediately following the Y170 YMNM, and Lck binds the C-terminus. Both Itk and Lck can phosphorylate tyrosine residues, which then allow SH2-containing proteins to bind to CD28. Tec binding to CD28 enhances IL-2 production and depends on the binding of its SH3 and PH domains to CD28 and PIP3, respectively. The C-terminal proline-rich motif in CD28 is important for bringing Lck and lipid rafts to the immune synapse via filamin A. Mutation of the two prolines within the C-terminal motif reduces proliferation and IL-2 production but induces Bcl-xL normally. Phosphorylation of the tyrosine within the PYAP motif (Y191 in mature human CD28) creates a high affinity binding site for the SH2 domain of the src kinase Lck, which in turn binds to the serine kinase PKC-θ.

[0602] In this foundational and natural SNP nonsynonymous mutation analysis, the inventors have identified a universal human CD28 intracellular domain framework, where certain positions are constant for universal compatibility with most human patients and human cells, and the conserved YMNM and PYAP tyrosines are retained for use in intracellular signaling cascades. In this regard, see SEQ ID NO: 15 (X = any amino acid), which shows the universal CD28 framework intracellular domain of the present invention. The present invention therefore provides an engineered protein (e.g., CAR or CAL) comprising an intracellular CD28 domain comprising SEQ ID NO: 15. In one example, the protein (e.g., CAR or CAL) is expressed by an immune cell, e.g., a T cell, a NK cell, or a TIL. In one example, the present invention provides a method of treating or reducing the risk of a disease or condition (e.g., as disclosed herein) in a human, the method comprising administering to the human an immune cell (e.g., a CAR cell or a CAL cell), the human comprising a nucleotide sequence of a CD28 intracellular domain encoding SEQ ID NO: 15. The protein CAR or CAL is therefore adapted for compatibility with the patient.

[0603] Table 6: Selected human CD28 mutations Transmembrane mutations [Table 8] Intracellular domain mutations [Table 9] TIFF0007577430000012.tif164162 * Part of the YMNM motif ** Part of the PYAP motif

[0604] (c) Human 4-1BB mutation CD137 is a member of the tumor necrosis factor (TNF) receptor family. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB, and it is induced by lymphocyte activation (ILA). CD137 is currently of interest to immunologists as a costimulatory immune checkpoint molecule. The best characterized activity of CD137 is its costimulatory activity on activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion, survival, and cytolytic activity. Furthermore, it can enhance immune activity to eliminate tumors in mice.

[0605] Ensembl transcript: ENST00000615230 Topology:Transmembrane:187-213 Intracellular domain: 214-255 (Position number relative to SEQ ID NO: 16)

[0606] Table 7: Selected human 4-1BB (CD137) mutations Intracellular domain mutations [Table 10] * TRAF2 binding site

[0607] Reference is made to Mol Cells.2001 Dec 31;12(3):304-12; "A novel leucine-rich repeat protein (LRR-1):potential involvement in 4-1BB-mediated signal transduction";Jang LK et al., which describes that 4-1BB, a member of the tumor necrosis factor receptor (TNFR) superfamily, is induced on CD4+ and CD8+ T cells upon engagement of the T cell receptor (TCR) / CD3 complex with MHC-bound antigen. 4-1BB plays an important role in transmitting costimulatory signals during T cell activation. However, 4-1BB-mediated signal transduction pathways have been studied. The authors performed a yeast two-hybrid assay to identify the intracellular signaling molecules that bind 4-1BB. A novel leucine-rich repeat (LRR)-containing protein, named LRR-1, was found to specifically interact with the cytoplasmic domain of 4-1BB. Overexpression of LRR-1 suppressed NF-κB activation induced by 4-1BB or TNF receptor-associated factor (TRAF)2. In addition, JNK1 activity, which is downregulated by LRR-1, was induced by 4-1BB. The authors conclude that these results indicate that LRR-1 negatively regulates the 4-1BB-mediated signaling cascade that leads to the activation of NF-kappaB and JNK1.

[0608] See also Mol Cell Biol. 1998 Jan;18(1):558-565; "4-1BB and Ox40 Are Members of a Tumor Necrosis Factor (TNF)-Nerve Growth Factor Receptor Subfamily That Bind TNF Receptor-Associated Factors and Activate Nuclear Factor κB"; Robert Arch & Craig Thompson, which explains that the TRAF-binding domains in the cytoplasmic tails of 4-1BB and OX40 are conserved across species. (A) Protein sequence alignment of the cytoplasmic domains of 4-1BB and Ox40. Amino acid residues shown to be important for the interaction of the TRAF molecules with either receptor were studied. In this report, the authors demonstrate that two members of the TNF-NGF receptor family, 4-1BB and OX40, can use TRAF molecules to trigger cytoplasmic signaling cascades. This report describes the ability of the cytoplasmic domains of two members of the TNF-NGF receptor family, 4-1BB and Ox40, to bind proteins of the TRAF family of intracellular adaptor molecules. Multimerization of the cytoplasmic domains of 4-1BB and Ox40 in transfected cells can activate the transcription factor NF-κB in a TRAF-dependent manner. Interestingly, increased expression of individual TRAF proteins can either positively or negatively affect the ability of these receptors to induce NF-κB activation. These data suggest that both differential binding affinities and relative abundance of individual TRAF proteins can affect cellular responses to receptor cross-linking. These results provide a possible explanation for the variable effects observed when members of the TNF-NGF receptor family are cross-linked on activated T cells.

[0609] The inventors have therefore realised the desirability of preserving the TRAF binding site in the 4-1BB intracellular domain used in the embodiments of the engineered proteins (e.g., CAR and CAL) and the desirability of the adaptation according to the invention, such that the engineered protein (e.g., CAR and CAL) domain is adapted for use with the intracellular machinery of human immune cells having chimeric receptors. The invention therefore provides an engineered transmembrane protein (CAR or CAL) or immune cell of the invention comprising the same, wherein the protein comprises an intracellular 4-1BB domain comprising Q236 and E247 (e.g., the numbering of the positions includes Q236-E237-E238-D239 and 247E-248E-249E-250E, with reference to SEQ ID NO: 16).

[0610] Based on SNP and mutation analysis, the inventors have identified a universal human 4-1BB intracellular domain framework, in which certain positions are constant for universal compatibility with most human patients and human cells, and in which TRAF binding residues are retained for use in intracellular signaling cascades. In this regard, see SEQ ID NO: 18, which shows the universal 4-1BB framework intracellular domain of the invention (X = any amino acid). The present invention therefore provides engineered protein CARs or CALs comprising an intracellular 4-1BB domain comprising SEQ ID NO: 18.

[0611] In one example, the engineered protein CAR or CAL is expressed by an immune cell, such as a T cell, NK cell, or TIL. In one example, the present invention provides a method of treating or reducing the risk of a disease or condition (e.g., as disclosed herein) in a human, the method comprising administering to the human an immune cell, CAR cell, or CAL cell, the human comprising a 4-1BB intracellular domain nucleotide sequence comprising Q236 and E247 (e.g., comprising Q236-E237-E238-D239 and 247E-248E-249E-250E, where the numbering of the positions refers to SEQ ID NO: 16) or comprising SEQ ID NO: 16. Thus, the protein CAR or CAL is adapted for compatibility with a human cell or patient.

[0612] Example 2: CD3δ-CAL T cell modulation by Blinatumomab The methods disclosed in the Examples of WO2015 / 058018 can be readily adapted to insert a transgene encoding a CAL into immune cells (instead of the transgene encoding a CAR disclosed in that patent application).

[0613] The CAL transgene comprises a nucleotide sequence encoding (in the N-terminal to C-terminal direction) the human CD3δ extracellular domain, CD8α hinge and transmembrane domain, 4-1BB intracellular domain and CD3ζ domain of SEQ ID NO: 4 herein. Suitably, the CAL sequence may be a modification of the CD16F-BB-ζ or CD16V-ΒΒ-ζ constructs of WO2015 / 058018, which have the CD3δ domain sequence instead of the CD16 sequence. The transgene is inserted into cells obtained from a human donor suffering from B cell precursor acute lymphoblastic leukemia (ALL), and the modified T cell population is expanded and expanded ex vivo. The CAL and transgene are amino acid polymorphisms that match the extracellular and intracellular CAL CD3 and 4-1BB domains. Optionally, the endogenous CD3δ and / or CD3ζ genes are knocked out in the modified cells, for example, using Cas9 targeted inactivation of the genes. Additionally, the endogenous TCR locus may be inactivated for TCR expression.

[0614] In one study, the modified CAL-T cells were infused back into a donor, followed by administration of blinatumomab as a crosslinking agent. Crosslinking of the CAL cells to CD19+ B cells results in the killing of cancer cells by the activated CAL-T cells in vivo, thereby treating ALL in the donor.

[0615] In another study, CAL-T cells are preincubated with blinatumomab prior to infusion into donors.

[0616] Donors will be monitored and titrated with blinatumomab to modulate CAL-T cell activity.

[0617]

Table 11

Claims

1. A composition or kit for targeting immune cells to target cells, comprising a chimeric antigen ligand (CAL)-immune cell for targeted binding to an antigen-specific crosslinking agent, A. The crosslinking agent i. a first antigen-binding site that specifically binds a first target antigen; and ii. a second antigen-binding site that specifically binds a second target antigen. a multispecific antigen-binding fragment comprising: B. The CAL-immune cell comprises a transmembrane ligand, the ligand iii. an extracellular portion comprising said second antigen linked to a transmembrane domain; iv. an intracellular portion comprising a first signaling domain for intracellular signaling when the cross-linking agent binds to the second antigen; including modified combinations of C. when the CAL-immune cells and crosslinking agent are combined with a target cell, the target cell comprises the first target antigen, and the first antigen is an extracellular antigen; v. the cross-linking agent binds to the first and second antigens to target the immune cells to the target cells; vi. thereby inducing intracellular signaling in said immune cells to modulate immune cell activity; wherein the molecular weight of the crosslinker is 60 kDa or less, and each antigen-binding site of the crosslinker comprises an antibody-binding site; Composition or kit.

2. (a) each binding site of the cross-linker comprises an antibody binding site, the antibody binding sites being linked scFvs; or (b) each binding site is selected from the group consisting of an scFv, a nanobody™, and a dAb.

3. The crosslinking agent is (a) a bispecific antigen-binding fragment comprising two scFv binding sites; or (b) a bispecific T cell engager antibody, a bispecific scFv, a dAb, a nanobody (optionally a nanobody dimer or trimer), a dAb multimer (optionally a dAb dimer or trimer), a diabody, or a Dual-affinity Re-targeting antibody (DART™).

4. 4. The composition or kit of any one of claims 1 to 3, wherein the crosslinking agent is Blinatumomab or a CD3 / CD19 binding derivative thereof (optionally wherein the target cell is an acute lymphoblastic leukemia (ALL) B cell), AMG211 or a CD3 / CEA binding derivative thereof (MEDI-565, MT111; optionally wherein the target cell is a gastrointestinal cancer cell); Pasotuxizumab or a CD3 / PSMA binding derivative thereof (optionally wherein the target cell is a prostate cancer cell); Solitomab or a CD3 / EpCAM binding derivative thereof (optionally wherein the target cell is a cancer cell); or AFM11 or a CD3 / CD19 binding derivative thereof (and optionally wherein the target cell is an ALL cell or a non-Hodgkin's lymphoma cell).

5. 5. The composition or kit of claim 1, wherein the binding affinity constant (KD) of the first binding site for the first antigen is at least 5-fold lower than the binding affinity constant of the second binding site for the second antigen and / or the second binding site has a binding affinity constant (KD) for the second antigen of 100 nM or less as determined by surface plasmon resonance (SPR).

6. The composition or kit according to any one of claims 1 to 5, wherein the second antigen is an extracellular antigen of an immune cell.

7. 7. The composition or kit of claim 6, wherein the second antigen is provided by a CD3 extracellular domain sequence; optionally a human CD3 extracellular domain sequence.

8. (a) the second antigen of said CAL is encoded in the cell by a non-endogenous nucleotide (S1) sequence that includes a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue (R1) of said antigen; (b) the genome of the cell comprises a second nucleotide sequence (S2), wherein the second nucleotide sequence (S2) encodes an amino acid sequence that comprises SNP1 and is identical to the amino acid sequence of the second antigen and comprises R1; or the second nucleotide sequence (S2) encodes an amino acid sequence that comprises SNP1 and is a naturally occurring variant of the amino acid sequence of the second antigen and comprises R1; wherein S2 is an endogenous genomic sequence of the cell and SNP1 is a non-synonymous SNP; A composition or kit according to any one of claims 1 to 7.

9. 9. A composition or kit according to any one of claims 1 to 8 for use in a method of treating or preventing a disease or condition in a human, said method comprising administering to said human said crosslinking agent and said cells; (a) the second antigen of the CAL is encoded in the cell by a non-endogenous nucleotide (S1) sequence that includes a human single nucleotide polymorphism (SNP1) that encodes an amino acid residue of the antigen; and (b) The composition or kit, wherein the CAL cells are contained in an autograft or allograft, and the method comprises administering the graft to a human in step C, wherein the CAL cells and target cells are combined, and the human genome comprises the SNP1 prior to said administration.

10. A composition or kit according to any one of claims 1 to 9, wherein the CAL-immune cells are combined with the cross-linking agent.

11. A composition or kit according to any one of claims 1 to 10 for use in a method for treating or reducing the risk of a disease or condition in a human, the method comprising administering to a human said CAL cells and said crosslinking agent, wherein said CAL cells and human target cells are combined and crosslinked by said crosslinking agent, thereby upregulating signalling in said CAL cells to increase target cytotoxicity of said CAL cells, thereby treating or reducing the risk of said disease or condition in a human.

12. 1. A method of targeting an immune cell to a target cell, comprising: A. providing a cross-linking agent, said cross-linking agent comprising i. a first antigen-binding site that specifically binds a first target antigen; and ii. a second antigen-binding site that specifically binds a second target antigen. providing a cross-linking agent which is a multispecific antigen-binding fragment comprising: B. Providing a chimeric antigen ligand (CAL)-immune cell, said immune cell comprising a transmembrane ligand, said ligand comprising iii. an extracellular portion comprising the second antigen linked to a transmembrane domain; and iv. an intracellular portion comprising a first signaling domain for intracellular signaling when the cross-linking agent binds to the second antigen; providing a chimeric antigen ligand (CAL)-immune cell comprising an altered combination of: C. combining the CAL-immune cells and a cross-linking agent with the target cells, the target cells comprising the first target antigen, the first antigen being an extracellular antigen; v. whereby said cross-linking agent binds said first and second antigens to target said immune cells to said target cells; vi. Thereby inducing intracellular signaling in said immune cells to regulate immune cell activity. Combining Including, wherein the molecular weight of the crosslinker is 60 kDa or less, and each antigen-binding site of the crosslinker comprises an antibody-binding site; The method is performed (i) in vitro or (ii) ex vivo to generate a graft in which target cells are killed, said graft being for administration to a patient to treat or reduce the risk of a disease or condition in a human.

Citation Information

Patent Citations

  • Novel treatments for pediatric acute lymphoblastic leukemia

    JP2012508163A

  • A method to enhance the activity of CART cells by co-introducing bispecific antibodies.

    JP2015524255A

  • Peptidic chimeric antigen receptor t cell switches and uses thereof

    WO2015057834A1

  • Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors

    WO2015058018A1